responsable,institucion_original,institucion_standard,cuidad,cod_postal,direccion,lat,lon,lineas_investigacion,area_clinica,proyecto_descripcion,proyecto_estado,descripcion_kw,ip,ip_nivel,linea_investigacion_caracter_inovador,entidades_finaciodoras,fondos_capital_riesgo,entidades_colaboradoras,ano_inicio,ano_fin,capacidad_trabajo
Hospital Clínico San Carlos,Hospital La Fe-IIS LA FE,Hospital Universitario La Fe,Valencia,46009,"Avinguda de Campanar, 21",39.484134,-0.391490,Metabolismo y Hepatotoxicidad de Fármacos,Hepatología,"Esta línea tiene como objetivo contribuir con nuevas estrategias que permitan el desarrollo de fármacos más eficaces y seguros mediante el estudio en modelos celulares hepáticos del metabolismo de fármacos, las interacciones
medicamentosas, mecanismos moleculares de
hepatotoxicidad y hepatotoxicidad idiosincrásica.",Activo,"Esta línea tiene como objetivo contribuir con nuevas estrategias que permitan el desarrollo de fármacos más eficaces y seguros mediante el estudio en modelos celulares hepáticos del metabolismo de fármacos, las interacciones
medicamentosas, mecanismos moleculares de
hepatotoxicidad y hepatotoxicidad idiosincrásica.",Castell JV,3,SI,UNION EUROPEA,NO,UNION EUROPEA,2011,2015,3
Hospital Clínico San Carlos,Hospital La Fe-IIS LA FE,Hospital Universitario La Fe,Valencia,46009,"Avinguda de Campanar, 21",39.484134,-0.391490,Metabonómica Hepática,Hepatología,La finalidad de esta línea de investigación es llevar a cabo estudios relacionados con la hepatología mediante la utilización de la espectrometría de masas y la quimiometría como estrategia de análisis metabonómico,Activo,La finalidad de esta línea de investigación es llevar a cabo estudios relacionados con la hepatología mediante la utilización de la espectrometría de masas y la quimiometría como estrategia de análisis metabonómico,Castell JV,3,SI,UNION EUROPEA,NO,UNION EUROPEA,2011,2015,3
Hospital Clínico San Carlos,Hospital La Fe-IIS LA FE,Hospital Universitario La Fe,Valencia,46009,"Avinguda de Campanar, 21",39.484134,-0.391490,Terapia Celular Hepática,Hepatología,"El objetivo en esta área es aplicar la terapia celular al tratamiento de ciertas patologías hepáticas (fallo hepático agudo, enfermedades metabólicas congénitas), convirtiéndola de ese modo en una estrategia terapéutica complementaria, o en parte sustitutiva al trasplante de órgano entero",Activo,"El objetivo en esta área es aplicar la terapia celular al tratamiento de ciertas patologías hepáticas (fallo hepático agudo, enfermedades metabólicas congénitas), convirtiéndola de ese modo en una estrategia terapéutica complementaria, o en parte sustitutiva al trasplante de órgano entero",Castell JV,3,SI,UNION EUROPEA,NO,UNION EUROPEA,2011,2015,3
Hospital Clínico San Carlos,Hospital La Fe-IIS LA FE,Hospital Universitario La Fe,Valencia,46009,"Avinguda de Campanar, 21",39.484134,-0.391490,"Cardiovascular. Estudios preclínicos con células troncales
adultas para el tratamiento del infarto de
miocardio",Patología cardiovasculares,"Estudios preclínicos con células troncales
adultas para el tratamiento del infarto de
miocardio",Activo,"Estudios preclínicos con células troncales
adultas para el tratamiento del infarto de
miocardio",SEPULVEDA P,3,SI,PLAN NACIONAL,NO,CIPF,2009,2013,3
Hospital Clínico San Carlos,Hospital La Fe-IIS LA FE,Hospital Universitario La Fe,Valencia,46009,"Avinguda de Campanar, 21",39.484134,-0.391490,Generación de iPSC de pacientes con cardiopatías congénitas,Patología cardiovasculares,"En relación con cardiopatías el grupo estudio procesos de reprogramación de keratinocitos y fibroblastos para el diseño de modelos celulares
de ambas enfermedades.",Activo,"En relación con cardiopatías el grupo estudio procesos de reprogramación de keratinocitos y fibroblastos para el diseño de modelos celulares
de ambas enfermedades.",SEPULVEDA P,3,SI,PLAN NACIONAL,NO,CIPF,2009,2014,3
Hospital Clínico San Carlos,Hospital La Fe-IIS LA FE,Hospital Universitario La Fe,Valencia,46009,"Avinguda de Campanar, 21",39.484134,-0.391490,Oncología. Trasplante de progenitores hematopoyéticos,Oncología,"El trasplante de sangre de cordón umbilical en pacientes adultos ha sido la principal área de investigación en el campo del trasplante de progenitores hematopoyéticos, siendo el grupo en la actualidad líder en este procedimiento.",Activo,"El trasplante de sangre de cordón umbilical en pacientes adultos ha sido la principal área de investigación en el campo del trasplante de progenitores hematopoyéticos, siendo el grupo en la actualidad líder en este procedimiento.",SANZ MA,3,SI,PLAN NACIONAL,NO,,2009,2012,3
Hospital Clínico San Carlos,Hospital La Fe-IIS LA FE,Hospital Universitario La Fe,Valencia,46009,"Avinguda de Campanar, 21",39.484134,-0.391490,"Desarrollo y validación de biomarcadores de
imagen",Diagnóstico por imagen / Medicina Nuclear / Radiología,"optimizar la eficiencia diagnóstica y terapéutica
del uso de biomarcadores de imagen con un abordaje multidisciplinar y multimodal, así como realizar la validación de su relación con la realidad estructural, fisiológica, biológica y molecular, y controlar su calidad técnica.",Activo,"optimizar la eficiencia diagnóstica y terapéutica
del uso de biomarcadores de imagen con un abordaje multidisciplinar y multimodal, así como realizar la validación de su relación con la realidad estructural, fisiológica, biológica y molecular, y controlar su calidad técnica.",MARTI-BONMATI L,3,SI,PLAN NACIONAL,NO,"BRACCO, PHILIPS, SIEMENS",2011,2014,3
Hospital Clínico San Carlos,Hospital La Fe-IIS LA FE,Hospital Universitario La Fe,Valencia,46009,"Avinguda de Campanar, 21",39.484134,-0.391490,"Identificación de nuevos genes implicados en
enfermedades neurosensoriales",Enfermedades raras,"Los esfuerzos del grupo en este campo se centran en la búsqueda de nuevos genes candidatos en aquellos pacientes en los que se ha descartado la presencia de mutaciones en aquellos genes conocidos asociados a la
enfermedad.",Activo,"Los esfuerzos del grupo en este campo se centran en la búsqueda de nuevos genes candidatos en aquellos pacientes en los que se ha descartado la presencia de mutaciones en aquellos genes conocidos asociados a la
enfermedad.",MILLAN JM,3,SI,UNION EUROPEA,NO,CIBERER,2009,2014,3
Hospital Clínico San Carlos,Hospital La Fe-IIS LA FE,Hospital Universitario La Fe,Valencia,46009,"Avinguda de Campanar, 21",39.484134,-0.391490,"Prototipo para realizar
endoscopias digestivas que facilita el avance a larga distancia del endoscopio,
a lo largo del intestino delgado",Gastroenterología,"Desarrollado por la Unidad de Endoscopia Digestiva del Hospital Universitario La
Fe e investigadores de la UPV",Activo,"Desarrollado por la Unidad de Endoscopia Digestiva del Hospital Universitario La
Fe e investigadores de la UPV",PONS V,3,SI,PLAN NACIONAL,NO,UPV,2008,2012,3
Hospital Clínico San Carlos,Hospital La Fe-IIS LA FE,Hospital Universitario La Fe,Valencia,46009,"Avinguda de Campanar, 21",39.484134,-0.391490,PROYECTO CUIDISS,Otros,Aplicación Informática para gestión del Cuadro de Mando Integral en Sistemas Hospitalarios de Gestión ,Activo,Aplicación Informática para gestión del Cuadro de Mando Integral en Sistemas Hospitalarios de Gestión ,VALDIVIESO B,3,SI,PLAN NACIONAL,NO,ENCAMINA,2011,2012,3
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,Tele monitorización (pacientes de edad avanzada con insuficiencia cardiaca crónica desde el centro sanitario) ,Patología cardiovasculares,"H@H. Definir un nuevo servicio socio-sanitario domiciliario para pacientes cardiológicos crónicos de edad avanzada. Tele monitorización de parámetros cardiovasculares fisiopatológico y respiratorios, permitiendo un seguimiento clínico a distancia de pacientes desde el centro hospitalario. ",Inactivo,"Telemedicina, Tele monitorización, Insuficiencia Cardiaca Crónica.", CONSORZIO PISA RICERCHE,Alto,Alto,ISCIII / AAL,NO,"HUVR
PISA RICERCHE
Otros",2009,2011,Medio
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,Interoperabilidad en historia clínica electrónica (Mejora de la atención sanitaria de ciudadanos cuando están fuera de su país permitiendo a los profesionales acceder a los datos clínicos del paciente.),Salud internacional,EPSOS. Desarrollar un framework de e Salud y una infraestructura basada en Tecnologías de Comunicación e Información que permita un acceso seguro a la información de salud del paciente. En concreto se realizará un piloto de interoperabilidad a gran escala entre distintos sistemas de salud europeos aplicada a la Receta electrónica y al resumen de Historia del paciente,Inactivo,"e-Salud, Interoperabilidad, receta electrónica y patient sumary",SAS,Alto,Alto,ICT-7PM,NO,"Les Hôpitaux universitaires de Genève
Zentralinstitut für die kassenärztliche Versorgung
Fraunhofergesellschaft zur Foerderung der angewandten Forschung
Instytut Logistyki i Magazynowania
Empirica
Universidade de Aveiro
Aristotelio panepistimio Thessalonikis
Institut für Bewegungswissenschaften und Sport
Kompetansesenter for Informasjonsteknologi I Helsevesenet AS
Yazılım Araştırma & Geliştirme ve Danışmanlık Ticaret Limited Sirketi
Lombardia Informatica S.p.A.
Pharmaxis S.A.
",2008,2011,Alto
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,"Tele rehabilitación (Plataforma realidad virtual para rehabilitación de pacientes que han sufrido un accidente cerebro vascular, en alta hospitalaria con rehabilitación motora) ",Rehabilitación,"REWIRE. Crear e implementar plataforma de realidad virtual para rehabilitación en domicilio de pacientes dados con alta hospitalaria. Plataforma formada por tres estaciones: plataforma del paciente, plataforma del hospital y plataforma regional.",Activo,"Telemedicina, tele rehabilitación,  Virtual Reality, Accidente cerebro vascular, rehabilitación motora.",Universitá degli Studi di Milano,Alto,Alto,7PM,NO,"Ecole Polytechnique Federale de Lausanne
U. Oxford
Eidgenossische Technische Hochschule Zurich
AB. Acus srl
IAVANTE
Technogym spa
Fundació Privada Barcelona Digital Centre Tecnológic
Neurologische Klinik Universitätsspital Zúrich
Jozef Stefan Institute
HUVR",2011,2014,Alto
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,"Plataformas tecnológicas, interoperabilidad (Desarrollo de redes regionales de salud y nueva generación de plataformas tecnológicas)",Salud internacional,"PICNIC. Desarrollar nuevos escenarios de atención sanitaria para describir de forma que se pueda presentar tanto a la industria como a otras autoridades sanitarias una imagen de la red regional de servicios sanitarias. Se desarrolla también una arquitectura de sistemas que soporte la interoperabilidad de servicios, y herramientas y componentes comunes para los servicios en una cooperación cercana a la industria",Inactivo,"Plataformas tecnológicas, Interoperabilidad",The Danish Centre for Health Telematics (FUNEN) ,,,5PM,NO,FUNEN; Technical Research Centre of Finland (VTT); South and East Belfast Trust (SEBT); Systems Team;  General Medical Services Board (GMS); North Western Health Board (NWHB); Andalucian Health Service (SAS); European Consulting and Management on Information Technology (ECOMIT); Institute of Computer Science (ICS); University of Ioannina (UOI); Medizinische Netzwerke Gmbh (MN GmbH); National University Hospital of Iceland; Reykjavik Hospital,2000,2003,
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,"Ensayo clínico multicentrico internacional, análisis de PK/PD, Impacto ecológico, mecanismos de caracterización de resistencia, pruebas rápidas para detección de microorganismos, prueba rápida de susceptibilidad antimicrobiana",Enfermedades respiratorias,"MagicBullet. Optimizar el tratamiento antibiótico de la neumonía asociada a la ventilación mecánica, una infección muy común en cuidados intensivos, especialmente en países donde el grado de desarrollo de la resistencia microbiana es muy elevado. ",Activo,Ensayo clínico dirigidos por investigadores de antibióticos fuera de patente,Servicio Andaluz de Salud (SAS),Alto,Alto,7PM,NO,"Servicio Andaluz de Salud; Universite Paris-Sud XI; Klinikum der Universitaet zu Koeln; Universita Cattolica del Sacro Cuore; National and Kapodistrian University of Athens; Fundacio Privada Clinic per la Recerca Biomedica; Servizo Galego de Saude; Halotech DNA, SL; Biomedal SL; Consorcio de Apoyo a la Investigacion Biomedica en RED",2012,2014,Alto
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,"Genetic testing in Europe - network for test development harmonization, validation and standardization of services",Genética,"EUROGENTEST. Pruebas genéticas en Europa: Red para el desarrollo de pruebas genéticas, armonización, validación y estandarización de servicios: La red EUROGENTEST tiene como objetivo el desarrollo de la infraestructura, herramientas,
recursos, directrices y procedimientos necesarios para alcanzar el establecimiento de unos servicios europeos de pruebas genéticas armonizados y de calidad, que puedan interactuar con servicios de otros continentes, servirles como modelo o ayudar a su creación.",Inactivo,RED DE EXCELENCIA,Universidad Católica de Lovaina,Alto,Alto,6PM,NO,"Enthoven Associates Design Consultants NV; Hospitales Universitarios de Ginebra; Hospitales infantiles universitarios del centro de Manchester; Bayerische Julius-Maximilians- Universitaet Wuerzburg; Universidad de Semmelweis; Instituto Internacional de Biología Molecular y Celular; Universidad Charles Praga-2 Escuela de Medicina; Universidad Nacional de Irlanda, Dublín; Centro de Investigación Conjunta; Hospital Oxford Radcliffe de la NHS; Hospital Universitario Infantil Basel; Institut National de la Santé et de la Recherche Médicale; Instituto Casa Sollievo Della Médicale Sofferenza IRCCS; Institut de Pathologie et de Génétique; Universidad de Turku; Lunds Universitet; Medizinische Hochschule Hannover; Instituto de Biologia Molecular e Celular; Centro Médico Universitario de Leiden; Universidad de Warwick; Grupo de Interés en Genética; Istituti Clinici di Perfezionamento-Milan; Grupo de apoyo a pacientes con trastornos de cromosomas poco frecuentes; Instituto de Genética Molecular e Ingeniería genética; Universidad Católica de Santiago de Guayaquil; M.R.C.-Holanda; Waypoint Systems ltd; Consultoría de Gestión e investigación; STAB VIDA, investigaçao e services em ciências biológicas Lda; PhenoSystems SA; Methexis Genomics NV; Chemagen Biopolymer-Technologie Aktiengesellschaft",2005,2010,Alto
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,"Trans-European cooperation and coordination of genome sequencing and functional genomics of human-pathogenic microorganisms
",Genética,"PATHOGENOMICS. PathoGenoMics supports the establishment of the ERA by:
1.improving the transparency and coherence of national research programmes / programme parts for genome research on pathogenic microorganisms (“pathogenomics”) by means of their tight and sustainable coordination and cooperation stimulating the continual cooperation and exchange of views of the leading funding bodies in the field as well as other relevant stakeholders (scientific associations, industrial associations, innovation agencies, etc.)
2.creating an internal market for pathogenomics with transnational movement/exchange of informations/knowledge, more abundant/mobile human resources, transnational systems for supporting innovation and technology transfer
3.defining a European Research and Training Agenda on pathogenomics as part of a European Research policy.
",Inactivo,RED DE EXCELENCIA,Forschungszentrum Jülich GmbH (Alemania),Alto,Alto,6PM,NO,"Austrian Federal Ministry of Science and Research; The Austrian Science Fund; Academy of Finland; Institut Pasteur; National Agency for Research; Forschungszentrum Jülich  GmbH (FZJ) Project Management Organization Jülich ; Federal Ministry of Education and Resarch; Hungarian Academy of Science; Hungarian Scientific Research Fund
; The Chief Scientist Office Israeli, Ministry of Health; The Science and Technology Foundation, Portugal; Ministry of Higher Education, Science and Technology Slovenia; Ministry of Science and Innovation, Spain

 



 ",2004,2012,Alto
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,"Evaluar la posible relación entre el riesgo de tumores cerebrales y factores de riesgo medioambientales, incluyendo el uso de tecnologías de comunicación",Oncología,"MOBIKIDS. El objetivo general del proyecto MOBI-Kids consiste en evaluar la posible relación entre el riesgo de tumores cerebrales y factores de riesgo medioambientales, incluyendo el uso de tecnologías de comunicación",Inactivo,"leucemia, tumores cerebrales  ","Fundación CREAL, Barcelona",Alto,Alto,7PM,NO,Monash University Australia; Medical University of Vienna Austria; University of Ottawa Canada ; Association pour la Recherche Epidémiologique dans les Cancers de l'Enfant et de l'Adolescent (ARECEA) France; France Telecom; Ludwig-Maximilians-University Munich Germany; University of Athens Greece; Tata Memorial Hospital  India; Gertner Institute for Epidemiology & Health Policy Research Israel; Università degli Studi di Torino Italy; Tokyo Women’s Medical University Japan; Dankook University College of Medicine Korea; University of Auckland New Zealand; Instituto de Salud Carlos III Spain; Universidad de Huelva Spain; Universidad de Valencia Spain; National Taiwan University College of Public Health Taiwan; Universiteit Utrecht The Netherlands; Health Protection Agency (HPA) UK                 ,2008,2012,Alto
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,EUROPEAN MULTICENTRE TICS IN CHILDREN STUDIES,Psiquiatría,"EMTICS. Estudio pre-clínicos para estudiar los factores de susceptibilidad de los tics adolescentes y pediátricos, con especial enfoque en la sintomatología obsesiva-compulsiva comorbida desde los puntos de vista clínicos, epidemiológicos, genéticos, microbiológicos e inmunológicos. Se pretende también trasladar los resultados de investigación en aplicación clínica gracias al desarrollo de modelos de predicción de desarrollo de enfermedades e investigación de estrategia de tratamiento así como establecer una infraestructura pan-europea para el estudio de tic.",Activo,Ensayo clínico,ACADEMISCH ZIEKENHUIS GRONINGEN (NETHERLANDS) ,Alto,Alto,7PM,NO,"UNIVERSITA DEGLI STUDI DI BARI ""ALDO MORO""; UNIVERSITY COLLEGE LONDON; LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN; URWYLER ADRIAN - CYTOLAB; ISTITUTO SUPERIORE DI SANITA; HEALTH PROTECTION AGENCY HPA; TECHNISCHE UNIVERSITAET DRESDEN; DEMOCRITUS UNIVERSITY OF THRACE; ProImmune Limited; NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.; CLALIT HEALTH SERVICES; THE UNIVERSITY OF BIRMINGHAM; UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA; Advanced Practical Diagnostics; QUEEN MARY AND WESTFIELD COLLEGE, UNIVERSITY OF LONDON; UNIVERSITA DEGLI STUDI DI CATANIA; Concentris Research Management GmbH; UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF; VADASKERT ALAPITVANY A GYERMEKEK LELKI EGESZSEGEERT; UNIVERSITAET ZUERICH; FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA; REGION HOVEDSTADEN; MEDIZINISCHE HOCHSCHULE HANNOVER; GUYS AND ST THOMAS' NHS FOUNDATIONTRUST; Azienda Sanitaria Locale della Provincia di Bari",2011,2016,Alto
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,Cerebellar magnetic stimulation: a potential new approach to treat patients with dystonia,Neurología,Cerebellar magnetic stimulation. To  investigate how the induction of long-term synaptic plasticity in the human cerebellum may reduce sustained involuntary muscle contractions in patients with dystonia.,Activo,Cerebellar magnetic stimulation,"Giacomo Koch, IRCCS S. Lucia Foundation, Rome, Italy",Alto,Alto,Jacques and Gloria Gossweiler Foundation  Research grants in the field of Neurology,NO,"Giacomo Koch, IRCCS S. Lucia Foundation, Rome, Italy",2011,2013,Medio
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,RED IBEROAMERICANA SOBRE PNEUMOCYSTOSIS,Enfermedades respiratorias,"IBEROPNEUMOCYSTIS. Establecer una Red Iberoamericana de especialistas en Pneumocystosis, que sirva de referencia en el ámbito Iberoaméricano, y permita ahondar en el conocimiento biológico de Pneumocystis jirovecii, su epidemiología y manifestaciones clínicas en el contexto propio de cada país participante, compartiendo conocimientos y desarrollos biotenológicos existentes. Promover la investigación en esta área hacia la optimización de los tratamientos disponibles y los métodos diagnósticos adaptados a la realidad de cada país, sentando las bases para el desarrollo de proyectos de investigación altamente competitivos tanto sobre las implicaciones clínicas de la infección/colonización por P. jirovecii como sobre su biodiversidad, y posibilitar la secuenciación de su genoma.

",Activo,"Enfermedades infecciosas (bacterianas, virales, fúngicas y parasitarias) ",Servicio Andaluz de Salud (SAS),Alto,Alto,Programa Iberoamericano de Ciencia y Tecnología para el Desarrollo (CYTED),NO,"INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ (CUBA); INSTITUTO NACIONAL DE HIGIENE “RAFAEL RANGEL” (Venezuela); CENTRO DE INVESTIGACIÓN Y ESTUDIOS AVANZADOS (Mexico); CENTRO SUPERIOR DE INVESTIGACIÓN EN SALUD PÚBLICA (España); HOSPITAL DE CLÍNICAS DE PORTO ALEGRE, UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL(Brazil); UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL (Brazil);  INSTITUT PASTEUR DE LILLE ET CENTRE INFECTION ET IMMUNITÉ DE LILLE  (Francia); ",2011,2014,Alto
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,Clinical relevance of multiple genetic markers in Pneumocystis jirovecii pneumonia (PcP): New high-throughput methodologies for molecular epidemiology and diagnosis,Genética,"FCT. identification of polymorphic genes associated with specific parameters of infection, as well as to establish Pj genetic haplotypes potentially related with increased disease severity, drug resistance or specific geographical locations.",Activo,Molecular epidemiology/diagnosis; Pneumocystis jirovecii pneumonia (PcP); AIDS; Multiple genetic markers,Portugal,Medio,Medio,FCT (Fundacao para a Ciencia e a Tecnologia),NO,Servicio Andaluz de Salud (SAS),2011,2013,Alto
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,"COST: European Network for the Study of Gilles de la Tourette Syndrome
",Neurología,"COST. To foster the creation of a pan-European, interdisciplinary scientific network with a goal to promote the study of GTS, improve the standards of care, and educate the public and professionals, combating stigmatisation of affected individuals. Best practice guidelines are going to be set and national projects are going to be unified into a large-scale effort that will uncover the genetic basis of GTS and disentangle the interplay between environment and genetics.

",Activo,neuropsychiatric disorder ,"Dept. of Molecular Biology and Genetics, Democritus University of Thrace, Greece",Alto,Alto,PROGRAMA COST - European Cooperation in Science and Technology,NO,"Medizinische Universität Wien; University Hospital Center, Belgica; Charles University, Republica Checa; Kennedy Center, Dinamarca; Copenhagen University Hospital Hvidovre, Dinamarca; University Hospital of Aarhus, Dinamarca; UPMC/INSERM, Francia; Faculty of Medicine University of Skopje, FYROM; University of Ulm, Alemania; Medical School Hannover, Alemania; Universitätsklinikum Carl Gustav Carus Dresden, Alemania; Klinik für Neurologie der Universität Ulm, Alemania; Sismanoglio Hospital, Grecia; Semmelweis University, Hungría; Vadaskert Child and Adolescent Psychiatry, Hungria; City General Hospital, Cork, Irlanda; Tel Aviv University, Israel; Catania University, Italia; Istituto Ortopedico Galeazzi SpA, Italia; University of Malta; Norwegian Resource Center for AD/HD, Tourette Syndrome and Narcolepsy; Medical University of Warsaw, Polonia; University of Bern, Suiza; Birmingham and Solihull Mental Health NHS Foundation Trust (BSMHFT) [Department of Neuropsychiatry], Uk; 




























",2010,2014,Alto
Hospital Clínico San Carlos,Nodo HUVR-FISEVI,Hospital Universitario Virgen del Rocío,Sevilla,41013,Calle Cardenal Ilundain,37.364881,-5.980603,Collaborative Genomic Studies of Tourette’s Disorder,Genética,TIC genetic. Clinical studies,Activo,neuropsychiatric disorder ,"University Medical Center Groningen, Países Bajos ",Alto,Alto,NIH (subaward from Rutgers State University NJ),NO,"University Medical Center Groningen, Países Bajos ",2012,2014,Alto
Hospital Clínico San Carlos,HUMV (Hospital Universitario Marqués de Valdecilla),Hospital Universitario Marqués de Valdecilla,Santander,39008,Av. Valdecilla,43.457991,-3.828395,Estudio del efecto de la dieta sobre el rendimiento de los niños,Neonatología / pediatría,The Effect of Diet on the Mental Performance of Children,Activo,Proyecto coordinado con 18 participantes,Equipo perteneciene al servicio Pediatría del HUMV,3,SI,UE,NO,"University of Granada, 
2 University of Munich Germany
3 UNILEVER The Netherlands
4 Erasmus University Medical Center The Netherlands
5 University Rovira I Virgili Spain
6 University of Surrey UK
7 University of Pécs Hungary
8 University Degli study di Milano Italy
9 University of Warsaw Poland
10 Birmingham Children’s Hospital UK
11 The Children´s Memorial Health Institute. Warsaw Poland
12 Research Institute Hospital Marqués de Valdecilla, Santander Spain
13 Institute for Market Research, Strategy and Planning Germany
14 Université Libre de Bruxelles Belgium
15 SHS International UK
16 University of Bristol UK
17 GSF National Research Centre, Munich Germany
18 Beta Technology Limited",2008,2013,
Hospital Clínico San Carlos,HUMV (Hospital Universitario Marqués de Valdecilla),Hospital Universitario Marqués de Valdecilla,Santander,39008,Av. Valdecilla,43.457991,-3.828395,"Inflammation – Translational Research and Adaptive
Immunity",Reumatología,"The development of new therapeutic agents against RA and RA-like diseases requires a dynamic interaction between studies in humans and in animal models of disease.
BTCure aims to advance this parallel work and bring it to a new level by recognising (1) the need for recognition of pre-symptomatic and emerging disease in humans; (2) the heterogeneous nature of human RA and RA-like diseases; (3) the need for new alignments between several animal models and the variants of human RA and RA-like disease and (4) the
potentials that an increased understanding of adaptive immunity provides for better
prevention, therapy and eventual cure of RA. With these tools at hand, we will be able to use new  understanding of aetiology and early pathology of human disease for a program aimed at
early and curative treatment of human RA and RA-like diseases",Activo,RA and RA-like diseases ,Equipo perteneciene al servicio de Reumatología del HUMV y al IFIMAV,3,SI,IMI,NO,"UCB,  Karolinska Instititutet, Academisch Ziekenhuis Leiden - LUMC, Universitaet Zuerich, University of Leeds UNIVLEEDS
6 Charité Universitätsmedizin Berlin, Amsterdam Medical University Center AMC,  Medizinische Universitaet Wien MUW, Diakonhjemmet Hospital DIAKON, Imperial College of Science, Technology and
Medicine Imperial, Universitätsklinikum Erlangen, University of Manchester, University of Glasgow, Stichting Katholieke Universiteit, 
CSIC, Foundation for Research and Technology-
Hellas (FORTH), IMBB FORTH, Centre Hospitalo Universitaire Montpellier, National University Of Ireland, Revmatologicky ustav, Fondazione Humanitas Per La Ricerca, Biomedical Sciences Research Center, Alexander Fleming’, Vari Institute, Kings College London, Deutsches Rheuma Forschungszentrum Berlin,  TcLand Expression TCLAND, Bristol Myers Squibb, Janssen Biologics, AstraZeneca, Boehringer Ingelheim, Pfizer, NovoNordisk As, Merck Serono, Phadia, Institut National de la Santé",2011,2016,
Hospital Clínico San Carlos,HUMV (Hospital Universitario Marqués de Valdecilla),Hospital Universitario Marqués de Valdecilla,Santander,39008,Av. Valdecilla,43.457991,-3.828395,"Programmes for chronic conditions/case management (including
remote management/monitoring) - Integrated care programmes",Otros,"Network of innovation clusters leaded by healthcare providers sharing vision, knowledge resources and developed tools.
PITeHS will define an innovation model to manage
the products of the different nodes in the following aspects: - New biomedical, contextual and ambient monitoring devices - New
applications and services based on mobile devices and Internet - New process models for care services for chronic and frail people,
focusing in comorbidity and co-disability. - A new Interoperability framework using European open standards based on a double model
strategy (EN13606, EN13940, …) - New strategies of capacitation and e-Learning, based in new interactive programs Social Innovation:
development of patient empowerment support mechanisms and tools",Inactivo,"Ageing Well at Home/Independent Living - Social inclusion -
Diseases and Disorders - Health Systems and Services -
Treatment - Medical Devices",Equipo perteneciente a hospitalización domiciliaria del HUMV,3,SI,No aplica,NO,"Hospital Virgen del Rocío. Seville Sector Sanitario de Barbastro. SALUD. Huesca Hospital Puerta de Hierro. Madrid
Hospital A Coruña. Galicia Hospital Marqués de Valdecilla. Cantabria Hospital Clinic Barcelona Gerencia Atención Primaria. Albacete.
Castilla La Mancha Hospital Fuenlabrada. Madrid Complejo Hospitalario de Navarra. Pamplona Care provider: Red Cross, Madrid Red
Cross. Huesca. Aragón Industry – large: Telefónica I+D. Granada Vodafone Spain EVERIS Health. Zaragoza, Aragón Industry – SME:
BIOECM Soluciones SL. Madrid Wireless Galicia SL. A Coruña, Galicia RGB Medical Devices. Madrid Dialcom Networks SL. Zaragoza,
Aragón Public authority: Institute of Health Carlos III. Ministry of Economy and Competitivity. Service of Research , Innovation, and
Health Education. Dep. of Health. Gov. of Navarra Madrid Network. Regional Gov. Madrid Research/academia: Madrid Scientific Park
CITIC. Seville Public University of Navarra CETEMMSA Technological Centre. Barna",2012,2015,
Hospital Clínico San Carlos,HUMV (Hospital Universitario Marqués de Valdecilla),Hospital Universitario Marqués de Valdecilla,Santander,39008,Av. Valdecilla,43.457991,-3.828395,MICROCLONAL COMPETITION AND CELL PLASTICITY SHAPE CANCER PROGRESSION AND TREATMENT ESCAPE,Genética,"Tumor heterogeneity and cell plasticity can drive the dynamics of tumor growth and therapy
escape. This may help explaining the failure of the therapy targeting the mutated genes present in the main tumour clone. In this line of
evidence, we and others have already generated preliminary observations supporting our hypothesis in light of the microclonal composition
of tumor specimens (such as in Acute Myeloid Leukemia and Chronic Lymphocytic Leukemia) and the role of the microenvironment as
inducer of tumor heterogeneity (In Melanoma and Chronic Lymphocytic Leukemia).",Inactivo,Microclonal competition in cancer; multitargeted therapy.,Equipo perteneciente a Anatomía Patológica del HUMV e IFIMAV,3,SI,No aplica,NO,,2013,2018,
Hospital Clínico San Carlos,HUMV (Hospital Universitario Marqués de Valdecilla),Hospital Universitario Marqués de Valdecilla,Santander,39008,Av. Valdecilla,43.457991,-3.828395,Role of Nramp on Metal Uptake in Protozoan Parasites,Inmunología,"Soluble iron is a virulence factor for microbial pathogens, and that during co-evolution with their hosts, both have developed sophisticated metal trafficking systems. However, knowledge of metal uptake mechanisms in protozoan parasites is sparse compared to those from bacteria and yeasts. Over two decades, our labs have developed critical tools (in vitro culture; genome and transcriptome; transfection system) to enable state-of-the-art approaches for metal
uptake research on the parasite Perkinsus, a close relative of Plasmodium and Toxoplasma parasites. Based on this experience and taking advantage of the available genetic tools for Toxoplasma, we propose to elucidate its metal uptake mechanisms as a model for understanding their role in biomedically relevant parasites. Highly interactive and synergistic Research Projects will be led by scientists with complementary expertise in parasite metal uptake, bioinformatics (Drs Cellier, Vasta), host-parasite interactions (Drs Vasta, Robledo), microbial pathology (Dr Vivas).
Accomplishment of our objectives will provide insight into the relationship between metal uptake and parasite virulence, and lead to novel intervention strategies.",Inactivo,"Nramp transporter, parasitology, structural biology, microbial pathology",Equipo perteneciente a Microbiología del HUMV,3,,HFSP,NO,"UMB-SOM-IMET Baltimore -USA, Cellier, INRS-Institut Armand-Frappier - Canada, University of Maryland School of Medicine",2013,2015,
Hospital Clínico San Carlos,HUMV (Hospital Universitario Marqués de Valdecilla),Hospital Universitario Marqués de Valdecilla,Santander,39008,Av. Valdecilla,43.457991,-3.828395,Novel Methods and Approaches towards the Understanding of Brain Diseases,Neurología,UNDERSTANDING NEURODEVELOPMENTAL MECHANISMS OF SCHIZOPHRENIA: A TRANSLATIONAL STRATEGY INTEGRATING CLINICAL AND BASIC FINDINGS,Inactivo,"Brain, SCHIZOPHRENIA",Equipo perteneciente al servicio de Psiquiatría del HUMV,3,SI,No aplica,no,"Instituto de Neurociencias UMHCSIC, University of Göttingen, IRCCS “E. MEDEA”, ",,,
Hospital Clínico San Carlos,HUMV (Hospital Universitario Marqués de Valdecilla),Hospital Universitario Marqués de Valdecilla,Santander,39008,Av. Valdecilla,43.457991,-3.828395,Neurodegenerative diseasses,Otros,Biomarker based diagnosis of rapid progressive dementias - optimisation of diagnostic protocols,Activo,"Neurodegenerative, dementia",Equipo perteneciente al servicio de Neurología del HUMV,3,SI,UE,NO,"Hopital Lariboisiere AP-HP, UMR-INRA-EVNT, Heinrich Heine University Medical School –Düsseldorf, Ludwig-Maximilians-University Munich, Aristotle University of Thessaloniki, IRCCS Neuromed - Istituto Mediterraneo di Neuroscienze-University “Sapienza”-Rome, Medical University of Lodz, University of Coimbra, Slovak Medical University Bratislava, University Psychiatric Hospital – Ljubljana, Carlos III National Health Institute, CIBERNED, Swedish Institute of Communicable Disease Control, University Hospital Zürich, UCL Institute of Neurology, Western General Hospital",2012,2015,
Hospital Clínico San Carlos,HUMV (Hospital Universitario Marqués de Valdecilla),Hospital Universitario Marqués de Valdecilla,Santander,39008,Av. Valdecilla,43.457991,-3.828395,Neurodegenerative diseasses: Enfermedad de Charcot-Marie-Tooth de type 1A (CMT1A),Neurología,Validation of prognostic and disease biomarkers for Charcot-Marie-Tooth disease 1A,Activo,Neurodegenerative diseasses,Equipo perteneciente al servicio de Neurología del HUMV,3,SI,AFM (Asociación Francesa contra las Miopatías),NO,,2010,2013,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Psiquiatría y salud mental,Psiquiatría,"Enfermedades mentales graves (Desorden Bipolar, Intervención en psicosis, etc)",Activo,,Local,,,Privada,NO,Varios,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Psiquiatría y salud mental,Psiquiatría,"Reacciones psisomáticas y psicobiológico al stress (dolor crónico, psico-oncología, obesidad, VIH, etc)",Activo,,Local,,,Privada,,Varios,2010,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neurología y Enfermedades Crebrovasculares,Neurología,Enfermedades cerebrovasculares,,,,,,,,Janssen-Cilag,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neurología y Enfermedades Crebrovasculares,Neurología,Enfermedades neurodegenerativas. Demencias y trastornos del movimiento,,,,,,,,Varios,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neurología y Enfermedades Crebrovasculares,Neurología,Neuroinmunología. Esclerosis múltiple,,,,,,,,Varios,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neurología y Enfermedades Crebrovasculares,Neurología,Enfermedad neuromuscular y ataxias espinocerebelosas,,,,,,,,Varios,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neurología y Enfermedades Crebrovasculares,Neurología,Enfermedades de motorneurona: Esclerosis lateral amiotrófica,,,,,,,,Varios,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neurología y Enfermedades Crebrovasculares,Neurología,Epilepsia,,,,,,,,Varios,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neurología y Enfermedades Crebrovasculares,Neurología,Trastornos del desarrollo y maduración neurológica (TRADESMA),,,,,,,,Varios,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neurología y Enfermedades Crebrovasculares,Neurología,SIFAP I,,,Internacional,3,,,,University of Rostock,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Enfermedades Neurodegenerativas,Neurología,Transcripción del factor Nrf2 como target para reducción de la neurodegeneración y neuroinflamación en el Parkinson,Activo,,,,,Privada,,Michael J Fox Foundation for Parkinson's Research,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neurobiología de la respuesta inflamatoria,Neurología,Respuesta inflamatoria en pacientes con síndrome coronario agudo,,,,,,,,Novartis,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Investigación en Cardiología Clínica e Invasiva,Patología cardiovasculares,Síndromes Coronarios Agudos: reperfusión y complicaciones en el infarto agudo de miocardio; Estratificación de riesgos a través de marcadores clínicos y biológicos,,,,,,,,Varias privadas,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Investigación en Cardiología Clínica e Invasiva,Patología cardiovasculares,Insuficiencia cardiaca crónica y aguda: pronóstico y tratamiento,,,,,,,,Varias privadas,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Investigación en Cardiología Clínica e Invasiva,Patología cardiovasculares,"Cardilogía intervencionista: intervenciones coronarias, nuevos medicamentos antiarrítmicos, desfibriladores y apnea del sueño.",,,,,,,,Varias privadas,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Epidemiología cardiovascular y nutrición,Patología cardiovasculares,"Epidemiología, prevención y pronóstico de la insuficiencia cardiaca, obesidad e hipertensión arterial",,,,,,,,Varias privadas,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Coagulopatías y alteraciones de la hemostasia,Hematología,Hemofilia A y B,,,,,,,,Angelo Bianchi Bonomi y otros ,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Fisiología y farmacología vascular,Toxicología / Farmacología,Productos derivados del COX y función y remodelado vasculares,,,,,,,,L'Oreal-Unesco,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,SIDA y enfermedades infecciosas,Enfermedades infecciosas,Second line therapy in HIV infection Eastern and Southern Africa,,,,,,,,Earnest Trial,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,SIDA y enfermedades infecciosas,Enfermedades infecciosas,Red Europea EECC Antirretrovirales,,,,,,,,NEAT,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,SIDA y enfermedades infecciosas,Enfermedades infecciosas,Momento de inicio de terapia antirretroviral,,,,,,,,Universidad de Minnesota,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,SIDA y enfermedades infecciosas,Enfermedades infecciosas,Estudio internacional para la caracterización de adultos con gripe A,,,,,,,,Copenhagen HIV Programme,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Micobacterias,Microbiología,Latent Tuberculosis: new tools for the detection and clearance,,,,,,,,UE VII PM,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Micobacterias,Microbiología,Caracterización de plásmidos en micobacterias,,,,,,,,Centro de Estudios de América Latina,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Inmuno-reumatología,Reumatología,Interacciones celulares en pathogénesis y RA,,,,,,,,Roche,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Inmuno-reumatología,Reumatología,Estudio COP,,,,,,,,F. Hoffmann-La Roche,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Inmuno-reumatología,Reumatología,Tratamiento de osteoporosis en mujeres posmenopáusicas y hombres.,,,,,,,,Laboratorios Servier,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Fisiología linfocitaria en inmunodeficiencias,Inmunología,Proyecto EuroFlow,,,,,,,,Mixto,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neonatología,Neonatología / pediatría,Neo Mero,,,,,,,,UE VII PM,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neonatología,Neonatología / pediatría,Neo Circ,,,,,,,,UE VII PM,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neonatología,Neonatología / pediatría,Visceral Leishmaniais and Malnutrition in Ethiopia,,,,,,,,FCSAI,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neonatología,Neonatología / pediatría,Riesgo cardiovascular y cardiopatías congénitas,,,,,,,,Abbot Laboratories,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Nefrología,Neonatología / pediatría,Normalidad funcional peritoneal: líquidos de diálisis,,,,,,,,Varias privadas,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Nefrología,Nefrología / Urología,Nefropatía Diabética,,,,,,,,Varias privadas,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Enfermedades respiratorias,Enfermedades respiratorias,Marcadores biológicos en cáncer de pulmón,,,,,,,,Varios,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Enfermedades respiratorias,Enfermedades respiratorias,Asma persistente en adultos,,,,,,,,Novartis,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Hepatología molecular,Hepatología,Hepatitis B crónica en paises occidentales y asiáticos,,,,,,,,Novartis,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Enfermedades alérgicas,Inmunología,Diagnóstico y tratamiento de las enfermedades alérgicas,,,,,,,,UE VII PM,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Instituto de Genética Molecular,Genética,Diagnóstico y determinación de alteraciones genéticas,,,,,,,,Varias,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Oncología traslacional,Oncología,"Estudios diagnóstico y clasificación cáncer pulmón, colorectal y  mama",,,,,,,,"La Roche, varias",,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Enfermedades metabólicas hereditarias,Enfermedades metabólicas,Enfermedad metabólica (Intoxication-type). e-Predice,,,,,,,,UE VII PM,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Genética,Genética,International Cooperative Growth Study,,,,,,,,Biogen,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Enfermedades respiratorias,Enfermedades respiratorias,Asma persistente en adultos,,,,,,,,Novartis,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Cirugía,Cirugía,Mejora de hemostasia en cirugía,,,,,,,,Nycomed,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Cardiología,Patología cardiovasculares,Adiposidad abdominal y cardiopatías,,,,,,,,Pfizer,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Cardiología,Patología cardiovasculares,Prevención fibrilación auricular postoperatoria. Estudio Calypso.,,,,,,,,Sanofi,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Inmuno-reumatología,Reumatología,Artrosis de rodilla,,,,,,,,Lab del Dr. Esteve,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neurología y enfermedades cerebrovasculares,Neurología,Espasticidad de los miembros superiores,,,,,,,,Ipsen,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Modelos celulares y animales para la detección y caracterización de células madre leucémicas,Genética,Mieloma múltiple,,,,,,,,Varios,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Modelos celulares y animales para la detección y caracterización de células madre leucémicas,Genética,Cáncer  medular tiroideo no extirpable,,,,,,,,Merck,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Coagulopatías y alteraciones de la hemostasis,Hematología,Enfermedad EVW-Programa VIP,,,,,,,,Rho Inc,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Inmuno-reumatología,Reumatología,Tratamiento osteoporosis en mujeres posmenopáusicas,,,,,,,,Laboratorios Servier,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neurología y enfernedades cerebrovasculares,Neurología,Predicción del deterioro cognitivo y demencia,,,,,,,,Araclon Biotech,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Patofisiología osea y biomateriales,Biomateriales,Reducción de pérdida osea periprotésica en pacientes con artroplastia total de cadera,,,,,,,,Laboratorios Servier,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Neurología,Neurología,Respuesta secundaria a toxina botulínica en pacientes con distonía cervical idiopática,,,,,,,,Ipsen,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Oncología,Oncología,Leucemia mieloide crónica resistentes a tratamiento ,,,,,,,,Bristol Myers,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Enfermedades cerebrovasculares y neurológicas,Neurología,Registro europeo de uso de fármacos antiepilépticos en pacientes SLG,,,,,,,,Varios,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Grandes sistemas,Otros,Clasificación de adultos que padecen síntomas de ERGE y descripción de los perfiles de síntomas más frecuentes y sus características,,,,,,,,Janssen Cilag,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Enfermedades cerebrovasculares y neurológicas,Neurología,Estudio observacional europeo en pacientes con epilepsia que requieren al menos dos fármacos antiepilépticos,,,,,,,,Glaxo Smith Klne Research and Development,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Oncología,Oncología,Estudio europeo sobre el dolor neuropático oncológico (Europecan),,,,,,,,Pfizer,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Terapias experimentales y biomarcadores en cáncer,Genética,Identificación de perfiles de expresión génica para identificación de pacientes resistentes a tratamiento con quimio.,,,,,,,,Varias privadas,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Cirugía de malformaciones congénitas,Cirugía,Cirugía fetal,,,,,,,,Varios,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Terapia Celular y genometástasis,Genética,Terapia celular con células derivadas de la grasa para el tratamiento de varias patologías fistulosas.,,,,,,,,Varios,,,
Hospital Clínico San Carlos,IdiPAZ,Hospital Universitario La Paz,Madrid,28046,Paseo de la Castellana 261,40.472398,-3.687230,Ingeniería celular,Oftalmología,Transplante de endotelia corneal,,,,,,,,Varios,,,
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,Investigación clínica en psiquiatría y salud mental,Psiquiatría,"CHILDTRAUMA: PSYCHOLOGICAL NETWORK SUPPORT TO VIOLENCE TRAUMATIZED CHILDREN: DISASTERS, CONFLICTS",Inactivo,"trauma; víctimas; catástrofes naturales; atentados; guerras. 
","López-Ibor Aliño, Juan José ",3,SI,CE (6º PM),NO,9 entidades. España es coordinador del proyecto,2005,2008,3
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,Unidad de Arritmias,Patología cardiovasculares,MYHEART: Fighting cardio-vascular diseases by prevention and early diagnosis,Inactivo,"Cardiology, chronic diseases, information processing, IBC Intelligent Biomedical Clothes","Pérez VillaCastín, Julián ",3,SI,CE (6º PM),NO,42 Entidades forman el consorcio,2003,2009,3
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,Alergías,Enfermedades respiratorias,"EUROPREVAL: The Prevalence, Cost and Basis of Food Allergy across Europe",Inactivo,"Food, Allergy, Epidemiology, Health and Well-being","Fernández Rivas, Montserrat ",3,SI,CE (6º PM),NO,69 Entidades forman el consorcio,2005,2009,3
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,Hematología,Hematología,ithanet: Infrastructure for thalassaemia Research Network,Inactivo,,"Villegas Martínez, Ana ",3,SI,CE (6º PM),NO,,2006,2008,3
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,Unidad de Arritmias,Patología cardiovasculares,HEARTCYCLE: Compliance and effectiveness in HF and CHD closedloop management,Activo,"Cardiovascular Disease, Heart Failure, hypertension, diabetes, arrhythmias ","Pérez VillaCastín, Julián ",3,SI,CE (7º PM),,18 Entidades forman el consorcio,2008,2012,3
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,Unidad de Arritmias,Patología cardiovasculares,EUHEART: Personalised & Integrated Cardiac Care: Patient-specific Cardiovascular Modelling and Simulation for In Silico Disease Understanding & Management and for Medical Device Evaluation & Optimization,Activo,"ICT, computational models, biophysical models, cardiac groups, multi-modal images, valvular, aortic, ventricular assist, cardiac rhythm  ",Julián Pérez VillaCastín,,SI,CE (7 PM),NO,18 Entidades forman el consorcio,2008,2012,3
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,"Tecnología, diseño e innovación quirúrgica",Diagnóstico por imagen / Medicina Nuclear / Radiología,"AMI4EUROPE: Advanced, Cross-Disciplinary & Integrated Medical Imaging for all Europeans through a Network of Regional Clusters and Development Strategies",Activo,"NANOMEDICINE, ICT-FOR HEALTH, ADVANCE
MEDICAL IMAGING","Mayol Martínez, Julio Ángel",3,SI,CE (7 PM),NO,22 Entidades forman el consorcio,2010,2013,3
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,Endocrinología de enfermedades metabólicas,Endocrinología,METABO: CONTROLLING CHRONIC DISEASES RELATED TO METABOLIC DISORDERS,Activo,"comprehensive platform, multi-parametric, metabolic, diabetes ","CALLE PASCUAL, ALFONSO LUIS",3,SI,CE (7 PM),NO,21 Entidades forman el consorcio,2008,2012,3
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,Imagen Cardiovascular,Diagnóstico por imagen / Medicina Nuclear / Radiología,EVINCI: EVALUATION OF INTEGRATED CARDIAC IMAGING FORMTHE DETECTION AND CHARACTERIZATION OF ISCHEMIC HEART DISEASE,Activo,"CORONARY HEART DISEASE, IMAGING, SCINTIGRAPHY, POSITRON, EMISSION TOMOGRAPHY, MAGNETIC RESONANCE IMAGING, ECHOCARDIOGRAPHY","Zamorano Gómez, José Luis",3,SI,CE (7 PM),NO,17 Entidades forman el consorcio,2009,2012,3
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,Imagen Cardiovascular,Diagnóstico por imagen / Medicina Nuclear / Radiología,"DOPPLER: Determining Optimal non-invasive Parameters for the Prediction of LEft
- ventricular morphologic and functional Remodeling in Chronic Ischemic Patients",Activo,cardiac imaging; chronic ischemic heart disease; prognosis; remodelling,"Zamorano Gómez, José Luis",3,SI,CE (7 PM),NO,,2009,2014,3
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,Diabetes Mellitus/Obesidad,Endocrinología,YLIOPISTO: Trial to Reduce IDDM in the Genetically at Risk -study. ,Activo,,"Serrano Ríos, Manuel",3,SI,National Institutes of Health (NIH) EEUU,NO,16 Entidades forman el consorcio,2002,2014,
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,Técnicas de Imagen de Diagnóstico Intracoronario,Patología cardiovasculares,"PRESTIGE: PREvention of Late Stent Thrombosis by an Interdisciplinary Global
- European effort ""
",Activo,,"Alfonso Manterola, Fernando",3,SI,,,,,,
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,Alergías,Enfermedades respiratorias,FAST: TOWARDS SAFE AND EFFECTIVE IMMUNOTHERAPY OF PERSISTENT LIFE-THREATENING FOOD ALLERGIES,Activo,"food allergies, healthy diet, allergen-specific immunotherapy, hypo-allergenic, allergen ","Fernández Rivas, Montserrat ",3,SI,CE (7 PM),NO,15 Entidades forman el consorcio,2008,2015,3
Hospital Clínico San Carlos,Hospital Clínico San Carlos,Hospital Clínico San Carlos,Madrid,28040,Calle Profesor Martín Lagos,40.439837,-3.718964,Neurociencias Aplicadas (alt: Neuromodulación y neuroreparación),Neurología,GINA: Biomaterials scaffolding for brain reconstruction in stroke,Activo,"mammals, ischaemic zones, scaffolding materials ","Barcia Albacar, Juan Antonio",3,SI,MICINN (ERANET NEURON),NO,5 Entidades forman el consorcio,2011,2014,3
Hospital Clínico San Carlos,IRYCIS,Hospital Universitario Ramón y Cajal,Madrid,28034,"Carretera de Colmenar Viejo, km 9",40.484283,-3.690368,"ÁREA 4 IRYCIS. EPIDEMIOLOGÍA CLÍNICA
Línea de Investigación: ""Métodos para la investigación en epidemiología clínica”; sublínea ""Diagnóstico e impacto de las reacciones alérgicas"": En esta sublínea se encuentran aplicaciones concretas de la epidemiología clínica al diagnóstico clínico y molecular de la alergia a los alimentos, el estudio de su impacto socioeconómico y sobre la calidad de vida y al diagnóstico de las reacciones anafilácticas en las mastocitosis",Otros,"The Prevalence, Cost and Basis Food Allergy Across Europe",,Descripción de inmunofenotipos en niños con alergia persistente a proteinas de leche de vaca mediante un ensayo microarray de peptidos,Dra. Belén de la Hoz Bachiller,1,,UNIÓN EUROPEA,,,2007,,
Hospital Clínico San Carlos,IRYCIS,Hospital Universitario Ramón y Cajal,Madrid,28034,"Carretera de Colmenar Viejo, km 9",40.484283,-3.690368,"ÁREA 2 IRYCIS: MICROBIOLOGÍA, INMUNOLOGÍA E INFECCIÓN. Grupo de Investigación: Biología y evolución de los microorganismos.
Línea de Investigación: Biología y evolución de las poblaciones, comunidades y sistemas microbianos, en particular en relación con la resistencia a antimicrobianos y su capacidad patogénica y epidemigénica. Sublínea ""Epidemiología de la Resistencia a Antibióticos""

",Microbiología,"""Translational Research on Combating Antimicrobial Resistance     HEALTH-F3-2008-223031""",,,Dr. Rafael Cantón  Moreno,1,,UNIÓN EUROPEA,,"1. INSTITUT D’INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER (IDIBAPS)
INSTITUTO DE TECNOLOGIA QUÍMICA E BIOLÓGICA - UNIVERSIDADE NOVA DE
LISBOA, (ITQB)
4. UNIVERSITÉ DE CAEN BASSE NORMANDIE, (UCBN)
5. ETHNIKI SCHOLI DIMOSIAS YGEIAS EIDIKOS LOGARIASMOS EREVNON , NATIONAL
SCHOOL OF PUBLIC HEALTH (NSPH)
6. TERVEYDEN JA HYVINVOINNIN LAITOS (THL)
7. UNIVERSITÀ DEGLI STUDI DI SIENA, (UNISI)
8. ACADEMISCH ZIEKENHUIS GRONINGEN, (UMCG)
9. EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES,
(ESCMID)
10. UNIVERSITE PARIS-SUD,
11. UNIVERSITY OF BATH, (UBath)
12. ROBERT KOCH INSTITUTE, (RKI)
13. HEALTH PROTECTION AGENCY, (HPA)
14, SERVICIO MADRILEÑO DE SALUD, (SERMAS)
15. SISTEMAS GENÓMICOS SL, (SG)",2009,2012,
Hospital Clínico San Carlos,IRYCIS,Hospital Universitario Ramón y Cajal,Madrid,28034,"Carretera de Colmenar Viejo, km 9",40.484283,-3.690368,ÁREA 3 IRYCIS: PATOLOGÍAS DE SISTEMAS  Y CÁNCER. Grupo de Investigación: Respuesta celular a isquemia. Línea de investigación:  Respuesta celular a isquemia,Otros,Good  Practice in Tradional Chinese Medicine Research in the Post-Genomic Era,,,Dra. Laura García Bermejo,1,,UNIÓN EUROPEA,,"King’s College London (KCL)
University of Vienna (UV)
L'Université Libre de Bruxelles (ULB)
Beijing University of Traditional Chinese Medicine (BUTCM)
Capital Medical University (CMU) 
Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences
Shanghai Institute of Acupuncture-Moxibustion and Meridians (SIAMM)
Shanghai University of Traditional Chinese Medicine (SUTCM)
University of Hong Kong (UHK)
Asper Biotech Plc (AB)
FibroTx Plc (FT)
VTT Technical Research Centre of Finland (VTT)
Dr. Willmar Schwabe GmbH & Co. KG (WSG)
Federal Institute for Drugs and Medical Devices (FIDMD)
The Heinrich-Heine-University of Düsseldorf (HHU)
University of Bonn (UB)
University of Hamburg (UH)
Trinity College Dublin (TCD)
University of Milan (UM)
University of Padova (UP)
Biohorma B.V (BH)
CMC Tasly Group BV (CMC)
Leiden University (LU)
University of Minho (UM)
University of Alcala (UA)
Foundation for Ramón y Cajal Hospital Research (FIBio-HRC)
Acu-herb Consultant, Sheffield (AHCS)
Phynova Plc
Royal Botanic Gardens, Kew (RBGK)
University of Cambridge (UC)
University of Southampton (US)
",2009,2012,
Hospital Clínico San Carlos,IRYCIS,Hospital Universitario Ramón y Cajal,Madrid,28034,"Carretera de Colmenar Viejo, km 9",40.484283,-3.690368,"ÁREA 2 IRYCIS: MICROBIOLOGÍA, INMUNOLOGÍA E INFECCIÓN. Grupo de Investigación: Biología y evolución de los microorganismos.
Línea de Investigación: Biología y evolución de las poblaciones, comunidades y sistemas microbianos, en particular en relación con la resistencia a antimicrobianos y su capacidad patogénica y epidemigénica. Sublínea ""Epidemiología de la Resistencia a Antibióticos""

",Microbiología,"""Translational Research on Combating Antimicrobial Resistance     HEALTH-F3-2008-223031""",,,Dr. Fernando Baquero Mochales,1,,UNIÓN EUROPEA,,"UPPSALA UNIVERSITET, the Coordinator (UU)
STATENS SERUM INSTITUT (SSI)
SERVICIO MADRILEÑO DE SALUD (SERMAS)
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CNB)
UNIVERSITAET ZUERICH (UZH)
INSTITUT PASTEUR (IP)
UNIVERSITY OF LEEDS (UNIVLEEDS)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
CARDIFF UNIVERSITY (CU)
UNIVERSITY OF SHEFFIELD (USFD)
UN
",2010,2013,
Hospital Clínico San Carlos,IRYCIS,Hospital Universitario Ramón y Cajal,Madrid,28034,"Carretera de Colmenar Viejo, km 9",40.484283,-3.690368,"ÁREA 4: EPIDEMILOGÍA CLÍNICA. “Métodos para la investigación en epidemiología clínica”. Sublínea ""Transferencia de resultados y conocimientos""",Microbiología,"U.E. EBM-CONNECT: Evidence-based Medicine CollaboratioN NEtwork for guideline development, teaChing and disseminaTion",,,Dr. Javier Zamora  Romero,1,,UNIÓN EUROPEA,,"(1)  Queen Mary, University of London
(2) World Health Organization of Switzerland
(3)  Academisch Medisch Centrum bij de Universiteit van Amsterdam of the Netherlands
(4)     Servicio Madrileno De Salud of Spain
(5)     The University of British Columbia of Canada

(6)     Centro Rosarino de Estudios Perinatales of Argentina

(7) The University of Birmingham whose administrative offices are at Edgbaston, Birmingham, B15 2TT, United Kingdom (hereinafter “Birmingham”); 
(7)     Shanghai Institute of Planned Parenthood Research of China
",2010,2014,
Hospital Clínico San Carlos,IRYCIS,Hospital Universitario Ramón y Cajal,Madrid,28034,"Carretera de Colmenar Viejo, km 9",40.484283,-3.690368,"ÁREA 3 IRYCYS: Patologías de Sistemas y Cáncer. Grupo Grupo Epidemiología Molecular y Marcadores Predictivos de Cáncer . Línea:  Cáncer de páncreas exocrino. 

",Oncología,"Canceralia: Development of novel diagnostic and therapeutic approaches to improve patient outcome in lung and pancreatic tomours. health-f2-2011-259737

",,,Dr. Alfredo Carrato Mena,1,,UNION EUROPEA,,"
CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO),UNIVERSITY OF LIVERPOOL (ULIV), 
IMPERIAL COLLEGE OF LONDON (ICL)
Thoraxklinik-Heidelberg gGmbH (UHEI),
KATHOLIEKE UNIVERSITEIT LEUVEN (KULeuven)
GE HEALTHCARE MEDICAL DIAGNOSTICS (GEHC-MDx), ",2011,2014,
Hospital Clínico San Carlos,IRYCIS,Hospital Universitario Ramón y Cajal,Madrid,28034,"Carretera de Colmenar Viejo, km 9",40.484283,-3.690368,"ÁREA 2 IRYCIS: MICROBIOLOGÍA, INMUNOLOGÍA E INFECCIÓN. Grupo de Investigación: Biología y evolución de los microorganismos.
Línea de Investigación: Biología y evolución de las poblaciones, comunidades y sistemas microbianos, en particular en relación con la resistencia a antimicrobianos y su capacidad patogénica y epidemigénica. Sublínea ""Epidemiología de la Resistencia a Antibióticos""

",Microbiología,EVOTAR: Evolution and transfer fo antibiotic resistance. HEALTH-F3-2011-282004,,,Dr. Fernando Baquero Mochales,1,,UNION EUROPEA,,"1 Universitair Medisch Centrum Utrecht NL
2 Servicio Madrileño de Salud - Instituto Ramón y Cajal de Investigación
Sanitaria SP
3 Agencia Estatal Consejo Superior de Investigaciones Científicas SP
4 Uppsala University SE
5 Danmarks Tekniske Universitet DK
6 Wageningen Universiteit NL
7 University of Copenhagen DK
8 Université Paris VII FR
9 Da Volterra FR
10 Universidad de Cantabria SP
11 Institut Pasteur FR
12 Instituto Biomar S.A. SP
13 Universidad Complutense de Madrid SP
14 Institut National de la Recherche Agronomique FR
15 The University of Edinburgh UK
16 University of Siena IT
17 MicroDish",2011,2015,
Hospital Clínico San Carlos,IRYCIS,Hospital Universitario Ramón y Cajal,Madrid,28034,"Carretera de Colmenar Viejo, km 9",40.484283,-3.690368,"ÁREA 2 IRYCIS: MICROBIOLOGÍA, INMUNOLOGÍA E INFECCIÓN. Grupo de Investigación: Biología y evolución de los microorganismos.
Línea de Investigación: Biología y evolución de las poblaciones, comunidades y sistemas microbianos, en particular en relación con la resistencia a antimicrobianos y su capacidad patogénica y epidemigénica. Sublínea ""Epidemiología de la Resistencia a Antibióticos""

",Microbiología,U.E. R-GNOSIS: Resistance in Gram-Negative Organism: Studying intevention strategies. HEALTH-F3-2011-282512,,,Dr. Rafael Cantón Moreno,1,,UNION EUROPEA,,"
University Medical Centre Utrecht
Université de Genève
Universiteit Antwerpen
Tel-Aviv Sourasky Medical Centre
Health Protection Agency
Université Paris Val de Marne
Université Paris Sud (Hôpital de Bicêtre)
Cardiff University
Southampton University
Spanish Society of Family Medicine
Hopital de la Charité
Da Volterra
Université Paris VII - Diderot
Statens Serum Institut
Oxford University
ARTTIC
Check-Points Health
GENEWAVE
AptaTeck bio LTD",2011,2016,
Hospital Clínico San Carlos, Gregorio Marañón - Universidad Carlos III (Itto de Investigación Sanitaria Gregorio Marañón),Hospital General Universitario Gregorio Marañón,Madrid,28007,Doctor Esquerdo 46,40.418835,-3.669297,Imagen molecular ,Diagnóstico por imagen / Medicina Nuclear / Radiología, Desarrollo de un equipo híbrido de imagen tomográfica de fluorescencia y tomografía computerizada para preclínica (FMTXCT),Activo, FMTXCT Hybrid fluorescence molecular tomography X-ray computed tomography,"Juan José Vaquero (Dpto. de Bioingeniería,UC3M), Vasilis Ntziachristos ( Coordinator, Institute for Biological and Medical Imaging, GSF)",3,SI,CE (VIIPM),NO,"Forschungszentrum fuer Umwelt und Gesundheit (GSF) (coordinador)
Commissariat a  L'Energie Atomique (CEA)
Foundation for Research and Technology Hellas (FORTH)
University College of London (UCL)
Universität Zürich (UZH)
Verfahren und Apparate der Medizinischen Physik (VAMP)
",2008,2012,2
Hospital Clínico San Carlos, Gregorio Marañón - Universidad Carlos III (Itto de Investigación Sanitaria Gregorio Marañón),Hospital General Universitario Gregorio Marañón,Madrid,28007,Doctor Esquerdo 46,40.418835,-3.669297,Imagen molecular ,Diagnóstico por imagen / Medicina Nuclear / Radiología,Mejora del diagnósitco de tuberculosis a través de nuevas técnicas de imagen molecular,Activo,Model-based preclinical  anti-tuberculosis drug combinations,"Juan José Vaquero (Dpto. de Bioingeniería,UC3M),",3,SI,"CE (IMI), EFPIA",NO,"GlaxoSmithKline Invest y Desarrollo (COORDINADOR) University of Liverpool (ULIV) - Coordinador Científico
Sanofi Aventis R&D        Uppsala University (UUPP)
Max Planck Institute of Molecular Cell Biology and Genetics, Dresden (MPI-CBG)
Max Planck Institute for Infection Biology, Berlin (MPI-IB)
Erasmus University Medical Centre, Rotterdam (EUMC)
Health Protection Agency, Porton Down (HPA-PD)
Institut Pasteur, Paris (IP-P)
Helperby Therapeutics (HPBY)
University of St Andrew’s (USTAN)
Global Health Institute, Ecole Polytechnique Federale Lausanne (EPFL)
University of Leicester (ULEIC)
University College London (UCL)
VU university medical center, Amsterdam (VUMC)
Microsens (MCSN)
ZFScreens BV(ZF-S)
Point to Point (P2P)
GABO-mi (GABO)
Liverpool School of Tropical Medicine (LSTM)",2012,2016,3
Hospital Clínico San Carlos, Gregorio Marañón - Universidad Carlos III (Itto de Investigación Sanitaria Gregorio Marañón),Hospital General Universitario Gregorio Marañón,Madrid,28007,Doctor Esquerdo 46,40.418835,-3.669297,Geriatría,Otros,Desarrollo de soluciones TIC para la prevención de caídas ,Activo,Integrated Prevention  Detection sOlutioNs Tailored population  risks Factors associated with fALLs,"D. José Antonio Serra, Dª Nuria Montero, D. Javier Liarte  (Servicio de Geriatría Hosp. Gregorio Marañón)",2,SI,CE ( Competitiveness and Innovation Framework Programme (CIP actions),NO,"

Engineering - Ingegneria Informatica SPA
Singular Logic S.A.
Universitat Politechnica De Catalunya
Scuola Superiore Sant’Anna
Fondazione Santa Lucia
Stichting Nationaal Ouderenfonds
Frontida Zois 
Fundacio Hospital Asil de Granollers 
Social Welfare Centre of the Municipality of Kifisia
Azienda Usl Di Forli
Klinisk Informatik
Municipality of Stari Grad
DOCOBO
TESAN",,,
Hospital Clínico San Carlos, Hospital General Universitario Gregorio Marañón,Hospital General Universitario Gregorio Marañón,Madrid,28007,Doctor Esquerdo 46,40.418835,-3.669297,Dosimetría,Toxicología / Farmacología,Creating a sustainable network in biodosimetry that involves a large number of experienced laboratories throughout European Union (EU) will significantly improve dose assessment capacity,Activo,European Network in Biodosimetry ,"D. Rafael Herranz, Dª Mercedes Moreno, Dª Mª Jesús Prieto (Oncología Radioterápica del Hosp. Gregorio Marañón)",3,SI,CE (CSA (Coordination and Support Action)-) ,NO,"Bundesamt für Strahlenschutz (BfS), Germany   
Bundeswehr Institut für Radiologie in verbindung mit der Universtität Ulm (BIR), Germany  
 Commissariat a l´Energie Atomique, France   
Agenzia Nazionale per le Nuove Tecnologie, L´Energia e lo Sviluppo Economico Sostenibile Italy
 Helmholtz Zentrum München (HMGU), Germany   
Health Protection Agency (HPA), United Kingdom  
 Institute of Nuclear Chemistry and Technology (INCT), Poland  
 Institutul National de Sanatate Publica Romania   
Institut de Radioprotection et de Sûreté Nucléaire (IRSN), France  
Instituto Superiore di Sanità; (ISS), Italy 
Instituto Tecnologico e Nuclear Portugal   
Hospital Universitario y Politécnico La Fe, Spain
Leiden University Medical Center, The Netherlands
National Center for Radiobiology and Radiation Protection, Bulgaria
National Centre for Scientific Research“Demokritos”, Greece
National Research Institute for Radiobiology & Radiohygiene, Hungary
Norwegian Radiation Protection Authority (NRPA), Norway   
Radiation and Nuclear Safety Protection (STUK), Finland   
Stockholm University (SU), Sweden   
Universitat Autonoma de Barcelona (UAB), Spain   
Universiteit Gent (UGent), Belgium   
University of Tuscia Italy   ",,,
Hospital Clínico San Carlos, Hospital General Universitario Gregorio Marañón,Hospital General Universitario Gregorio Marañón,Madrid,28007,Doctor Esquerdo 46,40.418835,-3.669297,Trasplantes,Otros,define a methodology to assess the performance of organ procurement at hospital level. ,Activo,Organ Donation European Quality System,Dr. José Luis Escalante (Hosp. Gregorio Marañón) ,3,SI,CE(DG SANCO),NO,"AUSTRIA
Medical University of Vienna

CROATIA
Ministry of Health and Social Welfare

FRANCE
Agence de la Biomédecine

GERMANY
Deutsche Stiftung Organtransplantation

ITALY
Fondazione per l’Incremento dei Trapianti d’Organo e di Tessuti FITOT Onlus

POLAND
Poltransplant

PORTUGAL
Autoridade para Serviços de Sangue e de Transplantaçao

ROMANIA
Fundatia pentru Transplant

SPAIN
DTI Foundation

SWEDEN
Karolinska Institute

UNITED KINGDOM
NHS Blood and Transplant

",,,
Hospital Clínico San Carlos, Hospital General Universitario Gregorio Marañón,Hospital General Universitario Gregorio Marañón,Madrid,28007,Doctor Esquerdo 46,40.418835,-3.669297,Psiquiatría y salud mental,Psiquiatría,European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI),Activo,European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI),Dr. Celso Arango,3,SI,CE FP7-HEALTH,NO,"King’s College London
Cardiff University
Central Institute of Mental Health
Ankara Universitesi
Servicio Madrileño de Salud
Academisch Medisch Centrum – Universiteit van Amsterdam
Institut National de la Santé et de la Recherche Medicale (INSERM)
Katholieke Universiteit Leuven
University Mental Health Research Institute
Medizinische Universität Wien
Universität Basel
Universität zu Köln – Universitätsklinikum
Wingz b.v.
E.C.S. International BV
Omega Pro Proje Arastirma Gelistirme ve Danismanlik Ltd Þti
Mediamens B.V.
The University of Hong Kong
Universidad del Pais Vasco
The Chancellor, Masters and Scholars of the University of Cambridge
Royal College of Surgeons in Ireland
Ludwig-Maximilians-Universität München
Universita di Bologna
Universita Degli Studi di Palermo
Dipartimento di Neuroscienze e cliniche
University of Melbourne
",2010,2015,2
Hospital Clínico San Carlos, Hospital General Universitario Gregorio Marañón,Hospital General Universitario Gregorio Marañón,Madrid,28007,Doctor Esquerdo 46,40.418835,-3.669297,Psiquiatría y salud mental,Psiquiatría,OPtimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE),Activo,OPtimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE),Dr. Celso Arango,3,SI,CE FP7-HEALTH,NO,"Medical University Innsbruck
Universitair Centrum St.-Jozef

Psychiatrická klinika LF UK
Psychiatrické centrum Praha

Psychiatric University Centre Glostrup
Psychiatric Center Copenhagen

Institut National de la Santé et de la Reserche Médicale (INSERM)

Central Institute of Mental Health
Technische Universität München
Ludwig-Maximilians University Munich

Sheba Medical Centre

University of Naples SUN

University Medical Center Utrecht

University of Medical Sciences

Tangent Data (tel: 021 3233224)

Hospital General Universitario Gregório
Marañon
Hospital Clínico San Carlos
Instituto de Investigación Hospital 12 de
Octubre
Universidad de Oviedo
Hospital Clinic i Provincial

Privatklinik für Psychiatrie und Psychotherapie Oetwil am See/Zürich
King’s College London
University of Manchester",2010,2016,2
Hospital Clínico San Carlos, Hospital General Universitario Gregorio Marañón,Hospital General Universitario Gregorio Marañón,Madrid,28007,Doctor Esquerdo 46,40.418835,-3.669297,"Cardiovascular, terapia celular en post infarto de miocardio agudo",Patología cardiovasculares,BAMI: Terapia celular para la regeneración de la función cardiaca después de IAM,Activo,The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on all-cause mortality in acute myocardial infarction,Dr. Francisco Fernández Avilés ,3,SI,CE FP7-HEALTH,NO,"QUEEN MARY AND WESTFIELD COLLEGE, UNIVERSITY OF LONDON,                                                  UNIVERSITAET ROSTOCK, JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN , UNIVERSITY COLLEGE LONDON , KATHOLIEKE UNIVERSITEIT LEUVEN , INSTITUT CATALA DE LA SALUT , MEDIZINISCHE HOCHSCHULE HANNOVER , ITÄ-SUOMEN YLIOPISTO , EURAM LIMITED , THE UNIVERSITY OF EXETER, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS , UNIVERSITA CATTOLICA DEL SACRO CUORE , KING'S COLLEGE HOSPITAL NHS TRUST , ZLSKI UNIWERSYTET MEDYCZNY W KATOWICACH , OSLO UNIVERSITETSSYKEHUS HF , REGION HOVEDSTADEN , FAKULTNI NEMOCNICE BRNO , CARDIO3 BIOSCIENCES SA , CARDIOVASCULAR RESEARCH CENTER AALST VZW , T2CURE GMBH ",2011,2016,2
Hospital Clínico San Carlos,BIODONOSTIA,Hospital Donostia,Donostia,20014,Pº Doctor Beguiristain,43.296063,-1.973893,DIGESTIVO,Gastroenterología,HIGH ACCURACY DETECTION OF CYTOKINES AND ITS APPLICATION FOR MEDICAL DIAGNOSTIC AND AUTOINMUNE INFLAMMATORY DISEASES. ,Activo,"DETECTMUNE proposes to develop high resolution detection technology (in the range of 10-20 pg/ml) for these TNF-α and IL-6 cytokines in patient serum samples. Both proteins are considered essential for the establishment of a correlation between their presence in serum and the administration of anti-TNF-α in order to minimise side effects and cost per patient. Moreover, this information, together with clinical history data could be useful to establish a reliable test to decide whether or not a patient should be treated with monoclonal antibodies.",LUIS BUJANDA,,,La entidad financiadora es Departmento de Industria,NO,"LAAS-CNRS- FRANCE
Innopsys- FRANCE

",2011,2013,
Hospital Clínico San Carlos,BIODONOSTIA,Hospital Donostia,Donostia,20014,Pº Doctor Beguiristain,43.296063,-1.973893,EPIDEMIOLOGÍA DEL CÁNCER,Oncología,EUROPEAN CONSUMPTION VALIDATION. DEVELOPING A TRANS-EUROPEAN METHODOLOGY TO STUDY FOOD CONSUMPTION (EFCOVAL)                                                                                                                                                                                                                                 ,Inactivo,The strategic objective of EFCOVAL is to further develop and validate the food consumption instrument (EPIC-SOFT),MARIA PILAR AMIANO ETXEZARRETA,,,COMISIÓN EUROPEA,NO,Centre for Nutrition and Health-National Institute for Public Health and the Environment,2006,2010,
Hospital Clínico San Carlos,BIODONOSTIA,Hospital Donostia,Donostia,20014,Pº Doctor Beguiristain,43.296063,-1.973893,EPIDEMIOLOGÍA AMBIENTAL Y SALUD PÚBLICA,Embriología,VALPROIC ACID MONOTHERAPY IN PREGNANCY AND MAYOR CONGENITAL MALFORMATIONS,Inactivo,"It was assessed the associations between use of valproic acid during
the first trimester and 14 malformations by performing a case–control study
with the use of the European Surveillance of Congenital Anomalies (EUROCAT)
antiepileptic-study database, which is derived from population-based congenitalanomaly
registries.",LARRAITZ ARRIOLA LARRARTE,,,UNIVERSITY OF ULSTER,NO,UNIVERSITY OF ULSTER,2010,2011,
Hospital Clínico San Carlos,BIODONOSTIA,Hospital Donostia,Donostia,20014,Pº Doctor Beguiristain,43.296063,-1.973893,EPIDEMIOLOGÍA AMBIENTAL Y SALUD PÚBLICA,Patología cardiovasculares,"STUDY OF THE INTERPLAY IN GENETIC, BIOCHEMICAL AND LIFESTYLE FACTORS ON CORONARY HEART DISEASE INCIDENCE                                                                                                                                                                                                                         ",Activo,,MIREN DORRONSORO IRAETA,,,UNIVERSITY OF CAMBRIDGE,NO,Cardiovascular Epidemiology Unit-Dept of Public Health & Primary Care-University of Cambridge,2009,2013,
Hospital Clínico San Carlos,BIODONOSTIA,Hospital Donostia,Donostia,20014,Pº Doctor Beguiristain,43.296063,-1.973893,EPIDEMIOLOGÍA AMBIENTAL Y SALUD PÚBLICA,Oncología,EPIC-CVD: INDIVIDUALISED CVD RISK ASSESSMENT: TAILORING TARGETED AND COST-EFFECTIVE APPROACHES TO EUROPE´S DIVERSE POPULATIONS                                                                                                                                                                                                                             ,Activo,"Will improve primary prevention of CVD cross Europe by including information on risk behaviours and lifestyle biomarkers in risk scores and prevention strategies, including in teh context of existing risk factors, genetic make-up and biomarkers of intermediate pathways. The goal is to develop innovative and practical strategies that enhance prediction, promote behavioural change, and personalise prevention.",MIREN DORRONSORO IRAETA,,,COMISION EUROPEA ,NO,Cardiovascular Epidemiology Unit-Dept of Public Health & Primary Care-University of Cambridge,2012,2015,
Hospital Clínico San Carlos,BIODONOSTIA,Hospital Donostia,Donostia,20014,Pº Doctor Beguiristain,43.296063,-1.973893,INFESCCIOSAS,Enfermedades infecciosas," PORTABLE AUTOMATED TEST FOR FAST DETECTION AND SURVEILLANCE OF INFLUENZA (PORTFASTFLU)                                                                                                                                                                           

",Inactivo,"El objetivo principal del proyecto PortFastFlu  es el desarrollo y validación de una prueba rápida o ""point of care system"" para el diagnóstico de la gripe en muestras humanas y animales, que pueda ser utilizada tanto en países desarrollados como en vías de desarrollo. El dispositivo permitirá la detección de la infección por el virus de la gripe de una manera rápida y específica utilizando un cartucho desechable colocado en un instrumento analítico portátil y compacto. ",EMILIO PEREZ TRALLERO,,,,,GENEWAVE-FRANCE,2008,2010,
Hospital Clínico San Carlos,BIODONOSTIA,Hospital Donostia,Donostia,20014,Pº Doctor Beguiristain,43.296063,-1.973893,EPIDEMIOLOGÍA AMBIENTAL Y SALUD PÚBLICA,Salud internacional,"PHYSICAL ACTIVITY, NUTRITION, ALCOHOL, CESSATION OF SMOKIN, EATING OUT OF HOME AND OBESITY        ",Inactivo,,MIREN DORRONSORO IRAETA,,,COMISION EUROPEA ,NO,Universitair Medish Centrum Utrecht-Netherlands,2006,2009,
Hospital Clínico San Carlos,BIODONOSTIA,Hospital Donostia,Donostia,20014,Pº Doctor Beguiristain,43.296063,-1.973893,NEUROCIENCIAS,Genética,THE ROLE OF LRRK2 IN REGULATING CALCIUM STORES IN HUMAN FIBROBLASTS             ,Activo,"The preliminary evidence indicates that LRRK2 may regulate acidic calcium stores, with downstream effects on autophagy as well as a variety of other calcium-dependent cellular events. Thus, mutant LRRK2 may lead to aberrant calcium homeostasis, which could contribute to Parkinson´s disease (PD). The primary objective is to gain a direct understanding of the link between endogenous LRRK2 and calcium stores in a human cell culture model.",MARICRUZ RODRIGUEZ OROZ,,,THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH,NO,,2011,2014,
Hospital Clínico San Carlos,BIODONOSTIA,Hospital Donostia,Donostia,20014,Pº Doctor Beguiristain,43.296063,-1.973893,EPIDEMIOLOGÍA AMBIENTAL Y SALUD PÚBLICA,Genética,AN EXAMINATION  OF THE INTERACTION OF GENETIC AND LIFESTYLE FACTORS ON THE INCIDENCE OF TYPE 2 DIABETES                                                                                                                                                                                                                           ,Inactivo,"Research Line specific objectives
• To ascertain potential cases of type diabetes described within the existing EPIC
databases in order to establish a provisional ‘case’ group.
• To verify the diagnosis of incident T2D in all potential cases.
• To identify a strategy for control selection and to implement this strategy by selecting
suitable control individuals and providing details to allow sample retrieval.
• To retrieve plasma, serum and buffy coat samples from the EPIC central store for
identified cases and controls.
• To establish a central database for all the information collected as part of this project.
• To co-ordinate the activities for designing the analysis of data collected in the InterAct
project for the main effects analysis for genetics, diet, nutrition and physical activity,
and interaction.",LARRAITZ ARRIOLA LARRATE,,,COMISION EUROPEA ,NO,Medical reseach council-United Kingdom,2006,2011,
Hospital Clínico San Carlos,BIODONOSTIA,Hospital Donostia,Donostia,20014,Pº Doctor Beguiristain,43.296063,-1.973893,DIGESTIVO,Gastroenterología,SMART INTEGRATED BIODIAGNOSTIC SYSTEM FOR HEALTHCARE            ,Inactivo,"Driven by clinical applications and MNT & IST technology, SmartHEALTH will develop an open
integrated architecture for new biodiagnostic systems to support European companies exploiting
bioassays or new application concepts. Initial system has a disposable fluidic cartridge with a
desktop base-station linking to the ambient e-Health environment - health cards, patient data,
online services. This concept will be miniaturised and cost engineered into a portable and consumer
product. It will perform multianalyte sensing and interpretation, for nucleic acids, proteins and
others and will handle multiple biological sample types.",LUIS BUJANDA,,,COMISION EUROPEA ,NO,"The University of Newcastle upon Tyne-United Kingdom
 iXscient Ltd -United Kingdom",2005,2010,
Hospital Clínico San Carlos,BIODONOSTIA,Hospital Donostia,Donostia,20014,Pº Doctor Beguiristain,43.296063,-1.973893,EPIDEMIOLOGÍA AMBIENTAL Y SALUD PÚBLICA,Oncología,"EUROPEAN PROSPECTIVE INVESTIGATION INTO CANCER, CHRONIC DISEASES, NUTRICION AND LITFESTYLE       ",Inactivo,"Objective:
1. To coordinate research activities aimed at producing new scientific knowledge on the role of diet, obesity, physical activity, alcohol, tobacco and socioeconomic factors on the risk of cancer, coronary heart disease and stroke in 10 European countries.  
2. To enhance the development of statistical methods for multi-centre, Europe-wide studies on diet and chronic disease (e.g., using multi-level models, models for the detailed calibration of dietary intake assessments), as well as the use of biomarkers of dietary and other exposures to enhance between-country comparability of data. This will be achieved by organizing international scientific work-shops involving scientists in the EPIC network and other European institutions.  Scientific reports will be prepared by the end of year 2.

3. To disseminate knowledge on hypotheses and results from major European studies, including EPIC, in the field of diet and chronic disease, as well as on methodological issues related to biomarkers development and statistical analysis of multicentre, European studies. ",MIREN DORRONSORO IRAETA,,,COMISION EUROPEA ,NO,International Agency for Research and Cancer-France,2005,2011,
Hospital Clínico San Carlos,BIODONOSTIA,Hospital Donostia,Donostia,20014,Pº Doctor Beguiristain,43.296063,-1.973893,EPIDEMIOLOGÍA AMBIENTAL Y SALUD PÚBLICA,Salud internacional,INDIVIDUAL FOOD CONSUMPTION DATA AND EXPOSURE ASSESSMENT STUDIES FOR CHILDREN         ,Inactivo,,PILAR AMIANO ETXEZARRETA,,,GHENT UNIVERSITY DEPARTMENT OF PUBLIC HEALTH,NO,Ghent university,2008,2011,
Hospital Clínico San Carlos,BIODONOSTIA,Hospital Donostia,Donostia,20014,Pº Doctor Beguiristain,43.296063,-1.973893,EPIDEMIOLOGÍA AMBIENTAL Y SALUD PÚBLICA,Salud internacional,INNOVATION OF DIETARY ASSESSMENT METHODS IN EPIDEMIOLOGICAL STUDIES AND PUBLIC HEALTH  ,Inactivo,,PILAR AMIANO ETXEZARRETA,,,COMISION EUROPEA ,NO,German Institute of Human Nutrition-Germany,2007,2011,
Hospital Clínico San Carlos,IGTP-Fundació Privada Institut de Neurorehabilitació Guttmann,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,"Bioingeniería aplicada a la autonomía funcional de las personas (Tiene como objetivo principal el desarrollo y la innovación de sistemas de rehabilitación eficaces, eficientes, ecológicos y divertidos para el paciente, integrando fundamentos de neurociencia con soluciones de robótica, informática, realidad aumentada y retroalimentación sobre el nivel de ejecución en tiempo real basada en inteligencia artificial)",Rehabilitación,"BRAINABLE (Proyecto de I+D para investigar la utilidad y viabilidad de sistemas no invasivos de registro de la actividad cerebral aplicados al control de ayudas técnicas, sistemas domóticos, entornos virtuales y estimulación y rehabilitación cognitiva)",Activo,"Brain computer interface, disabled people, autonomy, assistive tecnologies",Josep Medina / Felip Miralles,2,SI,FP7 - ICT,,"Empresas, centros tecnológicos y universidades europeos",2010,2012,2
Hospital Clínico San Carlos,IGTP-Fundació Privada Institut de Neurorehabilitació Guttmann,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,"Bioingeniería aplicada a la autonomía funcional de las personas (Tiene como objetivo principal el desarrollo y la innovación de sistemas de rehabilitación eficaces, eficientes, ecológicos y divertidos para el paciente, integrando fundamentos de neurociencia con soluciones de robótica, informática, realidad aumentada y retroalimentación sobre el nivel de ejecución en tiempo real basada en inteligencia artificial)",Rehabilitación,"WAY (El objetivo de este proyecto es desarrollar y evaluar ayudas técnicas para la mano, prótesis u ortesis, con tecnologías no invasivas que unen el dispositivo electrónico con la voluntad del paciente mediante la combinación de señales biológicas y la aplicación de feedback sensorial)",Activo,"Hand orthotics and prosthetics, brain computer interface, disabled people",Josep Medina / Maria Chiara Carrozza,2,SI,FP7 - ICT,,"Empresas, centros tecnológicos y universidades europeos",2011,2014,2
Hospital Clínico San Carlos,IGTP-Fundació Privada Institut de Neurorehabilitació Guttmann,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,"TICs aplicadas a la rehabilitación neuropsicológica y estimulación cognitiva (El objetivo es aplicar tecnologías de la información y la comunicación para desarrollar una plataforma de rehabilitación neuropsicológica computarizada, aplicable a través de sistemas de telemedicina)",Rehabilitación,"CLEAR (Estudio de viabilidad de una plataforma de telerrehabilitación a nivel europeo. Participamos a través de PREVIRNEC, abordando el problema de la rehabilitación cognitiva en personas mayores de 45 años, entendiendo que el DCA previo acelera el proceso de deterioro cognitivo atribuible exclusivamente a la edad)",,"Telerehabilitation, disabled people, cognitive rehabilitation, elderly people",Teresa Roig / Sandro Scatareggia,2,SI,FP7 - ICT PSP,,"Empresas, centros tecnológicos y universidades europeos",2008,2012,2
Hospital Clínico San Carlos,IGTP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Development a device that allows easy and reproducible measurements of Bioimpedance at lung level to measure thoracic congestion in Hearth Failure patients,Patología cardiovasculares,Bio-Impedance Monitor vest in patients admitted with Heart Failure Trial:  BIM-HeFT,Activo,Monitorización de la impedancia producida por extravasación de líquido a la cavidad torácica en pacientes con fallo cardíaco,Antoni Bayés-Genís,3,SI,Philips,,Empresas,2011,2012,3
Hospital Clínico San Carlos,IGTP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Bioimplantes y monitorización online: el concepto “Smart Patch” (Tiene como objetivo abordar nuevas matrices bioactivas con células regenerativas con monitorización online de viabilidad del tejido miocárdico) ,Patología cardiovasculares,Desarrollo de una nueva generación de dispositivos de sistema de telemonitorización en el hogar: Heartcycle,Activo,Fundació La Marató de TV3. Este proyecto se basa en la aplicación de un implante bioactivo con sensores electrónicos incorporados en una membrana microporosa cargada con factores neoangiogénico y células madre para la regeneración del miocardio tras un infarto agudo en un modelo porcino.,Antoni Bayés-Genís,3,SI,Marató TV3,,Empresas y Hospitales europeos ,2008,2011,3
Hospital Clínico San Carlos,IGTP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,"Bioingeniería aplicada a la regeneración cardíaca (Tiene como principal objetivo el desarrollo de matrices biológicas con capacidad de liberar células madre, factores angiogénicos y seguimiento on-line para reparar la cicatriz postinfarto de miocardio)",Patología cardiovasculares,,Activo,SAF 2011. Se basa en la implantación de células progenitoras derivadas de grasa epicárdica mediante un parche de fibrina en el modelo murino de infarto agudo de miocardio. También se usará el modelo porcino de infarto para etstar el efecto protector de un parche de segunda generación: un implante bioactivo electrónico constituido por estas células previamente estimuladas electromecánicamente dentro de una matriz porosa con microelectrodos para facilitar el seguimiento de la viabilidad y regeneración dinámica del miocardio lesionado.,Antoni Bayés-Genís,3,SI,Philips,,"Empresas y Hospitales europeos de renombre (Alemania, Reino Unido)",2011,2012,3
Hospital Clínico San Carlos,IGTP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Implantes avanzados y materiales bioactivos para la regeneración cardíaca (Tiene como principal objetivo desarrollar una plataforma biotecnológica consistente en obtener células progenitoras preentrenadas electromecánicamente e implantarlas dentro nuevas matrices  biodegradables que permitan la supervivencia y diferenciación de las células hacia nuevo tejido miocárdico funcional.,Biomateriales,Regeneration of Cardiac Tissue Assisted by Bioactive Implants (RECATABI),Activo,RECATABI. Pataforma de bioingeniería con células progenitoras preestimuladas  electromecánicamente en cultivo e implantadas dentro de una nueva matriz biodegradable y compatible en un modelo de infarto de miocardio en oveja.,Antoni Bayés-Genís,3,SI,Unión europea (7th Framework Programme),,"Fraunhofer Institute for Cell Therapy & Immunology (Leipzig), Association CARDIO-MONDE, Laboratory of Biosurgical Research (París)",2009,2012,3
Hospital Clínico San Carlos,IGTiP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Fisiología del Ictus,Neurología,,Activo,,Teresa Gasull,3,SI,Pública y Privada,NO,Ferrer International,2008,,3
Hospital Clínico San Carlos,IGTiP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Recuperación del ictus,Neurología,,Activo,,Teresa Gasull,3,SI,Pública y Privada,NO,"Pittsburg University Medical Center, Tyco Healthcare Group LP, dba Covidien",2008,,2
Hospital Clínico San Carlos,IGTiP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,"Enfermedades Espinocerebelosas: Investigación Clínica, Epidemiología, Básica, Genética, Traslacional",Neurología,"Investigación bases genéticas y moleculares ataxias espinocerebelosas. Identificación de nuevos genes, déficits causales, biomarcadores, aplicación de terapias. Ensayos pre-clínicos y clínicos. Ensayos cribados in vitro,",Activo,,Antonio Matilla,3,SI,Pública y Privada,NO,"IDIBELL, Erasme Hospital, Hospital de Martorell, INSERM, Hospital La Paz, ",2012,,3
Hospital Clínico San Carlos,IGTiP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Estudios de Neurogenética: enfermedades neurodegenerativas y neurológicas,Neurología,"Investigación bases genéticas y moleculares enfermedades neurodegenerativas, y neurológicas",Activo,,Antonio Matilla,3,SI,Pública y Privada,NO,"Hospital La Paz, IDIBELL, Hospital Vall Hebron, Hospital Princesa, Hospital de Mérida, Hospital de Santiago de Compostela",2008,,3
Hospital Clínico San Carlos,IGTiP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Enfermedad de SanFilippo: ensayos pre-clínicos,Neurología,Terapias diversas en un modelo animal de la enfermedad de SanFilippo,Activo,,Antonio Matilla,3,SI,Privada,NO,,2012,,2
Hospital Clínico San Carlos,IGTP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Tumores hepáticos infantiles,Hepatología,Estudio proteómico del Hepatoblastoma: identificación de biomarcadores,Activo,,Carolina Armengol,3,,publico,,Hospitales europeos y españoles,2011,2013,3
Hospital Clínico San Carlos,IGTP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Tumores hepáticos infantiles,Hepatología,Integración alteraciones cromosómicas y expresión génica en Hepatoblastoma,Activo,,Carolina Armengol,3,,publico,,Hospitales europeos y españoles,2011,2013,3
Hospital Clínico San Carlos,IGTP_CIBER-EHD,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Enfermedad inflamatoria intestinal,Gastroenterología,Estduio clínico en fase prueba de concepto para testar la efectividad de un nuevo producto terapeutico en la colitis ulcerosa basado en lipidos y partes de bacterias beneficosas para las mucosas,Activo: en fase de acuerdo de colaboración ,"terapia innovadora en la colitis ulcerosa, ácidos grasos moinsaturados, agonistas de inmunidad inanata",Josep Mañe,3,SI,Pública y privada,NO,Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirá (México) y Laboratorios VITAE (España) ,2013,2015,3
Hospital Clínico San Carlos,IGTP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Enfermedad de Fabry,Enfermedades metabólicas,Biomarcadores,Activo: en fase de acuerdo de colaboración ,,Guillem Pintos,3,SI,Privada,NO,Shire,2013,2015,3
Hospital Clínico San Carlos,IGTP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Estudio de señales respiratorias,Neumología,Ingeniería de señales para aplicación clíncia,Activo: en fase de acuerdo de colaboración ,Estudio de señales respiratorias,José Antonio Fiz,3,SI,Pública y privada,NO,,2013,2015,3
Hospital Clínico San Carlos,IGTP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Alteraciones respiratorias del sueño,Neumología,Análisis mediante software de análisis de registro de imagen,Activo: en fase de acuerdo de colaboración ,Estudio de señales respiratorias,Jorge Abad,3,SI,Pública y privada,NO,Empresa software,2013,2015,3
Hospital Clínico San Carlos,IGTP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Alteraciones respiratorias del sueño,Neumología,Biobanco de enfermedades respiratorias en pacientes con apnea,Activo: en fase de acuerdo de colaboración ,Estudio de señales respiratorias,Jorge Abad,3,SI,Pública y privada,NO,Empresa software,2013,2015,3
Hospital Clínico San Carlos,IGTP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Regeneración celular,Inmunología,Microquimerismo,Activo,Microquimerismo,Marta Vives,3,SI,Pública y privada,NO,University of Bristol UK,2013,2015,3
Hospital Clínico San Carlos,IGTP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Regeneración celular,Inmunología,Biología molecular y autoinmunidad,Activo,Biología molecular y autoinmunidad,Marta Vives,3,SI,Pública y privada,NO,NARA University Japan,2013,2015,3
Hospital Clínico San Carlos,IGTP,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Biología Molecular y tuberculosis,Microbiología,Genómica Funcional del bacilo ,Activo,Biología Molecular y tuberculosis,José Domínguez,3,SI,Publico,NO,"Health Protection Agency. Collindale. London. UK, CIBERES",2012,2014,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja,Salud internacional,Fortalecimiento de universidades centro Americanas para la formación en E-Learning de investigación operativa sobre VIH y otras infecciones de transmisión sexual,Activo,"És un espai virtual d'aprenentatge relacionat amb les ITS que abasta diferents àmbits, des d'epidemiologia, clínica, monitoreig i avaluació, i els determinants de context, avalat per un equip docent multidisciplinari i internacional.
Aquest curs de 30 hores va dirigit al personal clínic (format i/o en formació) altres especialitats, personal investigador bàsic, mèdics/as de família, personal d'infermeria, personal farmacèutic clínic, indústria farmacèutica, gestors/as sanitaris, de Guatemala.",Local,3,SI,Pública,NO,"Departament de Medicina Preventiva i Salut Pública de la Universitat Autònoma de Barcelona
Facultat de Ciències Mèdiques de la Universitat Sant Carlos de Guatemala
Direcció general d'Investigació (DIGI) de la USAC
Institut d’Investigació Biomèdica de Bellvitge (IDIBELL)
Fundació Sida i Societat",2011,2012,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja,Salud internacional,Prevención de la transmisión materno-infantil de VIH y sífilis en Guatemala,Activo,"El presente proyecto tiene como objetivo contribuir a la reducción de la transmisión materno infantil de VIH y sífilis, trabajando en los distintos niveles de atención de salud con la capacidad instalada del Ministerio de Salud Pública y Asistencia Social de Guatemala (MSPAS) en cuanto a estableciminetos de salud:1er. Nivel (comunidad-Centro de convergencia,- PS (Puesto de salud)), 2º. Nivel (CS: Centro de Salud), 3er. Nivel (Hospital departamental) y a Recurso Humano: Equipos básicos de salud, enfermeras profesionales, auxiliares de enfermería, promotores, comadrones y radares.",Local,3,SI,Intervida,NO,"Dirección del Área de Salud de Escuintla, Programa Nacional de Sida del Ministerio de Salud Pública y Asistencia Social de Guatemala",2011,2013,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Estudio de la historia natural de la infección por VIH y los patrones de mortalidad en el contexto HAART,Salud internacional,Monitoring and Modelling prognosis in the era of HAART (ART-CC Collaboration),Activo,,Internacional,3,SI,Medical research Council (UK),NO,,2011,2013,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Monitorización y evaluación de intervenciones preventivas por VIH y ITS.,Salud internacional,SIALON II - Capacity building in HIV/syphilis prevalence estimation using non-invasive methods among MSM in Southern and Eastern Europe,Activo,"Segona edició del projecte Sialon I, el projecte Sialon II avança en l’harmonització de les metodologies de vigilància del VIH a països de la Unió Europea i veïns, generant dades comparables sobre indicadors conductuals i epidemiològics per les comunitats de HSH (indicadors ECDC i UNGASS/GARP) que ajudarà a identificar necessitats preventives insatisfetes, polítiques de prevenció inadequades i reforçarà una xarxa d’organismes àmplia, incloent organitzacions internacionals (ONUSIDA, OMS) i Europees (ECDC), Instituts Nacionals de Salut Pública i societat civil (ONG gay)",Internacional,3,SI,Pública,NO,"Grup SIALON II:
Centre for communicable Diseases and AIDS, Lituània
Institute of Hygiene and Tropical Medicine,Portugal
Slovak Medical University, Eslovàquia
National Institute of Public Health, República d'Eslovènia
Robert Koch Institute (RKI), Alemanya
National Centre of Infectious and Parasitic Diseases, Bulgària
Institute of Tropical Medicine, Bèlgica
National Institute of Infectious Diseases, Romania
National Institute of Public Health - National Institute of Hygiene, Polònia
Istituto Superiore di Sanita, Itàlia
Swedish Institute for Communicable Disease Control, Suècia",2011,2014,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Evaluación de nuevas herramientas diagnósticas por VIH y ITS,Salud internacional,HIV community-based testing practices in Europe (HIV – COBATEST),Activo,"L'objectiu general del projecte és promoure el diagnòstic precoç de la infecció pel VIH a Europa, mitjançant la millora de la implementació i avaluació de les pràctiques de realització de la prova amb consell assistit de base comunitària (CBVCT).

Objectius Específics:
     Descriure els programes i serveis de CBVCT a Europa.
     Identificar i descriure bones pràctiques en la implementació de CBVCT.
     Identificar un grup d'indicadors bàsics per a monitoritzar i avaluar l’activitat realitzada als CBVCT.
     Establir una xarxa europea de CBVCT en la que poder dur a terme recerca operativa
     Avaluar l'acceptabilitat, la viabilitat i l'impacte de la introducció del test ràpid del VIH en fluid oral a la xarxa de CBVCT. 

",Internacional,3,SI,Pública,NO,"Grup HIV- COBATEST - partners associats: 
- Regional Centre for Health Promotion, Regione del Veneto, Itàlia
- Association AIDES, Francia
- STOP AIDS Gay Men´s Hiv-organization, Dinamarca
- AIDS-Hilfe NRW e.V., Alemanya
- Institute of Sexology. 1st Medical Faculty Prague, Charles University, República Checa
- Institute of Public Health of the Republic of Slovenia
- National AIDS Centre of Poland",2010,2013,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,"Fortalecimiento de las capacidades locales de prevención, diagnóstico de VIH/SIDA y el diagnóstico y tratamiento de las ITS e infecciones prevalentes en el Departamento de Escuintla – Guatemala",Inactivo,"Objetivo General: Disminuida la prevalencia e incidencia del VIH/SIDA y el resto de infecciones de transmisión sexual (ITS), en población vulnerable y general del departamento de Escuintla en colaboración con el Ministerio de Salud de Guatemala. Objetivos Específicos: Mejorado el sistema de vigilancia e información sanitaria, la gestión clínica y el acceso a los servicios de diagnóstico, atención y prevención de ITS/VIH/SIDA en población vulnerable y general del departamento de Escuintla, Guatemala",Local,3,SI,Pública,NO,"Ministerio de Salud Pública y Asistencia Social; Fundación Preventiva de SIDA, Fernando Iturbide; Hospital Departamental de Escuintla; Hospital Roossevelt; Fundación Sobrevivientes; Programa Nacional de ITS/VIH/SIDA, Programa de Salud Reproductiva,  Dirección del Área de Salud de Escuintla, Sistema Integrado de Atención en Salud SIAS, Centro Nacional de Epidemiología del Ministerio de Salud Pública y Asistencia Social",2010,2011,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,"Fortalecimiento de las capacidades locales de prevención, diagnóstico de VIH/SIDA y el diagnóstico y tratamiento de las ITS e infecciones prevalentes en el Departamento de Escuintla – Guatemala",Inactivo,"Objetivo General: Disminuida la prevalencia e incidencia del VIH/SIDA y el resto de infecciones de transmisión sexual (ITS), en población vulnerable y general del departamento de Escuintla en colaboración con el Ministerio de Salud de Guatemala. Objetivos Específicos: Mejorado el sistema de vigilancia e información sanitaria, la gestión clínica y el acceso a los servicios de diagnóstico, atención y prevención de ITS/VIH/SIDA en población vulnerable y general del departamento de Escuintla, Guatemala",Local,4,SI,Pública,NO,"Ministerio de Salud Pública y Asistencia Social; Fundación Preventiva de SIDA, Fernando Iturbide; Hospital Departamental de Escuintla; Hospital Roossevelt; Fundación Sobrevivientes; Programa Nacional de ITS/VIH/SIDA, Programa de Salud Reproductiva,  Dirección del Área de Salud de Escuintla, Sistema Integrado de Atención en Salud SIAS, Centro Nacional de Epidemiología del Ministerio de Salud Pública y Asistencia Social",2011,2012,4
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,Apoyo a la formación universitaria de calidad en el ámbito de la salud sexual y reproductiva en Guatemala,Inactivo,"L’objectiu principal del projecte va ser realitzar un diagnòstic de context respecte a les necessitats de  formació i recerca universitària en l’àmbit de la salut i concretament, però no exclusivament, en salut pública i salut sexual reproductiva a Guatemala. Per tal de potenciar el procés de descentralització de la formació acadèmica en el país centreamericà, es va fer un esforç especial per veure les necessitats i possibilitats de col·laboració en el Departament d'Escuintla (i per extensió en la regió del Pacífic), a través de la Unidad de Apoyo Técnico (UAT) de l'Hospital Regional d'Escuintla, hospital universitari vinculat a la USAC.",Local,3,SI,Pública,NO,"Facultad de Ciencias Médicas, Universidad San Carlos de Guatemala
Dirección General de Investigación de la USAC",2010,2010,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,Definiciones conceptuales y recomendaciones para el fortalecimiento de sistemas de notificación de casos de VIH para America Latina y el Caribe,Inactivo,"Esta guía pretende ser una herramienta para el mejoramiento de los sistemas de vigilancia de casos de infección por el virus de la inmunodeficiencia humana (VIH). Presenta recomendaciones internacionales consensuadas tendentes a establecer los conceptos básicos y las normas de calidad que refuercen la vigilancia epidemiológica del VIH. Está dirigida a los responsables de programas nacionales y al personal a cargo de la vigilancia epidemiológica del VIH, desde el nivel nacional o central hasta el ámbito local y de servicios de salud, así como a los profesionales de los organismos internacionales y de las instituciones académicas que utilizan o apoyan los sistemas de vigilancia del VIH de los países.",Local,3,SI,Pública,NO,"Organització Mundial de la Salut
Fundació Sida i Societat",2010,2010,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,Definiciones conceptuales y recomendaciones para el fortalecimiento de sistemas de notificación de casos de VIH para America Latina y el Caribe,Inactivo,"Esta guía pretende ser una herramienta para el mejoramiento de los sistemas de vigilancia de casos de infección por el virus de la inmunodeficiencia humana (VIH). Presenta recomendaciones internacionales consensuadas tendentes a establecer los conceptos básicos y las normas de calidad que refuercen la vigilancia epidemiológica del VIH. Está dirigida a los responsables de programas nacionales y al personal a cargo de la vigilancia epidemiológica del VIH, desde el nivel nacional o central hasta el ámbito local y de servicios de salud, así como a los profesionales de los organismos internacionales y de las instituciones académicas que utilizan o apoyan los sistemas de vigilancia del VIH de los países.",Local,4,SI,Pública,NO,"Organització Mundial de la Salut
Fundació Sida i Societat",2011,2011,4
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,"Sistema integrado de información clínica, farmacológica y epidemiológica para personas viviendo con VIH/sida en Guatemala - MANGUA",Inactivo,El projecte MANGUA busca enfortir la descentralització i  monitoratge del tractament antiretroviral a Guatemala. Un component esssencial del projecte MANGUA és l'aplicatiu informàtic dissenyat per informatitzar la història clínica del VIH i facilitar la creació d'indicadors. L'objectiu del Ministerio de Salud Pública y Asistencia Social de Guatemala es implementar aquest programa en totes les unitats d'atenció integral del país.,Local,3,SI,Pública,NO,"Institut Català de Farmacologia
 Ministerio de Salud Pública y Asistencia Social de Guatemala ",2010,2012,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,"Salut comunitària per la prevenció i control del VIH i altres infeccions de transmissió sexual en 3 municpis del departament d'Escuintla, Guatemala",Activo,"Para contribuir a la prevención y control del VIH y de otras infecciones de transmisión
sexual (ITS) es imprescindible una actuación integral y coordinada a nivel de centros de atención primaria, en la comunidad y en organismos institucionales. El proyecto presenta 3 componentes interrelacionados. El primer componente consiste en ofrecer atención socio sanitaria en 2 clínicas de ITS integradas en centros de atención primaria del departamento de Escuintla y fortalecer sus laboratorios. El segundo componente, de acción comunitaria, fuertemente desarrollado, incluye charlas de prevención de ITS/VIH dirigida a diferentes poblaciones y formación de agentes en salud comunitarios mediante la educación entre iguales (proyecto Radares). El tercer componente pretende luchar contra los factores contextuales que influeyen en las ITS/VIH/Sida mediante proyectos para reforzar el tejido asociativo y las capacidades de mujeres trabajadoras del sexo (MTS) del departamento (Proyecto Redes). Se espera aumentar las capacidades humanas y sociales especialmente de colectivos vulnerables como las MTS y hombres que tienen sexo con hombres (HSH) y reforzar las capacidades de los centros de salud a través de la dotación técnica y formación de personal de salud.
",Local,3,SI,Pública,NO,"Dirección del Área de Salud de Escuintla, Municipalidad de Escuintla, Municipalidad de Santa Lucía Cotzumalguapa, Municipalidad del Puerto de San José",2009,2012,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,"PROYECTO UALE- Prevención, Control y Tratamiento de las Infecciones de Transmisión Sexual (ITS/VIH) en Escuintla. PROYECTO MANGUA- Apoyo Técnico al Ministerio de Salud Pública y Asistencia Social de la República de Guatemala y a Hospitales de Referencia en Ciudad de Guatemala en el desarrollo de una aplicación informática para el seguimiento y evaluación del tratamiento antirretroviral y la constitución de una cohorte de pacientes positivos",Inactivo,"L'objectiu general del projecte és contribuir  a la disminució de la prevalència i incidència del VIH/SIDA i ITS en la població del Departament d'Escuintla en col·laboració amb el Ministeri de Salut de Guatemala
Proyecto UALE: 3 clíniques d'ITS per població vulnerable al departament d'Escuintla, educació per a la prevenció del VIHa la comunitat, activitats de sensibilització i d'incidència política i de drets humans. Projecte MANGUA : desenvolupament i implementació d'un aplicatiu informàtic en els hospitals públics que atenen pacients VIH/SIDA a Guatemala amb la finalitat de disponsar d'informació per la presa de decisions a nivell de país. ",Local,3,SI,Pública,NO,"Dirección del Área de Salud de Escuintla, Programa Nacional de Sida del Ministerio de Salud Pública y Asistencia Social de Guatemala. Fundació Sida i Societat",2009,2011,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,"1. Métodos de monitorización y evaluación de las epidemias de VIH e infecciones de transmisión sexual (ITS). 2. Monitorización y evaluación de intervenciones preventivas por VIH y ITS.""",Salud internacional,"European MSM Internet Survey on knowledge, attitudes and behaviour as to HIV and STI (EMIS)",Inactivo,"L'objectiu principal d’EMIS va ser desenvolupar e implementar un qüestionari comú de vigilància conductual en homes que tenen relacions sexuals amb homes (HSH) a través de Internet seguint les recomanacions del ECDC dins del marc de la Vigilància de Segona Generació del VIH/ITS a Europa. Per altre banda, l’estudi pretenia transferir coneixements sobre enquestes via web en HSH a aquells països amb menys experiència o amb dificultats per dur a terme aquests tipus d’estudis a nivell nacional",Internacional,3,SI,Pública,NO,"Grup EMIS - Partners: 
- Robert Koch Institute, Germany
- Sigma Research, United Kingdom
- Maastricht Uni-versity, Netherlands
- Regional Centre for Health Promotion, Veneto Region, Verona, Italy",2009,2009,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,"Estrategia integral de prevención, control y atención de las ITS/VIH/SIDA y sus determinantes de contexto en Guatemala",Inactivo,"Intervenció multinivell de prevenció de VIH/ITS en població vulnerable del departament d'Escuintla que inclou 3 clíniques d'ITS, prevenció comunitària i activitats d'incidència política, sensibilització, mobilització comunitària i apoderament",Local,3,SI,Pública,NO,"Ministerio de Salud Pública y Asistencia Social de Guatemala
Dirección del Area de Salud de Escuintla",2008,2010,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,"Fortalecimiento de las capacidades locales de prevención, diagnóstico de VIH/SIDA y el diagnóstico y tratamiento de las ITS e infecciones prevalentes en el Departamento de Escuintla – Guatemala",Inactivo,"Objetivo General: Disminuida la prevalencia e incidencia del VIH/SIDA y el resto de infecciones de transmisión sexual (ITS), en población vulnerable y general del departamento de Escuintla en colaboración con el Ministerio de Salud de Guatemala. Objetivos Específicos: Mejorado el sistema de vigilancia e información sanitaria, la gestión clínica y el acceso a los servicios de diagnóstico, atención y prevención de ITS/VIH/SIDA en población vulnerable y general del departamento de Escuintla, Guatemala",Local,3,SI,Pública,NO,"Ministerio de Salud Pública y Asistencia Social; Fundación Preventiva de SIDA, Fernando Iturbide; Hospital Departamental de Escuintla; Hospital Roossevelt; Fundación Sobreviviente; Programa Nacional de ITS/VIH/SIDA, Programa de Salud Reproductiva,  Dirección del Área de Salud de Escuintla, Sistema Integrado de Atención en Salud SIAS, Centro Nacional de Epidemiología del Ministerio de Salud Pública y Asistencia Social",2008,2010,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,Intensificación de las acciones de prevención y atención integral del VIH/SIDA en grupos vulnerables y áreas prioritarias de Guatemala,Inactivo,L'objectiu general del projecte és contribuir  a la disminució de la prevalència i incidència del VIH/SIDA i ITS en la població del Departament d'Escuintla en col·laboració amb el Ministeri de Salut de Guatemala,Local,3,SI,Pública,NO,"Ministerio Salud Pública y Asistencia Social de Guatemala, Dirección Area Salud de Escuintla, Fundació sida i societat",2008,2009,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,Intensificación de las acciones de prevención y atención integral del VIH/SIDA en grupos vulnerables y áreas prioritarias de Guatemala,Inactivo,L'objectiu general del projecte és contribuir  a la disminució de la prevalència i incidència del VIH/SIDA i ITS en la població del Departament d'Escuintla en col·laboració amb el Ministeri de Salut de Guatemala,Local,3,SI,Pública,NO,"Ministerio Salud Pública y Asistencia Social de Guatemala, Dirección Area Salud de Escuintla, Fundació sida i societat",2008,2009,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,"Proyecto integral de prevención, control y tratamiento de las ITS/VIH/SIDA y sus determinantes de contexto en el Departamento de Escuintla, Guatemala",Inactivo,"El objetivo de la intervención es la disminución de la prevalencia e incidencia del VIH/SIDA e ITS en la población del Departamento de Escuintla en colaboración con e Ministerio de Salud de Guatemala (Guatemala), a través de la prevención, el acceso a la salud, incidir en el contexto de riesgo y la incidencia política. También se ha implementado un proyecto de atención integral a Victimas de violencia sexual en 4 centros de salud y un hospital del departamento y se ha fortalecido el laboratorio del hospital nacional de Escuintla para albergar en un futura una unidad de atención integral a pacientes VIH/sida en el hospital",Local,3,SI,Pública,NO,"Vice-Ministerio de Salud Pública y Asistencia Social de Guatemala (MSPAS), Programa Nacional de control de ITS/VIH/SIDA, Programa de Salud Reproductiva del MSPAS, Dirección del área de salud de Escuintla, Centro Nacional de Epidemiología de Guatemala, Hospital Regional de Escuintla, Fundación Preventiva Frenando Iturbide",2007,2009,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Monitorización y evaluación de intervenciones preventivas por VIH y ITS. Evaluación de nuevas herramientas diagnósticas por VIH y ITS,Salud internacional, Capacity building in HIV/syphilis prevalence estimation using non-invasive methods among MSM in Southern and Eastern Europe. Amb la col·laboració del govern local de Verona (SIALON I),Inactivo,"L'objectiu principal de SIALON I va ser obtenir informació vàlida sobre la prevalença de VIH, sífilis, conductes de risc i factors culturals en homes que tenen relacions sexuals amb homes (HSH), mitjançant mètodes d’apropament no invasius en països de l’est i sud d’Europa. A més, l’estudi pretenia desenvolupar recomanacions a nivell europeu sobre polítiques i estratègies de prevenció d’ ITS dirigides al col·lectiu d’ HSH. ",Internacional,3,SI,Pública,NO,"Grup SIALON :
- Regional Centre for Health Promotion, Veneto Region, Verona, Italy
- Regional Public Health and Health Promotion Centre, Maribor, Slovenia 
- ACCEPT Association, Bucharest, Romania
- National Reference Centre for HIV/AIDS - Slovak Medical University, Bratislava, Slovakia 
- National Institute of Public Health, Prague, Czech Republic ",2008,2010,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,"Estudio de la historia natural de la infección por VIH y los patrones de mortalidad en el contexto HAART.Desarrollo de técnicas de análisis estadístico, incluyendo la triangulación y modelización (estimación de la incidencia de infección por VIH, análisis matricial, etc.)""",Salud internacional,HIV Cohorts Analyzed Using Structural Approaches to Longitudinal data (HIV-CAUSAL),Inactivo,La colaboración HIV CAUSAL es una colaboración multinacional de estudios prospectivos de personas VIH positivas procedentes de seis países europeos y Estados Unidos,Internacional,3,SI,"National Institute of Allergy and Infectious Diseases, National Institutes of Health",NO,,2007,2011,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Estudio de la historia natural de la infección por VIH y los patrones de mortalidad en el contexto HAART.,Salud internacional,Monitoring and Modelling prognosis in the era of HAART (ART-CC Collaboration),Inactivo,"ART CC incluye 19 estudios de cohortes de Europa y América del Norte. Se estableció para estimar el pronóstico de pacientes VIH-1 positivos, sin tratamiento previo que inician la terapia antirretroviral de gran actividad (TAR). Sus principales objetivos son: Estimar el pronóstico de eventos clínicos (muertes por todas las causas y causas específicas, SIDA y los eventos definitorios de SIDA) a largo plazo en la era TARGA; y estimar el pronóstico relativo a las estrategias de tratamiento, con énfasis en la modelización causal.",Internacional,3,SI,Medical research Council (UK),NO,,2008,2011,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,"Disseny d'intervencions preventives multinivell i monitoratge del tractament antiretroviral en països de renda baixa.
",Salud internacional,"PROYECTO UALE- Prevención, Control y Tratamiento de las Infecciones de Transmisión Sexual (ITS/VIH) en Escuintla. PROYECTO MANGUA- Apoyo Técnico al Ministerio de Salud Pública y Asistencia Social de la República de Guatemala y a Hospitales de Referencia en Ciudad de Guatemala en el desarrollo de una aplicación informática para el seguimiento y evaluación del tratamiento antirretroviral y la constitución de una cohorte de pacientes positivos",Inactivo,"L'objectiu general del projecte és contribuir  a la disminució de la prevalència i incidència del VIH/SIDA i ITS en la població del Departament d'Escuintla en col·laboració amb el Ministeri de Salut de Guatemala
Proyecto UALE: 3 clíniques d'ITS per població vulnerable al departament d'Escuintla, educació per a la prevenció del VIHa la comunitat, activitats de sensibilització i d'incidència política i de drets humans. Projecte MANGUA : desenvolupament i implementació d'un aplicatiu informàtic en els hospitals públics que atenen pacients VIH/SIDA a Guatemala amb la finalitat de disponsar d'informació per la presa de decisions a nivell de país. ",Local,3,SI,Pública,NO,"CDC Guatemala, Proyecto calidad en salud/ USAID Guatemala, Centro de Investigación, capacitación y apoyo a la mujer (CICAM), Municipalidad de Sta Lucia Cotzumalguapa",2006,2008,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Diseño de intervenciones preventivas multinivel y monitorización del tratamiento antiretroviral en países de renta baja.,Salud internacional,Reducción de la vulnerabilidad de las TSC en Escuintla (Guatemala) respecto al VIH y ITS II,Inactivo,L'objectiu general del projecte és contribuir  a la disminució de la prevalència i incidència del VIH/SIDA i ITS en la població del treballadores del sexe Departament d'Escuintla en col·laboració amb el Ministeri de Salut de Guatemala,Local,3,SI,Pública,NO,"Dirección Area de Salud de Escuintla, Fundació Barcelona Sida 2002 ",2005,2006,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Monitorización y evaluación de intervenciones preventivas por VIH y ITS.,Salud internacional,European Project on Non-Occupational Post-Exposure Prophylaxis for HIV  (EURO-NONOPEP),Inactivo,Estandarditzar i avaluar la viabilitat d'una guia per a la profilaxis post-exposició no ocupacional de la infecció pel VIH a Europa,Internacional,3,SI,Pública,NO,"Centres coordinadors (per països):
Centre of Pneumology (Àustria)
Division of Infectious Diseases C.H.U. Saint-Pierre (Bèlgica)
Department  of Epidemiology,  State Serum Institute (Dinamarca)
Observatoire Regional de la Sante ORS PACA (França)
HELLENIC CENTER OF INFECTIOUS DISEASES (Grècia)
Robert Koch Institut Infectionsepidemiologoe /AidsZentrum (Alemanya)
Municipal Health Service, Dept. of  Infectious diseases (Holanda)
Department of Genito Urinary Medicine and Infectious diseases, St James Hospital (Irlanda)
DEPT. OF EPIDEMIOLOGY OF THE NATIONAL INSTITUT OF INFECTIOUS DISEASES. INMI “L. Spallanzani” IRCSS (Itàlia)
Serviço Doenças Infecciosas – Faculdade de Medicina & Hospital de São João - Porto (Portugal)
Clinic of Infectious Diseases, Medical Centre Ljubljana, HIV/AIDS Unit (Eslovènia)
DipartImento di Medicina Interna Ospedale CIVICO (Suïssa)
HPA-CDSC 61 Communicable Disease Surveillance Centre (Regne Unit)
",2001,2004,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Monitorización y evaluación de intervenciones preventivas por VIH y ITS.,Salud internacional,Los programas de intercambio de jeringuillas para la prevención de la infección por el HIV en los países en el sur de Europa (PESESUD-2),Inactivo,"The general aim of this project is the monitoring of Syringe Exchange Programs (SEPs) implemented in Southern European Countries. The objectives are :
1. to monitor the implementation and the delivery of services provided by SEPs in France, Italy, Spain and Portugal;
2. to establish an expert consensus about their standards of good practice and their evaluation;
3. to develop a basic form to collect routine standardised information of the identified SEPs and to develop a user-friendly software to analyse data and make reports;
4. to promote the exchange of education materials distributed a different SEPs in the Southern European Countries;
5. to maintain and strengthen the Southern-European network of SEPs.

",Internacional,3,SI,Pública,NO,"Médecins du Monde (França) 
Agenzia di Sanità Pubblica. Regione Lazio (Itàlia) 
Comissáo Nacional Luta Contra a Sida y Associaçao Nacional das Farmácias (Portugal)",1998,2000,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Monitorización y evaluación de intervenciones preventivas por VIH y ITS.,Salud internacional,Los programas de intercambio de jeringuillas para la prevención de la infección por el HIV en los países en el sur de Europa (PESESUD-1),Inactivo,"The general aim of this project is the monitoring of Syringe Exchange Programs (SEPs) implemented in Southern European Countries. The objectives are :
1. to monitor the implementation and the delivery of services provided by SEPs in France, Italy, Spain and Portugal;
2. to establish an expert consensus about their standards of good practice and their evaluation;
3. to develop a basic form to collect routine standardised information of the identified SEPs and to develop a user-friendly software to analyse data and make reports;
4. to promote the exchange of education materials distributed a different SEPs in the Southern European Countries;
5. to maintain and strengthen the Southern-European network of SEPs.",Internacional,3,SI,Pública,NO,"Médecins du Monde (França) 
Agenzia di Sanità Pubblica. Regione Lazio (Itàlia) 
Comissáo Nacional Luta Contra a Sida y Associaçao Nacional das Farmácias (Portugal)",1996,1998,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Métodos de monitorización y evaluación de las epidemias de VIH e infecciones de transmisión sexual (ITS).,Salud internacional,Factores de riesgo por el sarcoma de Kaposi en pacientes con SIDA: un estudio europeo de casos y controles (EUROSHAKS-2),Inactivo,"Identificar possibles factors de risc genètics, de comportament, biològics i ambientals per al VIH associat al Sarcoma de Kaposi a través d'un estudi cas-control multicèntric",Internacional,3,SI,Pública,NO,"Espanya:
Hospital Clínic, Hospital Germans Trias i Pujol, Hospital de Sant Pau, Hospital de Bellvitge, Hospital Vall d'Hebron, Hospital del Mar, Hospital 12 d'Octubre

Bèlgica: St. Pierre Hospital

Itàlia: H San Raffaele

Grècia: ""A. Sygros"" Hospital

Regne Unit: St Stephen's Centre
",1995,1997,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Métodos de monitorización y evaluación de las epidemias de VIH e infecciones de transmisión sexual (ITS).,Salud internacional,Factors de riesc pel sarcoma de Kaposi en pacients amb SIDA: un estudi europeu de casos i controls (EUROSHAKS-1),Inactivo,"Identificar possibles factors de risc genètics, de comportament, biològics i ambientals per al VIH associat al Sarcoma de Kaposi a través d'un estudi cas-control multicèntric",Internacional,3,SI,Pública,NO,"Espanya: Hospital Clínic, Hospital Germans Trias i Pujol, Hospital de Sant Pau, Hospital de Bellvitge, Hospital Vall d'Hebron, Hospital del Mar, Hospital 12 d'Octubre

Bèlgica: St. Pierre Hospital

Itàlia: H San Raffaele

Grècia: ""A. Sygros"" Hospital

Regne Unit: St Stephen's Centre
",1993,1995,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Estudio de la historia natural de la infección por VIH y los patrones de mortalidad en el contexto HAART,Salud internacional,HIV Cohorts Analyzed Using Structural Approaches to Longitudinal data (HIV-CAUSAL),Activo,The HIV-CAUSAL Collaboration is a multinational collaboration of prospective studies of HIV-infected individuals from six European countries and the United States. HIV-CAUSAL stands for HIV Cohorts Analyzed Using Structural Approaches to Longitudinal data.,Internacional,3,SI,Harvard University Center for AIDS Research (CFAR) ,NO,,2011,2012,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Estudio de la historia natural de la infección por VIH y los patrones de mortalidad en el contexto HAART,Salud internacional,COHERE,Activo,"COHERE es una estructura que se organizó en 2005. Su misión es llevar a cabo la investigación epidemiológica sobre el pronóstico y la evolución de las personas con VIH de toda Europa, incluyendo mujeres embarazadas, niños y adultos.",Internacional,3,SI,European Union Seventh Framework Programme,NO,"COHERE is a collaborative group of 33 adult, paediatric, and mother/child HIV cohorts across Europe. The collaboration allows comparisons across age categories and provides a mechanism to rapidly compile datasets to address novel research questions that cannot be studied adequately in individual cohorts.",2007,2013,3
Hospital Clínico San Carlos,IGTP_CEEISCAT,Hospital Universitario Gremans Trias i Pujol,Badalona,8916,Carretera Canyet,41.472133,2.234281,Estudi de la història natural de la infecció per VIH i els patrons de mortalitat en el context HAART,Salud internacional,Eurocoord,Activo,"EuroCoord es una red de excelencia establecida por varios de las más grandes cohortes de VIH y colaboraciones en Europa - CASCADE, COHERE, EuroSIDA y PENTA.",Internacional,3,SI,European Union Seventh Framework Programme,NO,"EuroCoord is a Network of Excellence established by several of the biggest HIV cohorts and collaborations within Europe - CASCADE, COHERE, EuroSIDA, and PENTA. This large, integrated network exploits the scientific strengths of each collaboration to ensure that the best, most competitive HIV research is performed.",2007,2013,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,"RED TEMATICA DE INVESTIGACIÓN COOPERATIVA DE CANCER (RD06/0020/0097)
V Plan Nacional de I+D+I (2004-2007) y VI Plan Nacional de I+D+I (2008-2011)
",Oncología,RED TEMATICA DE INVESTIGACIÓN COOPERATIVA DE CANCER (RD06/0020/0097),Activo,Oncology,LOCAL,3,NO,PÚBLICA NACIONAL,NO,"INSTITUT D´INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL)
HOSPITAL UNIVERSITARI DE BELLVITGE
INSTITUT DE RECERCA ONCOLOGICA / INSTITUT
INSTITUT PASTEUR DE PARÍS
UNIVERSITAT DE BARCELONA",2007,2010,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,ANÁLISIS DE LAS VÍAS DE TRANSDUCCIÓN DE SEÑAL INDUCIDAS POR TGF-BETA EN CÉLULAS HEPÁTICAS HUMANAS COMO ESTRATEGIA PARA EL DESARROLLO DE NUEVAS TERAPIAS EN PATOLOGÍAS DEL HÍGADO (BFU2009-07219),Hematología,ANÁLISIS DE LAS VÍAS DE TRANSDUCCIÓN DE SEÑAL INDUCIDAS POR TGF-BETA EN CÉLULAS HEPÁTICAS HUMANAS COMO ESTRATEGIA PARA EL DESARROLLO DE NUEVAS TERAPIAS EN PATOLOGÍAS DEL HÍGADO (BFU2009-07219),Activo,Hepathology,LOCAL,3,SI,PÚBLICA NACIONAL,NO,"INSTITUT D´INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL)
INSTITUT PASTEUR DE PARÍS
UNIVERSIDAD COMPLUTENSE DE MADRID",2010,2012,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,CANCERDIP - The use of Methylated DNA Immunoprecipitation MeDIP in cancer for better clinical management.,Oncología,"Aberrant DNA methylation is the most common molecular lesion of the cancer cell. Neither gene mutation nor cytogenetic abnormalities are as common in human tumours as DNA methylation alterations. The stability of our genome and correct gene expression is maintained to a great extent thanks to a perfectly preestablished pattern of DNA methylation and histone modifications. In cancer this idealistic scenario breaks down due to an interesting phenomenon whereby the regulatory regions (CpG islands) of certain tumour suppressor genes become hypermethylated, inactivating the gene as a consequence,
whilst a wave of hypomethylation occurs in the genome. Indeed, CpG island promoter hypermethylation has a tumour-type-specific pattern, where each gene tends to be methylated in the cancer cells driven from a particular tissue, but not from others. It is also widely accepted that the multiprotein complex associated with the methylated DNA is also crucially involved in the repression of gene expression. Another aspect crucial for the interest of epigenetics in cancer is that promoter hypermethylation of the CpG island of tumours suppressor genes occurs early in tumorigenesis. Furthermore, it has been extensively reported that CpG promoter hypermethylation can be used as predictor of cancer behaviour and a predictor of response to treatment. This characteristic makes promoter hypermethylation combined with the epigenetic associated proteins profile, a potential biomarker for early detection of cancer and for the individualization of cancer treatment. We are going to use a novel technique based in chromatin immunoprecipitation, the Methylated DNA Immunoprecipitation (MeDIP) technique that will easily permit us to obtain an epigenomic profile which will be used to personalize cancer treatment and facilitate tumour diagnosis, prognosis and monitoring.",Inactivo,"Cancer, Epigenetics, DNA methylation, DNA  Immunoprecipitation, MeDIP, chromatin-modifying protein complexes.",LOCAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1. IDIBELL
2. Université Libre de Bruxelles
3. Radboud Universiteit Nijmegen - Stichting Katholieke Universiteit
4. Seconda Universita Degli Studi Di Napoli
5. Max Planck Gesellschaft Zur Foerderung Der Wissenschaften E.V
6. Diagenode SA",2009,2011,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,INDABIP: INNOVATIVE DIAGNOSTIC APPROACHES FOR BIOMARKERS IN PARKINSON DISEASE.,Neurología,"Parkinson disease (PD), a specific type of a group of neurodegenerative disorders called synucleinopathies, is the second most common neurodegenerative disorder worldwide. Many neurodegenerative disorders are preceded by a pre-symptomatic phase, probably lasting years, during which degeneration and death of neurons occurs before any clinical symptoms appear. One major goal of clinical research is to improve early detection of these diseases by developing tools to move diagnosis backward in the neurodegeneration temporal course. Thus, the central objective of this INDABIP proposal is the identification of molecular markers that hallmark the onset of a cellular dysfunction in the brain areas involved in PD. These markers would enable to identify at-risk groups both for disease onset and progression during the pre-clinical period.
INDABIP combines in a very unique form the latest technologies in biomarkers research provided by the companies to be applied on invaluable human material in one of the largest brain tissue collection ever approached combined finally with further research and validation on cell and in vivo models. Within our consortium we will have access to more than 120 neuropathologically-confirmed brains in Barcelona, Munich and from Brain-Net Germany.
The putative biomarkers will be analyzed boinformatically and the more promising ones submitted to a validation program including quantitative PCR, WB and inmunohistochemistry confirmation. Additionally, a rigurous analysis of the literature and the use of a in vitro model to reproduce some of the aspects of the progression of the disease will help to perform a careful assessment of the potential of some biomarkers as pharmacological targets.",Inactivo,"Parkinson disease; synucleinopathies ; biomarkers, early diagnostics, molecular diagnostics, pharmacological targets, transcriptomics, microRNA, differential splicing, protomics, bioinformatics, data mining.",LOCAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1. Oryzon Genomics
2. Ludwig-Maximilians - University of Munich
3. ACTIGENICS
4. GENFIT
5. IDIBELL
6. Kuopio University
7. Université de Lille",2006,2010,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,BrainNet Europe II - Network of European Brain and Tissue Banks for Clinical and Basic Neuroscience,Neurología,"BrainNet Europe II is a network of 19 established brain banks across Europe. Having established a network of ten brain banks in preparation for BrainNet Europe II we now aim to integrate new members, to spread excellence in collecting human high quality post mortem brain tissue and to foster research in the cellular and molecular basis of neurological and mental disorders and diseases, gender aspects and the ageing process.",Inactivo,Neurology,INTERNACIONAL,3,NO,PÚBLICA INTERNACIONAL,NO,"Ludwig Maximilians Universitaet Muenchen LMU Germany 
University of Kuopio UKU Finland 
University of Edinburgh UEDIN United Kingdom
Huddinge Brain Bank HBB Sweden 
University of Vienna INUV Austria 
Istituto Carlo Besta INNCB Italy 
University of Barcelona Bellvitge/UB Spain 
Institut National de la Santé et de la Recherche INSERM France
King´s College London KCL United Kingdom
Netherlands Brain Bank foundation NBB Netherlands
National and Capodistrian University of Athens NCUA Greece 
Università de Bologna UNIBO Italy 
National Institute of Psychiatry and Neurology OPNI Hungary 
Human Brain Tissue Bank HBTB Hungary
Georg-August University Goettingen UKG-GOE Germany 
Saarland University USAAR-MED Germany 
Imperial College of Science Technology and Medicine Imperial United Kingdom
Hospices Civils de Lyon HCL France 
University Wuerzburg University Wuerzburg
GABO mbH & Co. KG",2006,2009,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,"NeuroPrion - Prevention, control and management of prion diseases",Neurología,"NeuroPrion links 52 laboratories across Europe undertaking excellent research in the field of
TSEs. This represents a majority and hence critical mass of actors in the field. NeuroPrion
recognises that there are considerable strengths in the European TSE research effort and will
reinforce these. Nevertheless, there is fragmentation resulting in some barriers which can be
overcome and some areas which can be strengthened.",Inactivo,Neurology,INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"Commissariat à l'Energie Atomique
Institut National de la Recherche Agronomique
Agence Française de Sécurité Sanitaire des Aliments
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche édicale
Association pour la Recherche et le Développement   des Méthodes et Processus Industriels
The University of Edinburgh
Department for Environment, Food& Rural Affairs
Institute for Animal Health
Health Protection Agency
National University of Ireland, Dublin
Heinrich-Heine-Universität Düsseldorf
Ludwig-Maximilians- Universität
Federal Research Centre for Virus Diseases of Animals
Robert Koch-Institut
Centraal Instituut voor
DierziekteControle-Lelystad, part of DLO foundation
Istituto Nazionale Neurologico Carlo Besta
Istituto Superiore di Sanità
Istituto di Ricerche Farmacologiche ""Mario Negri""
Cea- Centro Encefalopatie Animali Istituto  Zooprofilattico Sperimentale del Piemonte, Liguria e Vallee d'Aosta'
Alma Mater Studiorum - Università di Bologna  Dipertimento di Scienze Neurologiche
Institut für Neurologie Universität Wien
University of Zürich
National Veterinary Institute
European Commission - Joint Research Centre
Hadassah Medical Organization
Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria
Institut Neuropatologia/Hospital  Universitari Bellvitge
Universidad de Zaragoza






",2006,2008,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,PLAYMANCER: A EUROPEAN SERIOUS GAMING 3D ENVIRONMENT (FP7-215839),Otros,"The potential of games for entertainment and learning has been demonstrated thoroughly from research and clearly in the market place. Unfortunately, the investments committed to entertainment dwarfs that which is committed for more serious purposes. Furthermore, game development has become more complex, expensive, and burdened with a long development cycle. This creates barriers to independent game developers, and inhibits the introduction of innovative games, or new game genres, i.e. serious games, or games accessible to communities with special needs. 

PlayMancer is a Games for Health research project aiming at implementing an environment for serious games by augmenting existing 3D gaming engines. More specifically, the objectives of PlayMancer are:
1. to construct a fit-to-purpose gaming environment, mainly augmenting the gaming experience with innovative ICT modes of interaction between the player and the game world;
2. to apply the principles of Universally Accessible Games into 3D-based games through the specification of I/O configuration;
3. to evaluate the proposed environment and gaming infrastructure by developing and testing a series of serious games modules as applied to two application domains: physical rehabilitation, and therapeutic support / lifestyle management programs for behavioral and addictive disorders.
",Inactivo,"ICT, Games, Health",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1. Systema Teknolotzis AE
2. TXT e-solutions spa
3. Netunion s.a.r.l.
4. University of Patras
5. Technische Universitaet Wien
6. IDIBELL
7. Universite de Geneve",2007,2010,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,ESTOOLS - Platforms for biomedical discovery with human ES cells,Genética,"The goal of ESTOOLS is to develop and implement the necessary tools to elucidate the genetic and molecular networks that control the self renewal, commitment and terminal differentiation of hES cells. Neural commitment provides a paradigm for understanding the mechanisms by which ES cells choose between self renewal and lineage commitment. Furthermore, neuronal and glial differentiation of hES cells offer major new experimental avenues for cellular neurobiology and pathogenesis, with the potential for application in pharmaceutical and toxicological screening and cell replacement therapies.",Inactivo,"ES cells, molecular genetic, tools",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1. The University of Sheffield
2. SCS UK Ltd.
3. The University of Basel
4. The Hebrew University of Jerusalem
5. The University of Turku
6. The University of Bonn
7. The University of Milan
8. The Medical Research Council
9.The Spanish National Cancer Centre
10. Axordia Ltd.
11.The Institute of Experimental Medicine
12. The University of Lund
13.Karolinska Institutet
14. Vereniging Het Nederlands Kanker Instituut
15.Helsingin Yliopisto
16. SCT Stem Cell Technologies Ltd.
17.The University of Edinburgh
18. The University of Technology, Dresden
19.University of Cambridge
20. Imperial College London
21.IDIBELL",2008,2010,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,"TARGET MELANOMA - Molecular Dissection of Melanoma Progression: An integrated Pan-European Approach
",Oncología,"Transformed melanocytes use several strategies to enable their progression to advanced melanoma and metastasis, including genetic and epigenetic alterations, along with disruptions to gene and protein expression. This consortium aims to identify novel biomarkers for predicting the progression and prognosis of melanoma. To achieve this, a concerted collaborative effort is proposed here between key academic and industrial partners, centred on intersectorial training of experienced researchers. Our first goal is to identify novel methylated genes via several complementary screening methods, followed by validation extensive melanoma cohorts available to the consortium. We will use the following strategies to identify methylated genes: (1) an array-based technique called MeDIP-ON-CHIP, (2) a high-throughput bisulphite-based technique developed by Illumina (to simultaneously analyse up to 800 genes over 96 samples) and (3) in silico analysis of DNA microarray data. To validate these methylation targets, we will use both qualitative and quantitative methylation-specific PCR (MSP) and determine if these methylation events correlate with melanoma progression, i.e. from benign and atypical nevi to primary and metastatic tumours. Our second goal is to validate genes that associate with melanoma progression and prognosis. For this aspect of the project, we will concentrate on the application of tissue microarray technology and associated image analysis approaches to validate molecular determinants of melanoma
progression. Prioritised targets will then be functionally validated by a unique in vitro assay that models extravasation, or exit of cancer cells out
of the blood stream, a key step in the metastatic process. Overall, these studies will give clues to melanoma progression, and may identify
important targets for melanoma treatment. In addition, this industry-academic partnership will provide a valuable cross-disciplinary training
ground for emerging researchers.",Activo,"Oncology, melanoma, epigenetics,",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1. University College Dublin
2. IDIBELL
3. Maastricht University
4. Katholieke Universiteit Leuven
5. Uppsala University
6. OncoMethylome BVBA
7. SlidePath, INVENT DCU
8. Cellix Ltd, St James’ Hospital
9.OncoMark Ltd",2009,2013,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,RISET: Reprogramming the immune System for the Establishment of Tolerance ,Inmunología,"Transplantation dramatically improves the survival of patients with end-stage failure of vital organs. However, as a direct consequence of the  immunosuppressive drugs permanently required to prevent rejection, recipients have a significantly incresed risk of infection and malignancies. Moreover, these drugs are expensive, do not prevent long-term damage of the graft, and exert toxic effects outside the immune system. The induction of transplant tolerance, defined as permanent acceptance of the graft in absence of continuous immunosuppression, would be a major step forward. Recent advances in post-genomic immunology suggest that this goal is achievable in a near future. Indeed, new biotechnology products have been shown to promote long-term transplant acceptance in pre-clinical models.
RISET will focus on the translation of these advances into industrial development and clinical practice. First, diagnostic tests to identify transplanted patients for whom immunosuppressive treatment could be safely minimized or withdrawn will be developed. These tests will be applied to patients under conventional treatment as well as to patients enrolled in pilot clinical investigations based on cellular products with potential for tolerance induction. Because of the nature of this research, effective communication with patient organizations and regulatory bodies will be organized, and related ethical and societal questions will be specifically addressed. In parallel, relevant models of tolerance will be used to identify new genes, molecules or cell types that will form the basis for novel diagnostics and therapeutic approaches. The use of knowledge will be facilitated by the involvement of SMEs in the consortium and the building of an industrial platform. To exploit innovative concepts emerging outside the consortium, RISET will be open to new industrial or academic partners for which a budget has been provisioned. An external advisory board will monitor the progress of the project.",Inactivo,"Transplants, inmunology",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1. UNIVERSITE LIBRE DE BRUXELLES
2. UNIVERSITÄT BERN
3. BLASTICON Biotechnologische Forschung GmbH
4. CHARITE – UNIVERSITY MEDICINE BERLIN
5. DEUTSCHES KREBSFORSCHUNGSZENTRUM
6. KING’s COLLEGE LONDON
7. INSERM U558
8. INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE
9. LEIDS UNIVERSITAIR MEDISCH CENTRUM
10. MEMOREC BIOTEC GmbH
11.OXFORD UNIVERSITY
12. FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR - Tiget
13.TC LAND
14. UNIVERSITE RENE DESCARTES PARIS
15.UNIVERSITY OF SCHLESWIG-HOLSTEIN
16. CENTRO NACIONAL DE TRASPLANTES Y
MEDICINA REGENERATIVA
17.WEIZMANN INSTITUTE OF SCIENCE
18. UNIVERSITY OF KONSTANZ
19.PROIMMUNE LIMITED
20. HENOGEN S.A.
21.MILTENYI Biotechnologische Forschung GmbH
22. UNIVERSITY OF REGENSBURG MEDICAL CENTER
23.UNIVERSITY OF BARCELONA
24. IDIBELL",2008,2010,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,"INTERACT: AN EXAMINATION OF INTERACTION OF GENETIC AND LIFESTYLE FACTORS ON THE INCIDENCE OF TYPE 2 DIABETES (LSHM-CT-2006-037197)
",Endocrinología,"The pattern of variation of the incidence of type 2 diabetes (T2D) suggests that the disorder originates from an interaction between genetic and lifestyle behaviour factors. The InterAct consortium will use observational and trial data to investigate these interactions and explore the implications of these discoveries for preventive action. The observational part of the project is built around a large case-control study nested within an existing multi-national cohort – the EPIC study. The cohort for this project is large, comprising 350,000 participants from 8 European countries. Standardised dietary and physical activity information is available at baseline, and there is an available DNA source and plasma for nutritional biomarkers. Follow up has been completed for an average of 8 years. The collaborators have tested the feasibility and validity of an approach to ascertaining and verifying incident cases of T2D and will amass a case set of 10,000 individuals. A control cohort free of diabetes at baseline and during follow-up is readily available. To ensure efficient and high quality data, DNA extraction and genotyping will be undertaken using centralised high throughput methods. InterAct will undertake a programme of research aimed at describing the association of dietary and nutritional factors with type 2 diabetes, and will describe the association of physical activity with future risk and the ways that these factors interact with obesity. The genetic elements of InterAct will be focused on genes for which there is biological plausibility for interaction. The choice of polymorphisms in candidate genes will be undertaken by a group leading efforts to discover diabetes genes through a variety of approaches including whole genome association studies and through connection to on-going work on nutrigenomics including the NUGO network. We will genotype all 20,000 individuals for genetic variants in 200 key genes and will analyse the data for gene-lifestyle interaction. In InterAct we will move beyond the observational data to test the causal inference of these gene-lifestyle interactions in existing intervention trials which have examined the effectiveness of lifestyle changes on diabetes incidence. These include the Finnish Diabetes Prevention Study, the Danish Inter99 project, the Indian Diabetes Prevention Study and DE-PLAN (a EU project “Diabetes in Europe – Prevention using lifestyle, physical activity and nutritional intervention). The demonstration of differential response to lifestyle change by genotype will not only provide greater aetiologic understanding, but will also present the opportunity to investigate possibilities to use genotypic data in risk stratification and identification of individuals who have the potential to benefit most from targeted lifestyle prevention. In addition, improved understanding of gene-lifestyle interaction and diabetes risk will allow exploration of the policy implications for governments and industry.",Inactivo,"Diabetes, Genetics,",INTERNACIONAL,3,NO,PÚBLICA INTERNACIONAL,NO,"1. Medical Research Council
2. University of Oxford
3. Wageningen University
4. Helsingin yliopisto
5. Imperial College of Science, Technology and Medicine
6. International Agency for Research on Cancer
7. University Medical Centre Utrecht
8. Rijksinstituut voor Volksgezondheid en Milieu
9.Università degli Studi di Napoli Federico II
10. Centro per lo Studio e la Prevenzione Oncologica
11.Associazione Iblea per la Ricerca Epidemiologica. Organizzazione non lucrativa di utilità sociale
12. Fondazione IRCCS Istituto Nazionale dei Tumori
13.Fondazione ISI
14. Danish Cancer Society
15.Aalborg Hospital
16. Lund University
17.Umea University
18. Deutsches Krebsforschungszentrum
19.Deutsches Institut fuer Ernaehrungsforschung Potsdam-Rehbruecke
20. Institut National de la Santé et de la Recherche Médicale
21.IDIBELL
22. Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
23.Fundación Vasca de Innovación e Investigación Sanitarias
24. Instituto de Salud Pública de Navarra
25.Andalusian School of Public Health
26. Consejeria de Salud y Servicios Sanitarios del Principado de Asturias
27.Genome Research Ltd.
28. Novo Nordisk A/S
29.Diabetes Research Centre Foundation
30. University of Kuopio",2006,2010,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,MCSCs - Migrating cancer stem cells (MCSCs) in breast and colon cancer,Oncología,"Although cancer stem cells (CSC) have received much attention in the recent scientific literature, they are still defined by their self-renewal capability, a feature that on its own does not encompass other essential characteristics of these cells, e.g. their capacity to detach and migrate away from the primary site and invade distal organs. This operational definition of the migrating cancer stem cell (MCSC) is integral to another feature of neoplastic diseases, namely tumour heterogeneity. CSCs give rise to differentiated cells by asymmetric division thus providing a reservoir of multipotent descendants together with proliferating but progressively differentiating cells. Recent experimental evidences point out that cancer stem cells are key factors not only in local invasion and distant metastasis but also in the development of drug resistance, thus representing the target for novel strategies towards tailor-made cancer therapies.
The increasing knowledge of the structure and regulation of the mouse and human genomes together with the awareness that migrating cancer stem cell could be the ultimate target for effective therapies offer unprecedented research opportunities.
This proposal is designed to seize these opportunities and is focused on understanding the function, regulation and evolution of MCSCs in a multicellular organism. To this end we plan to identify and isolate breast and colon MCSCs by taking advantage of unique reagents, animal models, and technical approaches, and translate the results on large collections of human cancers, disseminating cancer cells, and metastases. The ultimate goal is to describe and functionally analyse the MCSCs and their micro-environment (the MCSC niche) and define a “MCSC signature”, instrumental for the development of future tailor-made therapeutic approaches.",Inactivo,"Oncology, CSC, stem cells,",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1. Erasmus University Medical Center Rotterdam
2. University of Turin
3. Universitätsklinikum Freiburg
4. National Cancer Centre Spain
5. University of Regensburg
6. IDIBELL",2009,2010,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,PPP: DEFINING BEST PRACTICES IN PALLIATIVE CARE IN EUROPE,Otros,"Objectives: In cooperation with institutes in seven European countries, an international study will be undertaken in order to describe ‘best practice in palliative care’ in Europe. Therefore, we need to develop indicators that measure best practice in palliative care. ",Inactivo,palliative care,INTERNACIONAL,3,NO,PRIVADA INTERNACIONAL,NO,"Radboud University Nijmegen Medical Centre
University Hospital Leuven
University of Sheffield
Malteser Krankenhaus, Palliativ Medizin, Bonn
Ensemble soigner et acompagner à Paris
IDIBELL
Poznan University of Medical Sciences",2007,2010,2
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,PROLIGEN - Hypoxic Renal Proliferation,Nefrología / Urología,"PROLIGEN aims to enhance the endogenous regenerative capacity of injured kidneys based on information derived from genomics/proteomics and functional genomics. The approach of PROLIGEN is: a) To define and identify set of genes/proteins associated with functional recovery from renal injury. b) To build up high
throughput test systems to follow the basic biological process involved in regeneration and to use these read out systems for functional genomics. And c) to develop biologicals and cell based therapy to foster proliferation.
PROLIGEN differs from previous approaches in that we split the regeneration process into the different main biological process (apoptosis, formation of pro- versus anti-inflammatory mediators/macrophage phenotype and cell proliferation), and we aim to study regeneration as the result of their interdependence. We take into account that macrophages are at the centre of a complex regulatory network receiving and distributing signals from and to all biological process, thus affecting recovery. At variance with previous studies we particularly focus not only on the identification of markers relevant for regeneration rather than the use of functional genomic technology which provide a new network of gene function and new platforms to deliver a new cellular based therapy strategy.
Experiments will be carried out in vivo and in vitro using rodent, tubular cell and macrophage culture.
Genomics, functional genomics and recombinant protein synthesis SMEs and prominent experts in fundamental biological process associated to the renal  ischemia/reperfusion and regeneration processes will provide the necessary knowledge and critical mass to reach the goal of this project; namely and foremost, the development of intervention strategies for amelioration of acute renal failure and promotion of regeneration and healing.",Inactivo,,INTERNACIONAL,3,SI,PRIVADA INTERNACIONAL,NO,"Consejo Superior de Investigaciones Científicas CSIC-IIBB Spain
University of Frankfurt Medical School FFM Germany
Ciutat Universitaria de Bellvitge CSUB Spain
Leiden University LU Netherland
GENEDATA AG GENEDATA Switzerland
GALÁPAGOS nv GLPG Belgium
ProtEra S.r.l.",2006,2009,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,"PANACEA - Physical Activity, Nutrition, Alcohol, Cessation of smoking, Eating out of home And obesity",Otros,"The general objective of the PANACEA project is to identify and describe what factors determine weight, weight changes and obesity. The study will also try to identify information on the behavioural habits of people with obesity. The determinants of weight and weight changes that will be more specifically investigated are:

    physical activity
    nutrition
    alcohol
    cessation of smoking
    eating out of home.
",Inactivo,"Obesity, health, ",INTERNACIONAL,3,NO,PÚBLICA INTERNACIONAL,NO,"University Medical Centre Utrecht (Universitair Medisch Centrum Utrecht)
International Agency for Research on Cance
Inst. Nat. De LaSante et De La Recherche Medicale
Deutsche Krebsforschungzentrum
Deutsches Institut Ernaehrungsforschung Potsdam-R 
IDIBELL - Catalan Institute of Oncology
Medical Research CouncilEpidemiology Unit
University of Oxford - Dep. of Clinical Medicine
Helenic Health Foundation
Centro Per Lo Studio E La Prevenzione Oncologica
Inst. Nazionale Per Lo Studio E La Cura Dei Tumori
National Inst. of Public Health An the Environment
Lund University adjustment from year 1: 6374 euro Overhead year
Umea University
University of Tromso
EPOS IASIS Research and Development Limited
Imperial College - Epidemiology and Public Health 
Danish Cancer Society-Inst. of Cancer Epidemiology 
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Fund.Vasca deInnovacion e Investigacion Sanitarias",2007,2009,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,DYNAMO - HIA. Development of a dynamic modeling tool to assess health impact of policies,Otros,"How much health can be gained by banning smoking in pubs? Or by increasing tax on alcohol? Scientific knowledge to answer such questions often exists, but in disparate sources. No off-the-shelf, generally applicable tool is available to integrate this knowledge into a quantitative answer.
This project will develop and build an instrument to quantify the health impact of policies influencing health determinants. The instrument, a quantitative model called DYNAMO-HIA, will be generic (adaptable to the health determinants and outcomes relevant for the policy in question), applicable throughout the EU, and made available as software through the internet. Where possible, it will be based on existing instruments, which will be harmonized for this purpose.
As an illustration, the instrument will be used to estimate the health impact of favourable changes in 3 lifestyle-related health determinants (smoking, obesity, and alcohol consumption) on 2 major disease groups (cardiovascular disease and diabetes, and cancer).
",Inactivo,"Health, habits, policies",INTERNACIONAL,3,NO,PÚBLICA INTERNACIONAL,NO,"Erasmus Universitair Medisch Centrum, The Nederlands
Trinity College Dublin
Inst. Naz. per lo Studio e la cura dei Tumori
London School of Hygiene and Tropical Medicine
International Obesity TaskForce of IASO
Institut Catalá d'Oncologia (IDIBELL)
Rijksinstituut voor Volksgezondheid en Milieu",2007,2010,2
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,IDAMES Innovation of dietary assessment methods in epidemiological studies and public health,Otros,The aim of this project is to generate Standard Operating Procedures (SOPs) for innovative methods assessing diet in epidemiological studies that allow quantitative and detailed characterisation of individuals regarding their dietary intake including alcohol. ,Inactivo,,INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1. Centro per lo Studio e la Prevenzione Oncologica - CSPO
2. Deustches Krebsforshungszentrum DKFZ
3. Universitair Medisch Centrum Utrecht, Julius Center for Health Sciences and Primary Care - UMCU
4. Universitetet I Tromso Norway
5. Lunds Unversitet, Sweden
6. Kraeftens Bekaempelse / Institut for Epidemiologisk Kraeftforskning - Denmark.
7. Umea Universitet (UMU) Sweden
8. Fundación Vasca de Innovación e Investigación Sanitarias (BIOEF) Spain
9. Paula Stradina Kliniska Universitates Slimnica (Latvia)
10. Fundació Privada Institut d'Investigació Biomèdica de Bellvitge - IDIBELL
11. RijksInstituut voor Volksgezonheid en mMilieu The Nederlands
12. Institut National de la Santé et de la Recherche Médicale (INSERM) France
13. Hellenic Health Foundation (HHF) Greece
14. Deutsches Institut fuer Ernaehrungsforschung Postdam - Rehbruecke - DIfe Germany
15. Aalborg Sygehus (AAS) Denmark 
16. Eesti Geenivaramu, University of Tartu (Estonia)",2008,2009,2
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,SMARTER - Development of small modulators of gene activation and repression by targeting epigenetic regulators,Genética,"The identity of a given cell within a metazoan organism is primarily defined by the expression pattern of its genes. The activation and repression of particular genes is tightly regulated by the concerted action of transcription factors that recognize and bind specific DNA sequences within regulatory regions. Work done over the last 20 years established this basic regulatory mechanism of gene activation and repression, while recent experiments exposed an additional layer of regulation involving modifications of DNA and bound histones. These modifications are involved in cellular inheritance of transcriptional states through cell division and development and as they are not coupled to DNA sequence are referred to as epigenetic.
Many factors that impact on epigenetic phenomena are clearly distinct from basic transcription factors and are involved in regulating chromatin structure. Modulation of chromatin structure is frequently achieved by intrinsic enzymatic activities that either mark particular regions within the genome for activity or repression or use the hydrolysis of ATP to remodel nucleosomal arrays. This change of gene expression patterns in response to external and internal signals has a major influence on stem cell differentiation, the maintenance of tissue integrity and the adaptation of organisms to environmental changes. Recently small molecules that target histone deacetylases have been used for cancer treatment, which has opened new avenues in therapeutical research. However, small molecules targeting epigenetic regulators have so far not been the major focus of drug discovery efforts. The SMARTER project aims at the development of such compounds, which is the primary mission of Chroma, the SME participating in the consortium. The interaction between leading European chromatin labs and Chroma is expected to greatly strengthen its knowledge base and have a strong impact on its ability to enter drug candidates in clinical trials.",Inactivo,"genetics, targets, epigenetics",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"(1) Ludwig Maximilians University of Munich
(2) Chroma Therapeutics
(3) Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
(5) The Chancellor, Masters and Scholars of the University of Cambridge, The Old Schools, Trinity Lane, Cambridge, CB1 2TN
(6) Fundació Privada Institut d’Investigació Biomèdica de Bellvitge -IDIBELL",2009,2011,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,DISCHROM - Chromatin diseases: from basic mechanisms to therapy.,Genética,"The scope of this ITN is to promote research and training in the field of chromatin diseases. Chromatin diseases (CD) are genetic pathologies resulting from mutations in structural components of chromatin or in enzymes that biochemically modify chromatin, altering chromatin status and thereby causing drastic effects on gene expression. CD frequency ranges from very rare to quite common pathologies; so far for the vast majority of them no treatment is as yet available. Molecular studies on these pathologies thus have a twofold value: to shed light on the intricate interplays between different levels of control of gene expression acting in the mammalian nucleus and to pave the way toward new and more effective strategies to approach the treatment of this increasing class of diseases. Our students will take advantage of the integrated approach on multilayered gene regulation, the multidisciplinary nature and the cutting-edge methodologies, which are an integral part of this proposal. We thus expect to provide a framework for the very high-level training of young researchers, receiving a strong backgrounds in molecular, cellular and developmental biology, genomics, bioinformatics, chromatin biology and epigenetics. Furthermore, they will develop expertise in many cutting edge methodologies and tools, such as imaging, high throughput gene technologies, ChIP. As a result, the ESRs will be highly competitive in performing independent research in various areas of biology and will represent a new breed of scientists trained in contemporary post-genomic biology using advanced
technological tools to tackle human disease.",Activo,"epigenetics, chromatin diseases, medical genetics, DNA
methylation, drug based therapy, genome wide technology,
functional genomics,Health sciences",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"Inst. of Genetics and Biophysics , CNR, Italy
BSRC Al.Fleming, Greece
University of Cambridge, UK
University of Oxford, UK 
Catalan Institute of Oncology (ICO), Spain
University of Modena and Reggio Emilia, Italy
University of Insubria,Italy 
INSERM,Marseille, France 
Univ. College London, UK 
Diagenode sa, Belgium ",2009,2012,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,Epigenetics of critical periods in vocal communication – from mouse to man.,Genética,"Sensory experiences during critical periods of brain development dramatically shape the way we uniquely perceive the world around us. Epigenetics capture the interplay between environment and genetics to explain how even the same genotype can be carved into lasting phenotypic differences. Recent cellular and molecular insight into critical period regulation from animal models coupled with novel tools to unfold the epigenome finally allow us to approach the ‘nature-nurture debate’ on human language acquisition with appropriate biological sophistication. Our findings will have a broad impact on the basic understanding of brain development, as well as on educators, policymakers and clinicians concerning individual differences in the manifestation of lifelong learning and recovery from developmental brain disorders.
We propose to explore the epigenetics of critical periods for ‘language’ development, by uniting pioneers of mouse sensory physiology (Hensch), human developmental psychology (Werker) and cancer genetics (Esteller) from three countries. First, we will use similar parameters and methods to precisely characterize plasticity at different ages in human infant speech sound discrimination and mouse perception of ultrasonic vocalizations. Guided by previous human work, a statistical learning manipulation (distributional learning) will be applied both to human infants of different ages and to mice to characterize their plasticity profile for ethologically relevant input. Then, by directly altering the timing of these sensory critical periods, we aim to identify the perceptual, behavioral and epigenetic profile of vocal communication from mouse to man.
Gene-targeting in mice has revealed that the maturation of inhibitory (GABAergic) circuits within the neocortex triggers the onset of brain plasticity in the visual system. Pharmacological enhancement of GABA function with benzodiazepines accelerates the critical period through specific GABAA receptor channels. Here, we will investigate for the first time whether such a molecular switch acts in human brain development by systematic analysis of perceptual discrimination in infants exposed to related drugs perinatally. Finally, we will perform direct measurements of epigenetic changes in the specific, relevant brain regions of mice and compare the same genes in peripheral samples (blood/saliva) from human infants. The underlying epigenetic signature will be measured at four layers of molecular complexity: DNA methylation, histone modifications, chromatin remodeling and microRNAs. 
As a naturalistic complement to early listening experience and pharmacological manipulation described above, the linguistic performance of twin pairs will be compared across epigenetic markers to understand how different phenotypes can originate from the same genotype.
",Inactivo,Epigenetics of critical periods in vocal communication – from mouse to man.,INTERNACIONAL,3,SI,PRIVADA INTERNACIONAL,NO,"RIKEN Brain Science Institute (JAPAN)
University of British Columbia (UK)
Spanish National Cancer Center - CNIO (SPAIN)",2007,2008,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,SISKID Systems Biology towards Novel Chronic Kidney Disease Diagnosis and Treatment,Nefrología / Urología,"Chronic kidney disease (CKD) affects up to 10% of the population. Besides eventual progression towards end stage renal
disease CKD impacts the patient’s quality of life by causing serious comorbidities including cardiovascular complications
and bone metabolism disorders. On the everyday clinical level early stage diagnosis and tailored treatment of CKD are still
inadequate. In addition, CKD seems not to have reached its appropriate emplacement in an epidemiological and healthcare
perspective yet, and the pathophysiology of the disease on a molecular and cellular level is not well enough understood. Our
sysKID consortium was installed for precisely addressing these issues: To unravel the molecular and cellular mechanisms of
chronic kidney disease development, combine this information with clinical risk factors, and on this basis delineate chronic
kidney disease biomarkers. These markers will allow us to perform preclinical studies of novel therapy approaches for halting
disease progression, and will provide us with the materials for development and clinical evaluation of tools for early stage
diagnosis as well as prognosis and treatment monitoring. sysKID assures a successful implementation of these goals by
a truly international consortium of 25 leading research groups. We combine clinical know how, provide access to a huge
chronic kidney disease sample and clinical data pool, and build a Systems Biology framework for chronic kidney disease by
integrating molecular and cellular biology, computational biology, statistics and epidemiology. Our expert group is further
complemented by a high level advisory board covering science, product development, and the patient’s perspective. sysKID
implementation is structured for completing pre-clinical Proof of Concept studies of novel chronic kidney disease therapy
regimes, and further for completing clinical evaluation of an epidemiological screening tool as well as of early stage chronic
kidney disease diagnostic kits.",Activo,"chronic kidney disease, diabetic nephropathy, diagnostic assays, therapy regimes, omics experiments, systems biology, functional genomics, patient outcome, clinical data repositories",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1. emergentec biodevelopment GmbH, Rathausstrasse 5/3, 1010 Vienna, Austria, the Coordinator, in short “EMTEC”
2. Medizinische Universitaet Wien, Spitalgasse 23, 1090 Wien, Austria, in short “MUW“
3. Medizinische Universität Innsbruck, Christoph-Probst Platz 1, 6020 Innsbruck, Austria, in short “IMU“
4. Mosaiques Diagnostics GmbH, Mellendorfer Strasse 7-9, 30625 Hanover, Germany, in short “MOS“
5. ProScience Communications - die Agentur für Wissenschaftskommunikation GmbH, Andechser Weg 17, 82343 Poecking, Germany, in short “PROSCI“
6. Steno Diabetes Center A/S, Niels Steensens Vej 2, 2820 Gentofte, Denmark, in short “STENO“
7. Universitätsklinikum Erlangen, Maximiliansplatz 2, 91054 Erlangen, Germany, in short “UKER“
8. Academisch Ziekenhuis Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands, in short “UMCG“
9. Śląski Uniwersytet Medyczny w Katowicach, Poniatowskiego 15, 40-055 Katowice, Poland, in short “SUM”
10. Semmelweis Egyetem, Uelloei ut 26, 1085 Budapest, Hungary, in short “SE”
11. University of Glasgow, University Avenue, G12 8QQ Glasgow, United Kingdom, in short “UGL”
12. Biocrates Life Sciences AG, Innrain 66, 6020 Innsbruck, Austria, in short “BIOC”
13. Charite – Universitätsmedizin Berlin, Chariteplatz 1, 10117 Berlin, Germany, in short “CHARITE“
14. Biogazelle NV, Kruishoutemstraat 57, 9870 Zulte, Belgium, in short “BIOGAZ“
15. Celera Corporation, Harbor Bay Parkway 1401, 94502 Alameda, United States of America, in short “CRA”
16. Academisch Medisch Centrum bij de Universiteit van Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands, in short „AMC“
17. Consiglio Nazionale delle Ricerche, Piazzale Aldo Moro 7, 00185 Roma, Italy, in short “CNR“ SysKID Consortium Agreement
18. Universite Victor Segalen Bordeaux 2, Rue Leo Saignat 146, 33076 Bordeaux Cedex, France, in short “UB2”
19. Weizmann Institute of Science, Herzel Street 1, 76100 Rehovot, Israel, in short “WEIZMANN”
20. University College Dublin, National University of Ireland, Belfield Campus, Dublin 4, Ireland, in short “NUID UCD”
21. Istituto di Ricerche Farmacologiche Mario Negri, Via Giuseppe La Masa 19, 20156 Milano, Italy, in short “IRFMN”
22. Universität des Saarlandes, University Campus, 66123 Saarbrücken, Germany, in short “USAAR”
23. Fundacio Institut D’Investigacio Biomedica De Bellvitge, Av Gran Via Hospitalet, 199, 08907 Barcelona, Spain, in short “IDIBELL”
24. Amgen (Europe) GmbH, Dammstrasse 23, 6001 Zug, Switzerland, in short “AMGEN“ 
25. Biomarker Design Forschungs GmbH, Divischgasse 4, 1210 Vienna, Austria in short “BDF“",2010,2014,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,LeukoTreat—Therapeutic challenge in Leukodystrophies: Translational and ethical research towards clinical trials,Enfermedades raras,"Leukodystrophies (LDs) are inherited rare neurodegenerative diseases of the white matter and its main component, the
myelin, that are affecting predominantly children. Severity of the disease is related to the axonal dysfunction due to myelin
deficiency or destruction. Despite the achievement of remarkable advances made in the past decade, there is no current
curative therapy. The development of therapeutic approaches for myelin repair and neuroprotection constitutes the main
objective of the LeukoTreat project. Indeed LDs constitute prototypic pathologies to tackle myelin formation/destruction
issues as well as glial cells dysfunctions in neurodegeneration. The global aim is to promote the development of therapeutic
strategies for the largest number of LD affected patients and further applications to more common white matter disorders
and finally neurodegenerative diseases. For this purpose, the project will combine the expertise of (i) recognized European
research teams in the field of White Matter diseases (COST Myelinet), (ii) high-technology SMEs, (iii) experts in medical
ethics and (iv) LD patients and families associations. To develop efficient therapies, the LeukoTreat project is based
on 5 complementary approaches consisting in: (i) collecting information on the epidemiology, the natural history, the
genotype/phenotype correlation of LDs for at least 500 patients; (ii) validating/identifying biomarkers for therapeutic
decisions/follow up to isolate new therapeutic targets; (iii) developing pharmacological strategies with the ultimate objective to
launch at least 4 pharmacological clinical trials during 5 years following the project; (iv) developing innovative gene and cell
therapies with the ultimate objective to launch at least 3 clinical trials during the next 5 years; (v) tackling ethical impacts of
the proposed therapeutic challenges by integrating the participation of patients driven by a well-experienced research team
strongly skilled in ethics",Activo,Leukodystrophy; Myelin; Biomarkers; Lipidomics; Cellular stress; Gene regulation; Gene therapy; Cell therapy,INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"UNIVERSITE D'AUVERGNE CLERMONT FERRAND
OSPEDALE PEDIATRICO BAMBINO GESU OPBG Italy 
ISTITUTO GIANNINA GASLINI IGG Italy 
UNIVERSITAETSKLINIKUM BONN UKB Germany 
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE INSERM 
SOLUSCIENCE SA Soluscience France 
THE UNIVERSITY OF MANCHESTER UMAN UK 
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE IDIBELL Spain
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. MPG 
MEDIZINISCHE UNIVERSITAET WIEN MUW Austria
TROPHOS SA Trophos France
UNIVERSITY COLLEGE LONDON UCL UK
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR HSR Italy 
ACADEMISCH MEDISCH CENTRUM AMC Netherlands 
UNIVERSITE PARIS DESCARTES LEM France 
FRANCE EUROPE INNOVATION FEI France
ASSOCIATION EUROPEENNE CONTRE LES LEUCODYSTROPHIES ELA France
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE CMSUC UK
UNIVERSITE PARIS DIDEROT - PARIS 7 UPD-P7 France
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA FIINCB Italy 
UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITA
EBERHARD KARLS UNIVERSITAET TUEBINGEN",2010,2013,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,PREHDICT—health-economic modelling of PREvention strategies for Hpv-related Diseases in European CounTries  ,Inmunología,"The goals of the PREHDICT study are to determine prerequisites and strategies for vaccination in European countries and
to predict the impact of vaccination on screening programmes. To achieve these goals, a multiple HPV type transmission
model will be built to describe the type-specific incidence and clearance of HPV infections. This model will be linked to an
individual-based simulation model used for modelling the impact of screening. For HPV-related diseases other than cervical
cancer and genital warts, Markov models will be developed after critical review of the role of HPV. In the PREHDICT study,
country-specific cost-effectiveness analyses will be performed for the vaccination and include determination of the vaccination
age, the number of doses, the vaccination population, and the optimal catch-up vaccination age. Furthermore, the impact of
vaccination on screening programmes will be assessed. This involves determination of the screening technology, screening
frequency, and follow-up management of test-positive women. Special attention will be given to screening attendance and
its relation to vaccination attendance. To have models with strong empirical support, the PREHDICT team will collect the
most updated data on HPV infection, HPV-related disease, life-style factors, and demographics. Furthermore, HPV-type
specific analyses will be performed on the outcomes of a vaccination trial, 3 large screening trials, and one self-sampling
trial for screening non-attenders. By meta-analytical techniques, results will be pooled. The costs involved in the calculations
will include the costs of organizing, running, and monitoring a vaccination and/or screening programme. The results of the
PREHDICT study will be published in international peer-reviewed journals, posted on the WHO HPV information centre
website and will also be systematically disseminated to all major stakeholders, in particular to decision makers at European,
national and sub-national levels.",Activo,"vaccination, screening, HPV-related disease, transmission
model, individual-based model, cost-effectivenes",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1. Vrije Universiteit Medisch Centrum,  
2. Fundacio Privada Institut D’investigacio Biomedica de Bellvitge,  
3.  Azienda Ospedalerio-Universitaria San Giovanni Battista di Torino, 
4. Lunds universitet, , Sweden, 
5. Tampereen Yliopisto, Finland, 
6. Institut Scientifique de Santé Publique, Brussels , Belgium, 
7. London School of Hygiene and Tropical Medicine, UK  
8. Imperial College of Science, Technology and Medicine, UK  
9. European Cervical Cancer Association, , France  ",2010,2013,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,IMMEEDIA - Immunomodulatory Effects of Exercise in Type 1 Diabetes,Endocrinología,"Diabetes is a major metabolic disease with huge costs for healthcare system throughout the EU and worldwide. Type 1
Diabetes (T1DM) is a chronic condition in which pancreas produces little or no insulin, believed to result from a disorder
of immunoregulation. For decades it has been known that regular aerobic exercise improves insulin sensitivity in diabetic
patients, reducing insulin requirements. Traditionally, physical exercise has been promoted in type 2 diabetes, where
insulin action is deficient in the context of insulin resistance and/or inappropriate insulin secretion. However, even in T1DM,
in the dysregulation of immune system function, beta-cell toxicity is mediated by a complex interplay between oxidative
stress and inflammation, for which exercise could be protective. Preliminary observations in fact indicate that regularly
exercising T1DM-subjects have lower autoimmunity markers at an early stage of the disease. We want to ascertain the effect
of moderate regular exercise as the most convenient measure to avoid the onset/worsening of T1DM. To verify whether
exercise is capable of countering the T1DM-autoimmune process directed against beta-cells of the pancreatic islets, a
multi-centric study will include: a) administration of a tailored exercise training program in different cohorts of T1DM-subjects;
b) in-vivo animal experiments in which gain/loss-function models will be challenged with exercise; c) cell studies to analyse
the exercise effects on signal transduction pathways and cytokine responses; d) metabolic profiling and metabolomic
studies concerning the multicomponent analysis of biological fluids, tissue and cell extracts. Our consortium, through this
multi-approach strategy, will reveal how exercise may exert a potent immunomodulatory effect, reducing the autoimmune
response that in T1DM attacks and destroys the insulin producing cells.",Activo,"type 1 diabetes, exercise, autoimmunity, glucose metabolism",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"University of Milan
Karolinska Institutet
University of Barcelona – Hospital Universitari Bellvitge
San Raffaele Hospital, Milan
Diabetes Research Institute (DRI), Miami",2010,2014,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,CURELUNG - Determining (epi)genetic therapeutic signatures for improving lung cancer.,Oncología,"Lung cancer (LC) is still the most lethal type of cancer worldwide. The extremely poor prognosis for LC patients is partly
due to the lack of effective therapies. At present, most patients with pulmonary carcinomas are treated with chemotherapy.
This essentially consists of classic cytotoxic drugs which only improve survival in small cohorts in few cases. In spite of the
rapidly growing understanding of the epigenetic and genetic profile of LC, such knowledge has contributed little to improving
therapeutics. This scenario, however, is likely to change soon because several specific cancer therapies, targeting molecules
that are altered in cancer, are being developed or are already undergoing clinical trials. Thinking ahead, our proposal focuses,
on the one hand, on validating novel and specific therapeutic strategies, with particular emphasis on discovering (epi)genetic
alterations that could act as novel targets for therapies, and, on the other, on defining the (epi)genetic markers that could
determine the efficacy response or resistance to targeted therapies as well as the acquired resistance of the tumours to
therapy. To reach our goals, we have designed an integrative and interdisciplinary approach involving leading European
clinical scientists of international renown with prominent preclinical and basic research groups using high throughput and
state-of-the art platforms for genomics and gene expression analysis. To date, no such comprehensive information exists.
The results will be of great value for the stratification of lung tumours according to their genetic background for tailored
treatments. The development of an (epi)genetic-based therapeutic prediction model will hopefully set the basis for future
tailored treatment of LC as well as of other epithelial cancers.",Activo,"Lung cancer, targeted therapeutics, gene alteration profiling, epigenetic profiling",LOCAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1. Fundació Privada Institut d’Investigació Biomèdica de Bellvitge (IDIBELL)
2. The University of Liverpool
3. Université Joseph Fourier Grenoble 1
4. Fundación para la Investigación Médica Aplicada (FIMA)
5. Max Planck Gesellschaft Zur Foerderung Der Wissenschaften E.V.
6. Fondazione IRCCS Istituto Nazionale dei Tumori
7. Università degli Studi di Torino
8. Institut Gustave Roussy
9. Klinikum der Universität zu Köln
10. Krzysztof Kucharczyk Techniki Elektroforetyczne Spzoo
11. MRC HOLLAND B.V.",2011,2013,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,HEPTROMIC - Genomic predictors and oncogenic drivers in hepatocellular carcinoma,Oncología,Genomic predictors and oncogenic drivers in hepatocellular carcinoma,Activo,"Hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancers, and is a major health problem. Its incidence
is growing and with more than 700,000 annual cases worldwide -50,000 in Europe-, it is the 3rd cause of cancer-related
mortality. Most patients are diagnosed at advanced stages with dismal survival rates lower than 1 year, even after sorafenib,
the sole systemic therapy available. The main goal of the HEPTROMIC project is to produce breakthrough knowledge in two
critical aspects of HCC research: prognostic prediction and identification of oncogenic drivers susceptible for intervention,
leading towards more personalized treatment algorithms. The HEPTROMIC Consortium proposes a 3-year translational
research study bringing together an outstanding team of researchers with clinical and genomic expertise along with
cutting-edge technology. Eight partners -six academic and two SMEs- will address the following objectives by applying
high-end transcriptome, methylome and deep sequencing technology in a large set of 1,140 human samples: Objective
1) Genomic characterization of poor prognosis subclass of hepatocellular carcinoma. Objective 2) Identification of driver
oncogenic events as potential treatment targets. Findings obtained will be confirmed in sophisticated experimental models
that closely mimics human liver cancer. Objective 3) Design of prognostic devices for clinical translation. This transfer of
knowledge will be led by SMEs with entrepreneurial management skills with experience in creating new products increasing
European competitiveness and boosting the innovative capacity of industries. Overall, the Consortium foresees impacts on
improved patient survival by refining prognosis and decision-making, identifying targets amenable for selective therapies and
by improving the allocation of resources. In summary, HEPTROMIC will strength links between the academic and industry
spheres, ultimately contributing to reduce liver cancer mortality.",LOCAL,3,SI,PÚBLICA INTERNACIONAL,NO,"CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER - IDIBAPS
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM
FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMEDICA DE BELLVITGE - IDIBELL
HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSHUNG GMBH
FONDAZIONE IRCCS INSTITUTO NAZIONALE DEI TUMORI
THE BROAD INSTITUTE INC CORPORATION
DIAGENODE SA
TCLAND EXPRESSION SA",2010,2013,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,COLTHERES - Modelling and predicting sensitivity to targeted therapies in colorectal cancers,Oncología,Modelling and predicting sensitivity to targeted therapies in colorectal cancers,Activo,Modelling and predicting sensitivity to targeted therapies in colorectal cancers,INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE,
Horizon Discovery Limited 
Agendia BV
STICHTING HET NEDERLANDS KANKER INSTITUUT, 
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON , 
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CAf GRANDA, 
KATHOLIEKE UNIVERSITEIT LEUVEN, THE UNIVERSITY OF LIVERPOOL
SWISS INSTITUTE OF BIOINFORMATICS
ARTTIC IN BRUSSELS SPRL, ",2011,2014,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,SYSCOL - Systems Biology of Colorectal Cancer,Oncología,"Colorectal cancer (CRC) is one of the most common cancers in both males and females, and it is perhaps the best understood of all epithelial tumors in terms of its molecular origin. Yet, despite large amount of work that has concentrated on understanding of colon tumorigenesis, we still do not know the full  Complement of molecular lesions that are individually necessary – and together sufficient – to cause colorectal cancer. Neither do we understand why some specific mutations that are relatively rare in other tumors (e.g. loss of the APC tumor suppressor) are extremely common in colorectal cancer.
We propose here to use the tools of systems biology to develop a quantitative and comprehensive model of colorectal tumorigenesis. The model will include a “wiring diagram” that identifies cell-type specific and oncogenic pathways that contribute to colon tumorigenesis, and explains in molecular detail how a genotype of an individual CRC leads to activation of downstream genes that drive uncontrolled cell growth. This model will subsequently be used to find novel therapeutic targets, to guide genetic screening to identify individuals with elevated risk for developing CRC, and to classify patients into molecular subgroups to select the treatment combination which is optimal for each patient (personalized medicine). The specific objectives of the SYSCOL project are:
1. Identify genetic markers for individual risk using genotyping and sequencing of germline DNA from sporadic and familial CRC cases and controls
2. Identify genes and regulatory elements that contribute to colorectal cancer cell growth 
3. Use data from Aims 1-2 to develop a quantitative model for colorectal tumorigenesis
4. Apply the model for identification of high-risk individuals, for molecular classification of the disease, and for identification of novel molecular treatment targets",Activo,"systems biology, disease model, colorectal cancer, gene expression, disease predisposition",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1 KAROLINSKA INSTITUTET KI Sweden 
2 THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UOXF.H5 United Kingdom
3 AARHUS UNIVERSITETSHOSPITAL, SKEJBY AUH, S Denmark
4 UNIVERSITE DE GENEVE UNIGE Switzerland
5 WEIZMANN INSTITUTE OF SCIENCE Weizmann Israel 
6 HELSINGIN YLIOPISTO UH Finland
7 JOHNS HOPKINS UNIVERSITY JHU United States
8 FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE IDIBELL Spain 
9 STICHTING KATHOLIEKE UNIVERSITEIT RU Netherlands 
10 INSTITUTE OF CANCER RESEARCH - ROYAL CANCER HOSPITAL ICR United Kingdom
12 GENEXPLAIN GMBH",2011,2015,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,MABSOT—Development of OPN-305 as an orphan drug for the treatment of Delayed Graft Function post solid organ transplantation,Nefrología / Urología,"Delayed graft function (DGF) is defined as the need for dialysis within seven days of renal transplantation (DGF promotes
allograft rejection, requires prolonged dialysis and hospitalisation, and increases the likelihood of graft failure and ultimately
the duration of renal graft survival-expectancy. The incidence of DGF occurs in 21-44% of cases following cadaveric
renal graft. Several rare diseases, particularly those of genetic origin, are associated with the requirement for solid organ
transplantation as the disease progresses. At Opsona Therapeutics we have developed a novel antibody (OPN305) which
has received OMP designation (EU/3/09/638) for use in the prevention of DGF. The scientific basis of this development is the
inhibition of Toll-like receptor 2 (TLR2)-mediated ischaemic reperfusion injury which has a pivotal role in the pathogenesis of
DGF and its sequelae. The MABSOT project is designed to progress the development of this OMP through Phase I and IIa
clinical trial. The successful completion of the programme will allow the continued development of OPN305 as an OMP for the
treatment of DGF in a range of solid organ transplant situations. OPN305 development will have significant benefit to these
patients and health care providers in reducing the prolonged hospitalisation of these individuals, providing greater longevity
associated with the transplanted organ and enhanced quality of life for these individuals.",Activo,"transplantation, delayed graft function, kidney, solid organ transplantation",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"(1) Opsona Therapeutics Limited (Co-ordinator)
(2) Kings College London (KCL)
(3) Euram Limited (Euram) 
(4) Katholieke Universiteit Leuven (KUL) 
(5) Institut d’Investigacio Biomedica de Bellvitge (IIBB)
(6) Institute for Clinical and Experimental Medicine (IKEM) 
(7) University of Newcastle-Upon-Tyne (UNT)
(8) University Medical Centre Groningen (UMCG) 
(9) ALMAC Diagnostics (ALMAC) ",2010,2013,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,EUROTARGET - European collaborative project on Targeted therapy in renal cell cancer: genetic and tumor-related biomarkers for response and toxicity,Nefrología / Urología,"Each year more than 63,000 new cases of kidney cancer are diagnosed in the European Union. Approx. 50% of all patients have metastasized renal cell cancer (mRCC) at presentation or develop metastases during follow-up. 5-year relative survival of mRCC has been extremely poor: between 5 and 10%. In the past few years, so-called targeted therapies that suppress angiogenesis have changed the clinical practice for patients with mRCC dramatically. Both response and toxicity to these expensive drugs is, however, extremely variable. With an increasing number of compounds becoming available, choice of compounds and sequence is becoming extraordinary challenging. Classical patient and tumor characteristics appear to have poor predictive ability. The aim of this project is to identify germline genetic markers that predict response and toxicity (by the use of high-resolution whole genome SNP arrays in groups of hundreds of patients treated with different agents), identify expression and epigenetic markers in tumors that predict response (by comparing expression and methylome arrays and kinase profiles in frozen tumor tissue from groups of patients who do (N=30) and do not (N=30) respond to different agents), to integrate these data from different  platforms by means of bioinformatics and to conduct focused functional studies on the results in order to improve understanding of the critical molecular and resistance pathways involved. A large European consortium that has recruited and will recruit large numbers of patients ensures that the new markers identified in a first discovery phase can be tested in a subsequent replication phase. We have the ambition to define new validated risk stratification criteria to be used in personalized patient management. These criteria allow prediction of individual therapy response and resistance and will enable the monitoring of successful treatment outcome while reducing unnecessary drug use and expense.",Inactivo,"Metastasized renal cell cancer; targeted therapy; genetic profiling; transcriptome; methylome; kinase activity, translational",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1) STICHTING KATHOLIEKE UNIVERSITEIT MORE PARTICULARLY THE RADBOUD UNIVERSITYNIJMEGEN MEDICAL CENTRE, the Netherlands
2) Academisch Ziekenhuis Leiden, The Netherlands
3) University of Cambridge, Addenbrooke’s Hospital, UK
4) University Hospitals, Friedrich-Schiller-University Jena, Germany
5) Central European Society for Anticancer Research-EWIV, Austria
6) deCODE Genetics, Reykavik, Iceland, deCODE 
7) Fundació Institut D’Investigació Biomèdica de Bellvitge, IDIBELL
8) PamGene International BV, The Netherlands, PAMGENE
9) Stichting Het Nederlands Kanker Instituut, Amsterdam, The Netherlands
10) National Institute of Health and Medical research, INSERM
11) Universitatea de Medicina si Farmacie ‘Carol Davila’ din Bucuresti, UMP-CD
12) University of Bonn, Germany
",2011,2016,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,"EUROWABB: An EU rare diseases registry for Wolfram syndrome, Alstrom syndrome and Bardet Biedl syndrome",Enfermedades raras,"The general objective of this project is to support efficient diagnosis, treatment, and research for the overlapping rare genetic diseases Wolfram, Alstrom and Bardet Biedl (WABB) syndromes in Europe. We will achieve this by implementing an EU registry for WABB, containing clinical, genetic diagnostic and outcome data. The purpose of the registry is: a) to establish the natural history of the 3 diseases (their characteristics, management and outcomes); b) to assess clinical effectiveness of management and quality of care; c) to provide an inventory of patients for recruitment to intervention studies; d) to establish genotype-phenotype correlations. We will achieve high usage of the registry by linking it to rapid genetic testing; and to up to date, accurate information, FAQS, and education material.
• The strategic relevance is its support for equal access to genetic testing, education of health professionals, and empowerment of patients. (Council Recommendation on action in the field of rare diseases); adequate inventorying of WABB diseases (Section II); supporting research (Section III); development of centres of expertise (Section IV); gathering expertise at European level (section V); empowering patient organizations as partners (Section VI); developing sustainability by underpinning a future European Reference Network for WABB diseases (Section VII); supporting the High Level Pharmaceutical Forum Recommendations (2008) to mobilise resources to generate shared information; and supporting an improvement in health outcomes, and therefore Healthy Life Years, a key Lisbon Strategy indicator.
• The contribution to The Second Health Programme is through: a) increased knowledge on these 3 rare diseases by pooling together data on larger number of patients; b) support for research by allowing access to investigators for epidemiological, clinical, genetic and interventional studies; c) effective dissemination of results via the Orphanet network, subject to security for the registry; d) advocacy for improved quality of services via EURORDIS at the European level, and member state specific Orphanet groups at the national level; e) balanced participation. Our project group includes researchers, clinicians, stakeholders, and policy makers from 7 EU member states.  
• Methods and means. We will use validated, quantitative questionnaires and focus groups of health professionals, to scope the support requirements of centres for submitting data to the Registry. We will develop a consensus on a core dataset for the Registry, then develop a multifunctional web based Registry with user friendly browser-based access. We will create a WABB microarray capable of identifying up to 600 different mutations. We will undertake quantitative questionnaires and focus groups for patients and health professionals to compile their learning and information needs; write education material and patient information on WABB diseases, and use it to support 'meet the expert' platforms, and fora for client groups. 
• Expected outcomes. There will be a step change in volume and quality of clinical research in WABB diseases. The registry will be also be transferable to scientists exploring the mechanisms underlying common diabetes and obesity. This will change our understanding of these rare diseases through increased knowledge of the natural history and genotype phenotype relations informing prognosis. WABB diseases will have increased visibility to the research and health provider communities through Orphanet and EURORDIS. There will be a change in clinical effectiveness of services for WABB patients. The registry will provide data for assessing the clinical effectiveness and cost-effectiveness of standard care and new interventions in a real-world setting. This will lead to improvements in quality of care. The Registry will identify disparities between health care outcomes and provide evidence for health service providers for improvements.",Activo,"International Agency for Research on Cancer (IARC)
Deutsches Krebsforschungszentrum (DKFZ)
Fundació Privada Institut D'Investigació Biomedica de Bellvitge (IDIBELL)
University of Antwerp (UA)
European Institute of Oncology (IEO)
Aristotle University of Thessaloniki (AUT)
Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke (DIFE)
Universitätsklinikum Heidelberg (UKL-HD)
MTM Laboratories AG (MTM)
Rajiv Gandhi Centre for Biotechnology (RGCB)",INTERNACIONAL,3,NO,PÚBLICA INTERNACIONAL,NO,"University of Birmingham
University of Glasgow
Centre National de la Recherche Scientifique
Fundació Institut Investigació Biomèdica de Bellvitge 
Università degli Studi di Padova
Medical University of Lodz
National Institue of Health and Medical Research (INSERM)
University of Tartu Alström Syndrome UK  
",2011,2013,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,ISN-SRC Program,Nefrología / Urología,Intercambio y movilidad entre países en el ámbito de la Nefrología.,Inactivo,"Movilidad, Nefrología. ",INTERNACIONAL,3,SI,PRIVADA INTERNACIONAL,NO,"Centro de Nefrología. Hospital de Clínicas Facultad de Medicina Universidad de la República, URUGUAY,UY
Centro de Nefrología y Transplante Renal. Hospital Universitario de Bellvitge Barcelona, SPAIN,ES",2011,2011,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,HPV-AHEAD—Role of human papillomavirus infection and other co-factors in the aetiology of head and neck cancer in India and Europe,Virología,"Human papillomavirus (HPV) is responsible for approximately 25% of head and neck cancer (HNC) worldwide and appears
to be associated with a better response to treatment and improved prognosis. Evidence suggests that HPV-induced HNC
has steadily increased in the USA and some European countries in the last decades. However, whether this is a worldwide
phenomenon and specific risk factors are associated with it remains to be proven. In addition, little is known on the natural
history and risk factors of oral HPV infection. HPV-AHEAD network aims to address these and other unanswered questions
on HNC etiology and epidemiology with a focus on the role of HPV. We will assemble and analyze a large collection of
plasma/sera and HNC tissues from 42 centres in 16 European countries as well as HNC tissues from 7 Indian centres
together with epidemiological and clinical data. HPV status in human specimens will be evaluated by different assays in
central laboratories. Epidemiological studies will be conducted to establish the overall proportion and type distribution of
HPV-positive HNC at different anatomical sites in European and Indian regions as well as the time trend of the proportion of
HPV-positive HNC in recent decades. Using the follow-up information on HNC patients, we will further investigate whether
HPV positivity confers a better prognosis and survival. We will also conduct a study in HPV-vaccinated and non-vaccinated
women in order to determine risk factors and natural history of oral HPV infections. In addition, we will search for new
surrogate markers for oral HPV infection to facilitate novel screening strategies. Finally, the HPV-AHEAD consortium aims
to transfer technology to Indian centres as well as to develop several strategies for the training of European and Indian
researchers in infections and cancers. This study will provide important insights for the screening, diagnosis, treatment and
prophylaxis of HPV-associated HNC in Europe, India and elsewhere.",Activo,"Head and Neck cancer, human papillomavirus, surrogate
HPV markers, vaccine efficacy",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"International Agency for Research on Cancer (IARC)
Deutsches Krebsforschungszentrum (DKFZ)
Fundació Privada Institut D'Investigació Biomedica de Bellvitge (IDIBELL)
University of Antwerp (UA)
European Institute of Oncology (IEO)
Aristotle University of Thessaloniki (AUT)
Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke (DIFE)
Universitätsklinikum Heidelberg (UKL-HD)
MTM Laboratories AG (MTM)
Rajiv Gandhi Centre for Biotechnology (RGCB)",2011,2015,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,BLUEPRINT of Haematopoietics epigenomes,Genética,"In response to the call for a high impact initiative on the human epigenome, the BLUEPRINT Consortium has been formed with the aim of generating at least 100 reference epigenomes and studying them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. BLUEPRINT will focus on distinct types of haematopoietic cells from healthy individuals and on their malignant leukaemic counterparts.
Reference epigenomes will be generated by state‐of‐the‐art technologies from highly purified cells for a comprehensive set of epigenetic marks in accordance with quality standards set by IHEC. This resource‐generating activity will be conducted at dedicated centres to be complemented by confederated  hypothesis‐driven research into blood‐based diseases, including common leukaemias and autoimmune disease (T1D), by epigenetic targets and compound identification, and by discovery and validation of epigenetic markers for diagnostic use. By focussing on 100 samples of known genetic variation BLUEPRINT will  complete an epigenome‐wide association study, maximizing the biomedical relevance of the reference epigenomes. Key to the success of BLUEPRINT will be the integration with other data sources (i.e. ICGC, 1000 genomes and ENCODE), comprehensive bioinformatic analysis, and user‐friendly dissemination to the wider scientific community. The involvement of innovative companies will energize epigenomic research in the  private sector by creating new targets for compounds and the development of smart technologies for better diagnostic tests. BLUEPRINT will outreach through a network of associated members and form critical alliances with leading networks in genomics and epigenomics within Europe and worldwide. Through its interdisciplinarity and scientific excellence combined with its strong commitment to networking, training and communication BLUEPRINT strives to become the cornerstone of the EU contribution to IHEC ",Activo,"Reference Epigenome, Haematopoiesis, Leukaemia, Type 1 Diabetes, DNA (hydroxy)methylation, Epi-targets, Biomarkers, Compounds screening, Genome-epigenome variation, Training, Outreach, Mouse models",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"STICHTING KATHOLIEKE UNIVERSITEIT, The Coordinator
UNIVERSITY COLLEGE LONDON
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
NOVARTIS FORSCHUNGSSTIFTUNG
CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS II
ISTITUTO EUROPEO DI ONCOLOGIA SRL
EUROPEAN MOLECULAR BIOLOGY LABORATORY
GENOME RESEARCH LIMITED, operating as the Welcome Trust Sanger Institute (WTSI)
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE
FUNDACIO PRIVADA PARC CIENTIFIC DE BARCELONA
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
UNIVERSITAET DES SAARLANDES
SECONDA UNIVERSITÀ DEGLI STUDI DI NAPOLI
FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA
QUEEN MARY AND WESTFIELD COLLEGE, UNIVERSITY OF LONDON
THE BABRAHAM INSTITUTE
CELLZOME AG
DIAGENODE SA
HALO GENOMICS AB
GENOMATIX SOFTWARE GmbH
OXFORD NANOPORE TECHNOLOGIES LTD
SIENA BIOTECH SPA
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
CONSORCI INSTITUT D’INVESTIGACIONS BIOMEDIQUES AUGUST Pi i SUNYER
WEIZMANN INSTITUTE OF SCIENCE
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
UNIVERSITAET ULM
THE UNIVERSITY OF EDINBURGH
LUNDS UNIVERSITET
KØBENHAVNS UNIVERSITET
UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA
VIVIA BIOTECH S.L.
UNIVERSITE DE GENEVE
ACADEMIC HOSPITAL GRONINGEN
CENTRE NATIONAL DE LA RECHERCE SCIENTIFIQUE
UNIVERSITAETSKLINIKUM ESSEN
UNIVERSITAET LEIPZIG
BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION
SIGOLIS AB
EUROPEAN RESEARCH AND PROJECT OFFICE GmbH",2011,2016,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,DEVELAGE - Pathways common to brain development and ageing: defining strategies for preventive therapy and diagnostics,Salud internacional,"The increasing number of elderly people will have a major impact on the prevalence of age-related diseases, which will pose major challenges to keep health systems in Europe sustainable. Current knowledge is insufficient to identify the transition of normal brain ageing into Alzheimer`s Disease (AD)-like brain damage. Elucidation of the genes and pathways contributing to the earliest stages of AD pathology and associated neurodegeneration should be instrumental to alow intervention w hen the condition is still reversible. The aim of the DEVELAGE project is to characterise shared molecular pathways between early developmental processes in the brain and brain ageing. Our concept is based on the hypothesis that disorders of neural development contribute to age-related neurodegeneration, that developmentally essential proteins might have a role in neurodegeneration, and that neurodegeneration-related proteins and genes are important during the development of the brain. The DEVELAGE approach is unique in that it is brain tissue-based, derived from neuropathological diagnosis with detailed molecular analysis of the spectrum of developmental and ageing changes in the very same brain samples used for a comprehensive array of investigations in humans as well as in experimental models at genetic, epigenetic, transcription and protein levels. DEVELAGE contributes to the  understanding of biological variation by examining relevant number of cases with different phases of ageing and neurodegeneration as well as developing brains with or without developmental disorders. Pathways examined in humans will be validated in animal models, including a non-human primate, and vice versa. 
The combination of human samples and animal models susceptible to experimental manipulation will promote the translation
of clinically relevant data into experimentally testable predictions and promotes the exploitation of therapeutically relevant
targets to reverse or halt disease progresssion.",Activo,"ageing, development, human brain, genomics, proteomics, transcriptomics, epigenetic, non-human primate model",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"1 Medizinische Universität Wien (MUW) Academic Austria
2 The Bellvitge Institute of Biomedical Research (IDIBELL) Academic Spain
3 Amsterdam Medical Center (AMC) Academic Netherlands
4 Sapienza University of Rome (SUR) Academic Italy
5 Tierärztliche Hochschule Hannover (TIHO) Academic Germany
6 University of Montpellier 2 (UMP2) Academic France
7 U676, Université Paris Diderot (INSERM) Academic France
8 biolution GmbH (biol)",2012,2014,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,DEXLIFE Mechanisms of prevention of type 2 diabetes by lifestyle intervention in subjects with pre-diabetes or at high-risk for progression,Endocrinología,"Type 2 diabetes (T2DM) is preventable by sustained changes in diet and physical exercise. Despite this, modern societies are already approaching 10% population prevalence of diabetes, and another 15% with pre-diabetes. The costs of T2DM are huge, approaching 10% of all health costs. Prevention of diabetes is a priority for national healthcare agencies and for the health insurance industry. Investment in prevention and lifestyle programmes requires a solid evidence-base for targeting and customising these interventions in a cost-effective manner. Translation of the findings from T2DM prevention studies to the benefit of general public health has not yet been possible.
DEXLIFE will identify novel diagnostic and predictive biomarkers (i) to detect the progression toward diabetes in high risk individuals and (ii) that are responsive to lifestyle interventions known to be effective in diabetes prevention. New biomarkers alone will be insufficient to alter the course of diabetes progression. We bring a strong translational focus to this proposal, by setting the main intervention in the real-life context of a major health insurance system. The  accumulated phenotyping repertoire from an extensive panel of –omic analyses will be refined and modelled into a new diagnostic panel for the allocation of high risk subjects to individualised preventive regimens.
Our multi-disciplinary team has a strong track record in clinical diabetes and metabolism. Several unique clinical cohorts
will provide the basis for a series of clinical, physiological and mechanistic investigations, which will identify, monitor and
analyse the impact of biomarkers over time. An exercise and dietary intervention study will be included in two specific cohorts,
enabling us to assess the impact of such interventions on plasma biomarkers and functional tissue-based markers. Project
clinical and industry partners will support the translation of our findings into clinical practice.",Activo,"Diabetes, prevention, clinical physiology, exercise, diet, metabolomics, epigenetics, mitochondria, transcriptomics, lipidomics, health insurance",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"STENO DIABETES CENTER A/S (DENMARK) - COORDINATOR
DUBLIN CITY UNIVERSITY (IRELAND)
VOLUNTARY HEALTH INSURANCE BOARD (IRELAND)
FUNDACIÓ PRIVADA INSTITUT DE RECERCA BIOMEDICA, IRB (SPAIN)
FUNDACIÓ INSTITUT D'INVESTIGACIÓ BIOMEDICA DE BELLVITGE - IDIBELL (SPAIN)
TEKNOLOGIAN TUTKIMUSKESKUS VTT (FINLAND)
ITÄ-SUOMEN YLIOPISTO (FINLAND)
METABOLON INC CORPORATION (UNITED STATES)
UNIVERSITY OF NEWCASTLE UPON TYNE (UK)
PINTAIL LTD (IRELAND)",2012,2015,3
Hospital Clínico San Carlos,Fundació Institut d'Investigació Biomèdica de Bellvitge - IDIBELL,Hospital Universitario de Bellvitge,L’Hospitalet de Llobregat,8907,Carrer de la Feixa Llarga,41.349472,2.098523,ADVANCE - Adenoviruses as novel clinical treatments. International training network,Virología,To integrate 8 leading academic centres and 4 private companies under a single umbrella to create an opportunity to train young scientists in adenovirus research.,Activo,"Health sciences, adenovirus, cancer, cardiovascular disease, vaccination, immunology, gene therapy",INTERNACIONAL,3,SI,PÚBLICA INTERNACIONAL,NO,"UNIVERSITY OF GLASGOW (UK) - COORDINATOR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIQUE (FRANCE)
UNIVERSITAET ZUERICH (SWITZERLAND)
UMEA UNIVERSTET (SWEDEN)
UUNIVERSITY OF OXFORD (UK)
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE (SPAIN)
ITA-SUOMEN YLIOPISTO (FINLAND)
CRUCELL HOLLAND BV (NETHERLANDS)
PSIOXUS THERAPEUTICS(UK)
ONCOS THERAPEUTICS OY (FINLAND)
MAGYAR TUDOMANYOS AKADEMIA ALLATORVOS-TUDOMANYI KUATOINTEZETE (HUNGARY)
BATAVIA BIOSERVICES BV (NETHERLANDS)",2012,2016,3
Hospital Clínico San Carlos,"Clinic.LIVER FIBROSIS LABORATORY,INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER ",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"Development of innovative drugs that display a restricted action within specific target cells or organs.Such locally acting drugs will have an improved safety and efficacy, as side-effects in other tissues will be prevented. They will investigate this therapeutic strategy for kinase inhibitors, a class of drugs that has tremendous therapeutic potential but that also is associated with unacceptable side effects. Kinase inhibitors will be conjugated to two classes of carrier systems, directed to either the liver or kidney. By this, we will develop locally acting drugs for the treatment of either hepatic or renal fibrosis. ",Patología musculoesquelética,"DIALOK:                                          Development of innovative assays and locally acting therapies aiming at critical kinases in hepatic and renal fibrosis. Rational and accelerated development of new, safer, more effective drugs including pharmacogenomics approaches 
",Inactivo,"locally acting drugs, Kinase inhibitors, hepatic fibrosis, renal fibrosis",Internacional (KREATECH BIOTECHNOLOGY B.V.; Amsterdam),,,,NO,"n:7 (2 empresas, 5 centros academicos) ",2006,2010,
Hospital Clínico San Carlos,"Clinic. DEPT. OF PATHOLOGY, HOSPITAL CLINICO PROVINCIAL DE BARCELONA",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"Personalized molecular approach in medicine with individual risk assessment and best suited care. Development of technology that allows molecular research at DNA and RNA level in paraffin embedded tissues. In this way it is easy to study lesions with long follow-up, rare diseases, viral persistence or molecular pattern of lesions with known therapy outcomes",Genética,"IMPACTS:                                                 Archive's tissues: improving molecular medicine research and clinical practice.Fundamental knowledge and basic tools for functional genomics in all organisms 
",Inactivo,archive tissues (AT),Internacional (CONSORZIO PER L'AREA DI RICERCA SCIENTIFICA E TECNOLOGICA DI TRIESTE)   ,,,,,n:21 ,2007,2010,
Hospital Clínico San Carlos,Clinic. INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER,Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,Chronic inflammatory disease: Multiple sclerosis.Knowledge of the mechanism determining response outcome of existing immunomodulatory therapies and identify novel therapeutic opportinuties,Neurología,"UEPHA-MS:                                              United Europeans for the development of PHArmacogenomics in Multiple Sclerosis. Obj: Promote and improve training opportunities in the novel areas of pharmacogenomics, biomarker research and system biology applied to MS.",Activo,"multiple sclerosis,pharmacogenomics, interferon, genomics, proteomics, systems biology",Local (Univ. Pais vasco),,,,,10 research teams,2008,2012,
Hospital Clínico San Carlos,"Clinic. Cardiology Department, Hospital CLINIC I PROVINCIAL DE BARCELONA",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,Cardiac implantable devices for patients with cardiac arrhythmia abnormalities,Patología cardiovasculares,Icardea:                                                        An Intelligent Platform for Personalized Remote Monitoring of the cardiac patients with electronic implant devices,Activo,"Adaptable remote monitoring of CIED patients, clinical guidelines, interoperability with HRs, PHRs","Internacional(SRDC YAZILIM ARASTIRMA VE GELISTIRME VE DANISMANLIK TICARET LIMITED SIRKETI, Turkey)",,,,,8,2010,2013,
Hospital Clínico San Carlos,Clinic. INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER,Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977, markers for personalized medication in allergy and multiple sclerosis,Inmunología,ComplesDis:                                         Unravelling complex diseases with complexity theory: from networks to the bedside,Inactivo,"bionformatics, computer sicence, genetic, autoimmunity",International(Göteborgs universitet),,,,,11,2008,2010,
Hospital Clínico San Carlos,"Clinic. Technological Innovation Unit, Hospital CLINIC I PROVINCIAL DE BARCELONA",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"Integrated Homecare (IHC) for stroke, HF, COPD patients (frequent chronic conditions)",Neumología,HOMECARE:                                             Clinical Continuity by Integrated Care,Activo,"homecare rehabilitation, stroke, COPD, heartg failure, integrated care, HTA","International(CAST, University of Southern Denmark)",,,,,12,2009,2012,
Hospital Clínico San Carlos," Clinic. Liver Unit,HCB_INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"Prognostic prediction and identification of oncogenic driverss susceptible for intervention, leading towards more personalized treatment algorithms",Oncología,HEPTROMIC:                                         Genomic predictors and oncogenic drivers in hepatocellular carcinoma. Design of prognostic devices for clinical translation,Activo,"genomic predictors, personalized treatment, prgnostic device",Local(HCB),,,,,8,2010,2013,
Hospital Clínico San Carlos,"Clinic. ICT Department, FCRB                                           ",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"patient avatar for an affordable personalised, predictive and integrative medicine. Predictive simulations to evaluate the probability of certain disease developing or progressing, predicting effects of present or future interventions",Otros,VPH-Share:                                                Virtual Physiological Human-structured human physiological research enviroment,Activo,"VPH, modelling, simulation, clinical data",International(University of Sheffield),,,,,24,2011,2015,
Hospital Clínico San Carlos,"Clinic. Centre for Diagnosis from Image, HCB",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,Development of IT infrastrcuture for the management and processing of heterogeneous data associated with the diagnosis and treatment of cerebral aneurysm and subrachnoid haemorrhage,Neurología, neurist:                                                           IP-Integrated Biomedical Informatics for the Management of Cerebral Aneurisms,Inactivo,"heterogeneous data management, aneurysms, IT infrastructure",Local (Universidad Pompeu Fabra),,,,,30,2006,2010,
Hospital Clínico San Carlos," Clinic. Hepatology and Hepatic Transplant Unit,HCB",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,new biotechnology products to promote long-term trasplant acceptance in pre-clinical models. Development of diagnostic tests to identify trasplanted patients for whom immunosuppressive treatment coul be safety minimized or withdrawn will be developed,Inmunología,RISET:                                                              IP-Reprogramming the Immune System for the Establishment of Tolerance,Inactivo,"Transplantation,immunology, genomics,tolerance",International (Université Libre de Bruxelles (ULB),,,,,22,2007,2011,
Hospital Clínico San Carlos,"Clinic. Technological Innovation Unit, Hospital CLINIC I PROVINCIAL DE BARCELONA",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"Open Telemedicine Platform based on a unified Service Oriented Architecture (SOA) providing media services, SIP-based control plan services and network services over the internet protocol (IP)",Otros,HIPERMED:                                                  High Performance Telemedicine platform,Inactivo,"open source software, telemedicine, open innovation","Local (Gigle Semiconductor, Fundación Privada i2CAT)",,,,,17,2009,2010,
Hospital Clínico San Carlos,"Clinic. Laboratory of Liver Fibrosis,INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,Exploitation of organ-simulating cellular devices as alternatives for long-term toxicity testing (Alternative testing strategies),Toxicología / Farmacología,"HeMiBio:                                                 Hepatic Microfluidic Bioreactor from human iPSC-derived hepatocytes, hepatic sinusoidal endothelial cells and stellate cell, suitable for inclusion in a repeated dose toxicity testing strategy of pharmaceuticalas/cosmetic ingredients",Activo,"hepatocytes, stellate cells, endothelial cells, stem cells, scaffolds, microfluidics, miniaturized bioreactor, sensors",International (Katholieke Universiteit Leuven),,,,,12 (academic/industrial partners) ,2011,2015,
Hospital Clínico San Carlos,"Clinic. FCRB-HCB, Department and Research group of Maternal-Fetal Medicine",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,endoscopic surgery: creation of assisted vision systems to enhance the surgeon's vision and increase reproducibility and safety in surgery,Cirugía,"ENDO-VV:                                          Endovascular Vision:new endoscopic tools for real time vascular assisted vision. Development of ready-to-use tools for digital identification of vessels during endoscopy, allowing real time enhanced vision, functional information and reconstruction of vessels map",Activo,"endovascular vision, endoscopic surgery, digital identification, real-time vision",Local (FCRB),,,,,3,2010,2014,
Hospital Clínico San Carlos,"Clinic. FCRB-HCB, Department and Research group of Maternal-Fetal Medicine",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,research around the major unsolved issue in ultrasound (US) techniques in medicine: the delimitation of irregular volumes and evaluation of tissue characteristics and perfusion,Diagnóstico por imagen / Medicina Nuclear / Radiología,Uvolumes:                                                  Novel Ultrasound-based Tridimensional tools for structural and functional evaluation of volumes of interest in human organs,Activo,"ultrasound, perfusion, fetal brain development",Local (FCRB),,,,,2,2008,2012,
Hospital Clínico San Carlos,"Clinic. FCRB,-HCB: Imaging Diagnostic Centre",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"Imaging technologies from bassic biological imaging with advanced light microscopy, in vivo molecular imaging of signle cells to animals model up to the clinical and epidemiological level of medical imaging of humans and populations",Patología musculoesquelética,EuroBioimaging:                                  Research infraestructure for imaging technologies in biological and biomedical sciences,Activo,"Biomedical imaging, Advanced light microscopy, medical imaging, molecular imaging, data managment",International(European molecular biology organization (EMBO),,,,,38,2010,2013,
Hospital Clínico San Carlos,"Clinic. FCRB-HCB, Department of Pathology",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"Epigenomic research, underlying biological processes and mechanisms into blood based disease, including common leukaemias and autoimmune disease. Discovery and validation of epigenetic markers for diagnostic use (development of smart technologies for better diagnostic tests)",Hematología,BLUEPRINT:                                                      A Blueprint of Haematopoietic Epigenomes. Epigenome-wide association study focussing on 100 samples of known genetic variation (reference epigenomes),Activo,"reference epigenome, hematopoiesis, leukaemia, Type 1 diabetes, DNA hydroxymethylation, epi-targets, biomarkers, genome-epigenome variation",International ( Stichting Katholieke Universiteit Radboud University Nijmegen),,,,,42,2011,2016,
Hospital Clínico San Carlos,"Clinic. FCRB-HCB, Lung Function Unit",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"Development of a simulation enviroment and a decision-support system. The three core elements are: Knowledge base (KB), an inference engine (IE), and a graphical visualisation enviroment (GVE)",Otros,SYNERGY-COPD:                                 Modelling and simulation enviroment for systems medicine -8Chronic Obstructive pulmonary disease-COPD- as a use case,Activo,"VPH, Systems medicine, COPD, Medical Simulation, Medical decision support, Ontology, Physiological model, Integrative healthcare",Local (Barcelona Digital Centre Tecnologic),,,,,9,2011,2014,
Hospital Clínico San Carlos,"Clinic. FCRB-HCB, Lung Function Unit",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"Innovative integrated care services: co-morbility challenge; articulation of healthcare and community services;organizational and educational issues; modularity, scalability and interoperability of the ICT platform; identification of business models ensuring service sustainability",Otros,NEXES:                                                  Supporting healthier and independent living for chronic patients and eldery,Inactivo,"Chronic patients, ageing, integrated care",Local (HCB),,,,,12,2008,2011,
Hospital Clínico San Carlos,"Clinic. FCRB-HCB, Lung Function Unit",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"data on mortality and hospital discharges, on health care, human resources and health care utilization costs. Explore the use of a group of essential measuraments of respiratory health and morbidity using innovative technological methods (sensors) to carry out measuraments, validate and transmit the data (fieldwork online) and use of  Telemedicine to provide training and support online to the fieldworkers",Otros,IMCA II:                                                   Indicadors for Monitoring COPD and Asthma In the EU,Activo,"COPD, telemedicine, sensors",Local (Fundación IMIM-Parc de Recerca Biomedica Barcelona),,,,,20,2006,2012,
Hospital Clínico San Carlos,"Clinic. FCRB-HCB, Department and Research group of Maternal-Fetal Medicine",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"Structured modular training programme for early stage researchers in the field of health sciences (laboratory techniques and molecular biology, genetic diagnosis, fetal cell and gene therapy, fetal pathology, post-natal follow-up, imaging and epidemiology)",Otros,"FETAL-MED:                                       Multidisciplinary Research Training Programme in Fetal Medicine and Health (Fetal therapy and surgery, Prenatal diagnosis, screening for chromosomal anomalies and fetal imaging, fetal growth retardation and preeclampsia, monochorionic twin pregnancy, pulmonary hypoplasia and perinatal neuropsychology)",Inactivo,"training programme, fetal medicine",Local (HCB),,,,,3,2006,2011,
Hospital Clínico San Carlos,"Clinic. HCB, INSTITUT CLÍNIC DE MEDICINA i DERMATOLOGIA",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,Dendritic cell (DC) Therapy and Targeting. Development of safe and potent adjuvants with combined immunostimulatory and delivery system properties that can target both antigen and immunomodulatory molecule to same DC(design vaccines for induction of broad and long-lasting protective immune responses in humans),Otros,iNanoDCs:                                                    Design of multifunctional nanoparticlestargeting TLR or Nod receptors for dendritic cell immune therapy,Activo,"multifunctional-nanoparticles, dendritic cells, cross priming, nod ligands, TLR ligandas, DC therapy, intracellular targeting",International (Centre National de la Recherche Scientifique),,,,,5,2011,2013,
Hospital Clínico San Carlos,Clinic. HCB:Cancer Research Unit,Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"Early daignosis, multiparametric analysis and quick monitoring of disease progression or therapeutic sensitivity in lung cancer",Oncología,POC4LIFE:                                      Multiparametric Quantum Dot Bioassay for Point of Care Diagnosis,Inactivo,"lung cancer, quantum dots, UV light source, fluorescence, immuno-diagnosis",International (Cezanne),,,,,10,2007,2011,
Hospital Clínico San Carlos,"Clinic. IDIBAPS: INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER,Systems Neuroscience group",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,Carry out research on the fusion of the human body with virtual or physical surrogates,Diagnóstico por imagen / Medicina Nuclear / Radiología,VERE:                                                          Virtual Embodiment and Robotic Re-Embodiment,Activo,"embodiment, virtual reality, robotics, haptics, brain-computer interface, neuroethics",Local (Universitat de Barcelona Facultat de Medicina),,,,,13,2010,2015,
Hospital Clínico San Carlos,"Clinic. HCB-IDIBAPS: INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER, Department of Pulmonology",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,Adoption of theranostics applications in Primary Care by pushing Point of Care Test (POCT),Enfermería,TheraEDGE:                                                      An Integrated platform enabling Theranostic applications at the Point of Primary Care,Activo,"Lab on Chip, lower respiratory tract infections, ICT platform",Local (NTE S.A.),,,,,15,2008,2012,
Hospital Clínico San Carlos,"Clinic. HCB, IIBB (Instituto de Investigaciones Biomedicas de Barcelona)",Hospital Clínico y Provincial de Barcelona,Barcelona,8306,Roselló 149,41.388523,2.150977,"Development of new probes and multimodal non-invasive imaging technology for early diagnosis, assessment of disease progression and treatment evaluation",Diagnóstico por imagen / Medicina Nuclear / Radiología,"DiMI:                                                      Diagnostic Molecular Imaging. Research and training related to molecular imaging for diagnostic purposes with special emphasis on ""bench-to-bedside"" (translational) applications.",Activo,"Multimodal imaging technology, early diagnosis, neuroscience",International (Klinikum der Universität München),,,,,52,2005,2012,
Hospital Clínico San Carlos,VHIR,Hospital Universitario Vall d'Hebron,Barcelona,8035,"Passeig de la Vall d’Hebron, 119",41.428033,2.143488,Physiopathology of diabetic retinopathy,Enfermedades metabólicas,Proyecto Europeo sobre nuevas formas de tratar diabetes,Activo,diabetic retinopathy,Local,1,SI,EU ,NO,18,2012,2017,1
Hospital Clínico San Carlos,VHIR,Hospital Universitario Vall d'Hebron,Barcelona,8035,"Passeig de la Vall d’Hebron, 119",41.428033,2.143488,Neurtraumatology and Neurosurgery,Neurología,Advanced Arterial Hypotension Adverse Event Prediction Through a Novel Bayesian Neural Network (AVERT-IT ),Activo,adverse event prediction,international,1,SI,EU ,NO,22,2008,2011,1
Hospital Clínico San Carlos,VHIR,Hospital Universitario Vall d'Hebron,Barcelona,8035,"Passeig de la Vall d’Hebron, 119",41.428033,2.143488,Neurovascular diseases,Neurología,cooling brain-stroke treatment,Activo,hipsotemia- stroke treatment,international,1,SI,EU ,NO,60,2012,2017,1
Hospital Clínico San Carlos,VHIR,Hospital Universitario Vall d'Hebron,Barcelona,8035,"Passeig de la Vall d’Hebron, 119",41.428033,2.143488,Experimental surgery,Diagnóstico por imagen / Medicina Nuclear / Radiología,advance technological know-how and to pursue progress and innovation in joint technology and application development in European robotics.,Activo,robotics,international,1,SI,EU ,NO,40,2009,2013,1
Hospital Clínico San Carlos,VHIR,Hospital Universitario Vall d'Hebron,Barcelona,8035,"Passeig de la Vall d’Hebron, 119",41.428033,2.143488,Oncology,Oncología,biomarkers and prostate cancer,Activo,prostate cancer,Local,1,SI,EU/Private,Si,5,2010,2014,1
Hospital Clínico San Carlos,VHIRº,Hospital Universitario Vall d'Hebron,Barcelona,8035,"Passeig de la Vall d’Hebron, 119",41.428033,2.143488,Clinical Research/innovation in Pneumonia/sepsis,Enfermedades respiratorias,varios,Activo,UCI,local,1,SI,EU/Private,NO,20,2009,-,1
Hospital Clínico San Carlos,Parc Taulí,Corporació Sanitaria Parc Taulí,Sabadell,8028,Parc Taulí 1,41.555263,2.112976,Healthcare cluster,Neurología,"Neurosciences: understanding mental disorders, dementia or neurodegenerative diseases.
Fostering and ensuring a multidisciplinary approach in fundamental and basic research",Activo,"Genetics, biomarkers, functional imaging, cognition & emotion, neurophysiology, pharmacological challenges in animal models",International,,,,NO,"CONSEIL RÉGIONAL PACA
EUROBIOMED
Bayern innovative 
InnoAG
Medipole",2011,2014,
Hospital Clínico San Carlos,Parc Taulí,Corporació Sanitaria Parc Taulí,Sabadell,8028,Parc Taulí 1,41.555263,2.112976,University of California - San Francisco,Otros,Acture respiratory distress syndrome and Critical Care ,Activo,"Acute Lung Injury, new therapy",International,,,,NO,"University of California - San Francisco
NIH",2012,2016,
Hospital Clínico San Carlos,Parc Taulí,Corporació Sanitaria Parc Taulí,Sabadell,8028,Parc Taulí 1,41.555263,2.112976,University of Haifa - Israel,Endocrinología,Patient guidance system that integrates hospital and monitoring data into a Personal Health Record (PHR) accessible by patients and care providers ,Activo,"Clinical decision-support systems, computer-interpretable guidelines, body area networks, monitoring devices, personalized medicine, personal, health record",International,,,,NO,"Universita decli studi di pavia
Universiteit Twente",2012,2016,
Hospital Clínico San Carlos,Institut de Recerca Hospital de Sant Pau,Hospital de la Santa Creu i Sant Pau,Barcelona,8026,Sant Quintí 89,41.411494,2.174270,Cardiologia Clínica y Translacional,Patología cardiovasculares,"Electrofisiología y arritmias cardiacas, fallo cardiaco, enfermedades isquémicas, nuevas técnicas diagnósticas",Activo,,Dr. Juan Cinca,3,SI,Ambas,NO,"Empresas, Universidades y otros Centros de Investigación",,,2
Hospital Clínico San Carlos,Institut de Recerca Hospital de Sant Pau,Hospital de la Santa Creu i Sant Pau,Barcelona,8026,Sant Quintí 89,41.411494,2.174270,"Endocrinología, Nutrición y Diabetes",Endocrinología,"Oncología endocrina, inmunogenética de la diabetes mellitus, optimización terapéutica, pancreas artificial, aplicaciones telemédicas, tratamiento y prevención de la obesidad y diabetes",Activo,,Dr. Alberto de Leiva,3,SI,Ambas,NO,"Empresas, Universidades y otros Centros de Investigación",,,3
Hospital Clínico San Carlos,Institut de Recerca Hospital de Sant Pau,Hospital de la Santa Creu i Sant Pau,Barcelona,8026,Sant Quintí 89,41.411494,2.174270,Oncogenesis y Antitumorales,Oncología,"Estudio del papel de los oncogenes, espcialmente en cáncer colorectal. Desarrollo de fármacos y nuevos tratamientos. Biomarcadores",Activo,,Dr. Ramón Mangues,3,SI,Ambas,SI,"Empresas, Universidades y otros Centros de Investigación",,,3
Hospital Clínico San Carlos,Institut de Recerca Hospital de Sant Pau,Hospital de la Santa Creu i Sant Pau,Barcelona,8026,Sant Quintí 89,41.411494,2.174270,Transtornos del Movimiento y Parkinson,Neurología,"Temblores y otros transtornos del movimiento, disfunciones cognitivas en Parkinson, nuevos modelos animales",Activo,,Dr. Jaime Kulisevsky,3,SI,Ambas,NO,"Empresas, Universidades y otros Centros de Investigación",,,3
Hospital Clínico San Carlos,Institut de Recerca Hospital de Sant Pau,Hospital de la Santa Creu i Sant Pau,Barcelona,8026,Sant Quintí 89,41.411494,2.174270,Genética en Enfermedades Neurodegenerativas,Neurología,"Genetica del Alzheimer, Parkinson, ALS y otras enfermedades neurodegenerativas",Activo,,Dr. Jordi Clarimón,3,SI,Ambas,NO,"Empresas, Universidades y otros Centros de Investigación",,,3
Hospital Clínico San Carlos,Institut de Recerca Hospital de Sant Pau,Hospital de la Santa Creu i Sant Pau,Barcelona,8026,Sant Quintí 89,41.411494,2.174270,Neurobiologia de las Demencias,Neurología,"Identificación de biomarcadores, caracterización molecular, interacción de proteinas y desarrollo de nuevos tratamientos en enfermedades neurodegenerativas",Activo,,Dr. Alberto Lleó,3,SI,Ambas,NO,"Empresas, Universidades y otros Centros de Investigación",,,3
Hospital Clínico San Carlos,Institut de Recerca Hospital de Sant Pau,Hospital de la Santa Creu i Sant Pau,Barcelona,8026,Sant Quintí 89,41.411494,2.174270,Genómica de Enfermedades Complejas,Genética,"Análisis genético de Trombofilia Idiopatica, Osteoporosis, Diabetes II e Insuficiencia Cronica Venosa, entre otras. Farmacogenómica",Activo,,Dr. José Manuel Soria,3,SI,Ambas,NO,"Empresas, Universidades y otros Centros de Investigación",,,3
Hospital Clínico San Carlos,Institut de Recerca Hospital de Sant Pau,Hospital de la Santa Creu i Sant Pau,Barcelona,8026,Sant Quintí 89,41.411494,2.174270,Hematología Clínica,Hematología,Estudio molecular y celular de la fisiopatologia de los cánceres hematológicos. ,Activo,,Dr. Jordi Sierra,3,SI,Ambas,NO,"Empresas, Universidades y otros Centros de Investigación",,,2
Hospital Clínico San Carlos,Institut de Recerca Hospital de Sant Pau,Hospital de la Santa Creu i Sant Pau,Barcelona,8026,Sant Quintí 89,41.411494,2.174270,I2Health Sant Pau,Otros,"Desarrollo y promoción del e-Health. Aplicaciones telemédicas, telerehabilitación y monitorización de pacientes en diferentes patologías",Activo,,Dr. Ildefonso Hervás,3,SI,Ambas,NO,"Empresas, Universidades y otros Centros de Investigación",,,3